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Outline of the study 
Pneumocystis carinii pneumonia (PCP) is an important opportunistic infection in patients 
infected with Human Immunodeficiency virus (HIV) First choice for prophylaxis and treat 
ment of PCP is co-trimoxazole (combination trimethoprim and sulphamethoxazole) The 
frequency of adverse reactions to cotrtmoxazole is, however, much higher (40 - 80%) in 
patients with HIV infection compared with other patients, even those who are immunode-
ficient The reason why HIV-infected individuals are so prone to develop adverse reactions 
to this medication was unknown A literature study was undertaken to gain more insight 
into this important clinical problem This resulted in the formulation of a hypothesis 
(chapter 1) that forms the basis of this study A series of investigations was carried out 
including studies of the metabolism of sulphamethoxazole and other sulphonamides 
(chapter 3-7), the assessment of the glutathione status in HIV infected patients (chapter 
8,9) and the exploration of possible treatment modifications (chapter 10,11) 
More in detail 
In chapter 1 the hypothesis on the adverse reactions to cotnmoxazole in HIV infection is 
formulated, and in chapter 2 it is outlined that the problem of the increased occurrence of 
side effects is not restricted to cotnmoxazole alone 
Since it was postulated that a metabolic product of sulphamethoxazole is important for 
the development of adverse reactions, its metabolism was studied extensively At first the 
isolation, identification and analysis of sulphamethoxazole and its metabolites in human 
urine and plasma is described (chapter 3) It was assumed that sulphamethoxazole hydro-
xylamine is important for the development of adverse reactions to cotnmoxazole This was 
based on in vitro studies with very limited in vivo data 
Chapter 4 describes the pharmacokinetics of sulphamethoxazole hydroxylamine in healthy 
volunteers In chapter 5 the pharmacokinetics of sulphamethoxazole and all its metaboli-
tes are described in healthy volunteers To gam insight whether the metabolism of sulpha-
methoxazole differed between healthy volunteers and HIV seropositives, the urinary reco-
very and kinetics of sulphamethoxazole and its metabolites were compared (chapter 6) 
It was postulated that an oxidated product of sulphamethoxazole was important for toxi-
city and therefore the oxidation of sulphamethoxazole was also studied in-vitro (chapter 
7) 
Apart from sulphamethoxazole metabolism, glutathione may also be critical for cotnmoxa-
zole toxicity Glutathione concentrations can be measured with different methods, some 
researchers used monochlorobimane as a label to determine glutathione levels This 
method was, however, never validated before In chapter 8 the use of monochlorobimane 
as a intracellular glutathione label is biochemically evaluated Validated methods for glu-
tathione determination include, among others, high performance liquid chromatography, 
and using these methods, glutathione concentrations were measured in plasma, whole 
blood and in cytosol of CD4+ T-cells and CD14+ cells of HIV-seropositive individuals and 
healthy controls (chapter 9) 
Two options for treatment modification were explored Trimethoprim is not only combined 
with sulphamethoxazole (cotrimoxazole) but also combined with sulphametrole (co-sol-
trim) Sulphamethoxazole and sulphametrole are differently metabolized and may therefo-
re have different toxicity profiles 
Chapter 10 describes a retrospective study in AIDS patients treated for Pneumocystis can-
nil pneumonia with trimethopnm-sulphametrole 
Sulphonamides are mostly combined with a dihyd rotola te reductase inhibitor and the 
aimed plasma concentration of the sulphonamide is much higher compared to the plasma 
concentration of trimethoprim or pyrimethamine Dose reduction of sulphonamides may 
reduce side effects and chapter 11 provides an experimental rationale for this assumption 
by the exploration of the synergistic activity of dihydrofolate reductase inhibitors and 
sulphonamides in vitro 
Chapter 12 gives a reappraisal of the hypothesis as formulated in chapter 1 
The more the hypothesis, the shorter the time span o/the truth. 
Robert M Pirsig 
Chapter ι 
Hypothesis: adverse reactions to cotrimoxazole 
in HIV infection. 
AJAM van der Ven, PP Koopmans, TB Vree, JWM van der Meer 
Lancet 1991, 338 431-433 
Abstract 
The origin of the increased frequency of side-effects to cotrimoxazole in HIV-positive 
patients is unknown Data on plasma concentrations of the parent compounds are incon­
clusive Evidence points to the hydroxylamine derivatives of sulphamethoxazole as the 
reactive metabolites that cause adverse reactions to cotrimoxazole HIV-positive individu­
als have a systemic glutathione deficiency, and therefore a reduced capacity to scavenge 
such metabolites This process would lead to an increased exposure to toxic intermediates 
and would explain the high frequency of adverse reactions to cotrimoxazole in these 
patients 
Pneumocystis carinii pneumonia (PCP) is an important opportunistic infection in patients 
with the acquired immunodeficiency syndrome (AIDS) Treatment with a high dose of 
cotnmoxazole-20 mg/kg trimethoprim and 100 mg/kg sulphamethoxazole-is recommen­
ded The frequency of adverse reactions to cotrimoxazole in patients with AIDS (40-80%) 
is much higher compared to other patients, even those who are immunodeficient (1-8) 
The explanation for this increased side-effect profile is unknown 
Trimethoprim as a possible cause of side-effects 
Controversy exists as to whether side effects depend on serum concentrations of trimet­
hoprim (4 7) Serum concentrations above 25 mg/l in patients with AIDS may be associa 
ted with leucopema, and dose reduction to maintain serum concentration between 5 and 
8 mg/l may reduce the risk of bone marrow suppression while preserving antimicrobial 
efficacy (7) Other studies have shown that the serum concentration of trimethoprim was 
4 8 % higher m patients treated with trimethoprim and dapsone compared to patients 
treated with trimethoprim and sulphamethoxazole, whereas adverse events were more 
common in the trimethoprim/sulphamethoxazole group (4,8) 
Trimethoprim inhibits dihydrofolate reductase and can cause megaloblastic anemia and 
neutropenia in patients whose folate stores are deficient In some patients, megaloblastic 
changes in the bone marrow have been found despite normal serum folate concentrations 
(6) However, other studies have either failed to find megaloblastic changes or report no 
therapeutic benefit with folmic acid A different mechanism that explains the haematolo-
gical changes has been described Antibodies to polymorphonuclear cells have been found 
m untreated HIV- infected patients and were shown to increase according to the degree 
of neutropenia in cotrimoxazole treated AIDS patients (9) Therefore no convincing data 
show that trimethoprim is the mam cause of side effects in such patients, although a con-
tributory role cannot be excluded 
Sulphamethoxazole as a possible cause of side-effects 
The relevance of serum concentrations of sulphamethoxazole to the development of adver 
se reactions in AIDS patients is also controversial (3-5) Some workers do not believe high 
serum sulphamethoxazole concentrations are a contributing factor (3), whereas other 
groups do share this belief (5) Other mechanisms may be more important, such as forma-
tion of sulphonamide metabolites 
Sulphamethoxazole is metabolized (figure) by N acetyltransferase (50 70%) to N4 acetyl 
sulphamethoxazole (N4) and by the cytochrome P450 system (10 15%) to 5 methylhydro 
xy sulphamethoxazole (SOH) Sulphamethoxazole can also be oxidized on the N4 position 
to form a hydroxylamme derivate (N40H)(10 13) The rate of production of this reactive 
intermediate may be influenced by the rate of acetylation of the parent compound (12), 
which suggests that the acetylator status is important Inherited differences in the rate of 
production of this reactive metabolite may also contribute to this process (13) The hydro-
xylamme metabolite is an electrophilic, reactive compound that can bind covalently to 
macroglobulms, it must be scavenged by the oxidant buffering capacity of glutathione 
before it is excreted in the urine In vitro studies show that hydroxylamme metabolites 
lead to increased cytotoxicity towards lymphocytes of patients with a clinical history of 
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sulphonamide hypersensitivity compared to control lymphocytes of non-allergic individuals 
(10-13) The cytotoxicity of these hydroxylamine dérivâtes diminished after coincubation 
with glutathione or N acetyl cysteine (10, 12) Hydroxylamine dérivâtes may have a direct 
cytotoxic action because of the ability of these electrophilic metabolites to bind to 
macroglobulins This process may lead to formation of haptens that could stimulate an 
immune response Scavenging of these hydroxylamine dérivâtes by glutathione might be 
crucial for the prevention of covalent binding and toxicity Hypersensitivity may be due to 
increased production of a reactive metabolite together with the relative inability of tissues 
to detoxify such an substance (14) 
Glutathione concentrations in HIV-positive individuals 
Glutathione is an important antioxidant In patients with AIDS, as well as in symptom-free 
HIV-positive individuals, glutathione concentrations in both serum and bronchoalveolar 
lavage fluid were significantly reduced (15, 16) The mechanisms that lead to this syste-
mic glutathione deficiency are unknown Decreased glutathione synthesis, increased cata-
bolismi, and increased use could all be involved (16) The reactive metabolites of sulpho-
namides are scavenged by glutathione The formation and scavenging of hydroxylamine 
dérivâtes take place throughout the body, since both the cytochrome-P450 system and 
glutathione are widely distributed 
Hypothesis 
The hydroxylamine dérivâtes of sulphamethoxazole are the reactive metabolites that cause 
the adverse reactions to cotrimoxazole HIV-positive individuals have a systemic glutathio-
ne deficiency, and therefore a reduced capacity to scavenge such reactive metabolites 
This process would lead to an increased exposure of toxic intermediates and would 
explain the high frequency of adverse reactions to cotrimoxazole in these patients When 
adverse reactions to cotrimoxazole do occur, dose reduction will often diminish the severi-
ty of these events This observation suggests a dose-related toxicity rather than true hyper-
sensitivity but, as discussed above, measurements of serum concentrations of the parent 
compounds trimethoprim and sulphamethoxazole do not clearly support this relation 
Toxicity may be caused by the metabolite rather than the parent compound Inherited dif-
ferences in the rate of production of these (toxic) metabolites, like the acetylator status 
(13), could add to an individual's susceptibility to adverse events and would explain the 
lower frequency of side-effects reported in African, Haitian, and black American patients 
with AIDS (17,18) The observation that side- effects occur after 8 to 12 days might sugge-
st a role for a metabolite, either by slow accumulation or by an immune response that the 
metabolite could initiate 
Although our hypothesis seems attractive because the formation of hydroxylamine dérivâ-
tes is theoretically likely, detection of these reactive species by methods like high-perfor-
mance liquid chromatography, has never been reported Furthermore, hydroxylamine déri-
vâtes can have either a direct toxic effect or function as a hapten, but which of the side-
effects of sulphamethoxazole in HIV positive patients are toxic or immunological remains 
unclear In addition, a possible contributory role of trimethoprim can not be excluded Like 
sulphamethoxazole, trimethoprim has a рага-amino group that could be oxidized to form 
hydroxylamines Glutathione synthesis requires the sulphur containing amino acids and 
their metabolism is linked to folic acid and cobolamin, trimethoprim could influence this 
synthetic pathway (19) 
There are two ways to substantiate this hypothesis Firstly, N-acetyl cysteine could be 
added to cotnmoxazole treatment N-acetyl cysteine replenishes cysteine and sustains glu­
tathione synthesis when the demand for glutathione is increased (20) Secondly, by selec­
ting sulphonamides that are not easily N-hydroxylated, the generation of reactive metabo­
lites might be prevented With these modifications of the standard regimes for the prophy­
laxis and treatment of Pneumocystis carinii pneumonia, side effects could be largely elimi­
nated 
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Chapter 2 
Drug intolerance in HIV disease. 
AJAM van der Ven, PP Koopmans, TB Vree, JWM van der Meer 
J Antimicrob Chemother 1994, 34 1-5 
Individuals seropositive for human immunodeficiency virus (HIV) are more susceptible to 
develop adverse reactions to a number of drugs compared to seronegatives ( Lee and 
Safrm, 1992, Coopman et al, 1993, Kovacs et al, 1984), the side effects caused by 
sulphonamides are especially well documented (Carr et al, 1993, Cordin et al, 1984, 
Hardy et al, 1992, Hughes et al, 1993, Leprot et al, 1988, Medina et al, 1990, Nayin et 
al, 1985, Porter et al, 1992, Schneider et al, 1992) 
In HIV seropositive individuals, sulphonamides are used in combination with inhibitors of 
dihydrofolate reductase for the prophylaxis and treatment of Pneumocystis carinii pneu-
monia (PCP) as well as for the treatment of toxoplasmosis The treatment of PCP with 
high dose sulphamethoxazole and trimethoprim (cotrimoxazole) is complicated by adverse 
reactions in 40 to 80% of the patients with acquired immunodeficiency syndrome (AIDS) 
as compared to less than 5% of seronegative patients with other immunodeficiencies 
(Kovacs et al, 1984) Adverse reactions mostly occur after 10-12 days of treatment but 
the 14 21 days recommended course can often be completed after lowering the dose, the 
frequency of toxicity is less fot the lower dosed prophylactic regimens In a comparative 
study of low dose (480 mg/day) and high-dose (960 mg/day) cotrimoxazole it was found 
that at lower dosages the side effects are not less frequent, but occur later in time 
(Schneider et al, 1992) These findings argue against a classic allergic nature of these 
side effects, but suggest that the occurrence of toxicity is dose-dependent and that accu-
mulation of drugs or their metabolites could be involved This implies that prescription of 
sulphonamides with long half-lives should be done with caution Sulphadoxine, mostly 
used in combination with pyrimethamine (Fansidar), is such a long acting sulphonamide 
with a half-life of 7-9 days The reports describing very serious reactions after using 
sulphadoxine for patients intolerant to cotrimoxazole (Saiag et al, 1992, Anonymous 
1988) are compatible with accumulation Cross hypersensitivity generally occurs between 
different sulphonamides, but its extent is not clearly established The use of dapsone m 
combination with inhibitors of dihydrofolate reductase in HIV infected patients is well 
documented (Medina et al, 1990), especially when also intolerant for cotrimoxazole 
(Jorde et al, 1992) Within this last category cross reactivity was recorded in 38 percent 
of the patients In all probability, this reflects the chemical structure similarities between 
dapsone and the sulphonamides 
l6 
> 
Prophylaxis of PCP with cotrimoxazole is highly effective and also offers protection 
against cerebral toxoplasmosis, so that rechallenge is recommended after treatment failu­
re of PCP due to toxicity of cotrimoxazole (Centres for disease control, 1992) Immediate 
hypersensitivity reactions are seldomly reported during rechallenge, although fever and 
rash occurs in 34-58% of the published studies (Carr, Penny and Cooper, 1993, Kennedy 
et al, 1993), treatment was discontinued in 50% because of intolerance while when 
rechallenged, initially with trimethoprim, and thereafter sulfamethoxazole, adverse reac­
tion were attributed to trimethoprim and cotrimoxazole in 16 and 58% respectively (Carr, 
Penny and Cooper, 1993) 
The treatment of PCP and toxoplasmosis in HIV infected patients also presents difficulties 
in relation to the use of pentamidine, clindamycine/pyrimethamine and atovaquone 
Pentamidine has a low therapeutic index and is complicated by a severe hypoglycemia 
and nephrotoxicity (Wharton et al, 1986) Atovaquone has almost exclusively been used 
in HIV patients and can therefore not be compared with other patient groups, cutaneous 
reactions have occurred in 20% of the patients treated with atovaquone for PCP (Hughes 
et al, 1993) Prophylactic use of clindamycin and pyrimethamine has been compared in a 
double-blind, placebo-controlled trial in HIV-infected patients at risk for toxoplasma 
encephalitis (Jacobson et al, 1992) The clindamycin arm of the trial was terminated pre­
maturely because of intolerance in 4 4 % of cases This degree of toxicity is not experien­
ced in HIV seronegative individuals and can neither be attributed to the dose (300 mg 
bd) nor to the duration of exposure (33 days) 
Adverse reactions to antituberculous drugs have occurred more frequently in patients with 
AIDS compared to those not infected with HIV (Chaisson et al, 1987, Small et al, 1991, 
Soriano et al, 1988, Nunn et al, 1991 ), particularly to rifampicm and thiacetazone 
Amoxicillin-clavulanic acid has caused fever and rash in 44 percent of the HIV infected 
patients (Battegay et al, 1989) which is far higher than in seronegative individuals Finally, 
numerous case-reports describe adverse reactions in HIV infected patients but no data are 
available for comparison with HIV seronegative persons Thus, HIV infection is associated 
with a predisposition to toxic effects of drugs of different classes and chemical structures 
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What are the underlying mechanisms of these side-effects7 The clinical features of drug hypersensi­
tivity in HIV infected subjects does not suggest it to be IgE mediated Factors such as coexisting 
cytomegalovirus or Epstein Barr virus infections, altered drug metabolism, acetylator phenotype, 
dose and duration of therapy, rate of HIV replication or glutathione deficiency might all contribute 
(Carr, Cooper and Penny, 1991, Lee et al, 1993, Сап et al, 1993, van der Veneto/, 1991) With 
respect to sulphonamides, we favour the hypothesis that adverse reactions could be attributed to 
the formation of reactive hydroxylamme metabolites of sulphonamides (Rieder et al, 1988, 1989, 
Shear et al, 1986) combined with a deficient glutathione system needed for scavenging these reac 
tive molecules 
The known metabolism of sulphamethoxazole (Figure) involves acetylation (leading to N4-acetyl-
sulphamethoxazole), glucuronidation (leading to Ni-glucuromde conjugate) and oxidation (Vree and 
Hekster, 1987) The latter reactions are cytochrome-P450 mediated and take place at the C5-carbon 
atom leading to 5-hydroxysulphamethoxazole and N4-acetyl-5-hydroxy-sulphamethoxazole The N4-
nitrogen atom can also be oxidized leading to the hydroxylamme metabolite This last compound is 
a relatively unstable metabolite and assumed to be responsible for the occurrence of side effects 
The suggestion that hydroxylamines play a role in adverse reactions is supported by in-vitro experi­
ments in which sulphamethoxazole hydroxylamme has been found to be cytotoxic for lymphocytes, 
while the parent compound has not (Rieder et al, 1988, 1989) Co incubation with glutathione 
reduced cytotoxicity Lymphocytes from patients with a history of sulphonamide allergy exhibited a 
more pronounced cytotoxicity after incubation with hydroxylamines compared to non allergic indivi­
duals Similar results were obtained testing lymphocytes from HIV seropositive individuals (Carr et 
al, 1993) As mentioned above, HIV seropositive individuals may be more susceptible to sulphame­
thoxazole hydroxylamme because of a (cellular) glutathione deficiency (Buhl et al, 1989, Eck et al, 
1989, van der Ven et al, unpublished) 
Recently, we have studied the formation and elimination of sulphamethoxazole hydroxylamme after 
a single oral dose of 800 mg sulphamethoxazole (van der Ven et al, 1994) In six healthy volun­
teers, the urinary recovery of sulphamethoxazole hydroxylamme accounted for 2 4% of the dose We 
did not observe increased hydroxylamme formation in slow acetylators, as was suggested before 
(Rieder et al, 1991) Acetylator phenotype was determined with sulphadimidine since for sulphamet 
hoxazole no slow and fast acetylators can be distinguished A similar kinetic study is currently car­
ried out with HIV seropositives, the comparison of these two kinetic studies will give information on 
oxidative pathways of sulphamethoxazole in HIV seronegative and seropositive individuals It should 
be noted that increased oxidation of caffeine has been demonstrated before in AIDS patients with 
acute illnesses (Lee et al, 1993) 
Whether the side effects to other drugs mentioned are due to reactive metabolites is unknown 
However, compounds other than sulphonamides may be metabolized to reactive intermediates 
(Cibaldi, 1992) For instance this has been established for dapsone, its hydroxylamme metabolite 
seems to be responsible for methemoglobinemia When dapsone is combined with Cimetidine, an 
inhibitor of N-oxidation reactions by a cytochrome P450 isoenzyme, both hydroxylamme formation 
and the incidence of methemoglobinemia are reduced (Coleman et al, 1990) 
Apart from the inhibition of cytochrome P450, other options to prevent side effects might be possi 
ble Firstly, gradual re exposure to low dosage of drugs previously not tolerated ("desensitization") 
has been reported (Gordin et al, 1984, Carr, Cooper and Penny, 1991, 1993) Secondly, N acetyl cys 
teine replenishes cysteine and sustains glutathione synthesis when the demand for glutathione 
is increased Finally, by selecting sulphonamides that are not easily N-hydroxylated, the 
generation of reactive metabolites may be prevented 
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Abstract 
From human urine the following metabolites of sulphamethoxazole (S) were isolated by 
preparative HPLC 5 methylhydroxysulphamethoxazole (SOH), N4-acetyl-5-methylhydroxy-
sulphamethoxazole (N4S0H) and sulphamethoxazole-Nl glucuronide (Sgluc) The comp-
ounds were identified by NMR, mass spectrometry, infrared spectrometry, hydrolysis by ß-
glucuronidase and ratio of capacity factors 
The analysis of S and the metabolites N4 acetylsulphamethoxazole (N4), (SOH), N4 hydro-
xysulphamethoxazole (N40H), (N4S0H), and Sgluc m human plasma and urine samples 
was performed with reversed-phase gradient HPLC with UV detection In plasma, S and N4 
could be detected in high concentrations, while the other metabolites were present in 
only minute concentrations In urine, S and the metabolites and conjugates were present 
The quantitation limit of the compounds in plasma are respectively S and N4 0 10 pg/ml, 
N4SOH 0 13 мд/rnl, N4OH 0 18 pg/ml, SOH 0 20 pg/ml and Sgluc 0 39 pg/ml In urine 
the quantitation limits are N4 and N4OH 1 4 pg/ml, S 1 5 pg/ml, N4SOH 1 9 м д / т і , 
SOH 3 5 gg/ml and Sgluc 4 1 pg/ml The method was applied to studies with healthy 
subjects and HIV positive patients 
Introduction 
The known metabolism of sulphamethoxazole (4-amino-N-(5-methyl-3 isoxazolyl-benzene 
sulphonamide, CAS number 723-46-6, S) involves acetylation and oxidation at the N4 
nitrogen atom leading to N4-acetylsulphamethoxazole (N4) and N-hydroxysulphamethoxa-
zole (N40H) The latter compound is thought to be responsible for the occurrence of side 
effects of long term prophylactic treatment of Pneumocystis carimi pneumonia in HIV 
positive patients [1] Hydroxylation takes also place at the C5 methyl group, leading to 5-
methylhydroxysulphamethoxazole (SOH) and N4-acetyl 5-methylhydroxysulphamethoxazole 
(N4S0H) [2-10] Moreover sulphamethoxazole is glucuronidated at the N1 atom, leading 
to sulphamethoxazole-Ni-glucuromde [2,6-9] This metabolic profile of S, shown in fig 1, 
has been elucidated by paper chromatography with detection reagents [2,6-9] and isocra-
tic HPLC analysis [4, 5, 11] 
Analysis of the sulphonamides in blood and urine was performed with the well known 
Bratton & Marshall method [12] until in 1972 the first HPLC method for separation of 
sulphonamides was reported [13] 
Recently we investigated the pharmacokinetics of the N4-hydroxylamme of 
sulphamethoxazole in human volunteers by isocratic as well as gradient HPLC and disco­
vered a glucuronide conjugate of sulphamethoxazole (Sgluc) which was not detected befo­
re by HPLC analysis [14] 
HPLC analysis of N-glucuronides of sulphonamides had already been described for sulpha-
dimethoxme [15, 16], sulpha-6-monomethoxine [17], sulphamethomidine [18] and 
sulphaphenazole [19], but not yet for S 
For a full pharmacokinetic analysis of sulphamethoxazole, all metabolites should be avai­
lable for the validation of the analytical method 
The aims of this investigation were 
a) the isolation and identification of three metabolites of sulphamethoxazole 5-methylhy-
droxysulphamethoxazole, N4-acetyl 5-methylhydroxysulphamethoxazole and sulphame-
thoxazole-Ni-glucuronide by preparative HPLC and standard spectrometry techniques, 
and 
b) to develop a simple and direct gradient HPLC analysis of S with its metabolites and 
glucuronide conjugate in human plasma and urine 
Experimental 
Chemicals 
S and N4 were obtained from Hoffmann-LaRoche (Mijdrecht, Netherlands). The metaboli­
tes SOH, N4SOH and Sgluc were isolated from human urine and were HPLC pure. N40H 
was synthesized by Synthon (Nijmegen, Netherlands) All other reagents were of ρ a quali­
ty and obtained from Merck (Darmstadt, Germany) 
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Amberlite XAD-2 absorption resin and Celite 545 were obtained from Fluka (Perstorp 
Analytical, Oud Beyerland, Netherlands) 
Four ß-glucuronidase enzymes were obtained From Sigma, St Louis, MO, USA ß-glucuroni-
dase type Bl (Bovine liver, Cat No C-0251), type H2 (Helix pomatm, Cat No C-0876), 
type Lll (lyophilized powder from limpets Patella vulgata, Cat No G-8132), type VIIA 
(Escherichia coli, Cat No G-7646) 
Subject 
To one healthy human subject (male, 35 y, 85 kg) a single oral dose of 800 mg S in a 
gelatin capsule was administered with 100 ml tap water after an overnight fast The 
study had the approval of the hospital ethics committee and informed consent was obtai-
ned from the volunteer 
Sampling 
Blood samples were drawn and collected in heparimzed eppendorf vials (2 ml) at regular 
time intervals during 2 days after administration by means of fingertip puncture with 
Monolet lancets (Monoject, St Louis, USA) After centrifuging at 3000 g plasma samples 
were stored at -20°C pending analysis 
Urine was collected upon untimed voiding The total time of sample collection was 96 h 
Three samples of 7 ml of each void were stored at -20°C pending analysis 
The remainder of the urine was collected for 48 h in a tank and stored at 20°C, pending 
isolation 
Sample treatment 
Plasma samples (100 μΙ) were deprotemized with 100 μΙ acetonitnle, centrifuged at 3000 
g, and 20 μΙ of the supernatant was injected onto the column For the measurement of 
N40H, urine was centrifuged at 3000 g for 5 mm, the supernatant was diluted 1 9 with 
0 2 M KH2P04 buffer pH 5 0 and 20 μΙ was injected onto the column 
For the measurement of S and the other metabolites, 50 μΙ diethylamine was added to 
the urine sample of 7 ml (pH 10) to increase the solubility of all sulphonamides The 
urine was then centrifuged at 3000 g for 5 mm, and subsequently the supernatant was 
diluted 1 9 with 0 2 M K2PO4 buffer pH 5 0 and 20 μΙ was injected onto the column 
Gradient HPLC analysis of S and metabolites 
The HPLC system consisted of a Spectra Physics SP 8775 autosampler (Spectra Physics, 
Eindhoven, Netherlands), a Spectra Physics SP 8800 ternary HPLC pump, a Spectroflow 
783 UV detector (Separations, H I Ambacht, Netherlands) and a Spectra Physics SP 4290 
integrator The column was a Sphensorb ODS 5 μπι, 250 mm χ 4 6 mm ID (Cat no 28812, 
Chrompack, Bergen op Zoom, Netherlands) with a guard column (75 mm χ 2 1 mm), pac­
ked with pellicular reversed phase (Chrompack Cat no 28653) The mobile phase was a 
mixture of acetonitnle, dimethylformamide (DMF) and a mixture of 0 9 g H3P04 (85% 
w/w) and 0 225 g tetramethylammoniumchloride (TMACI) in 1 L H2O (pH 2 1 ) 
At t=0, the mobile phase consisted of 1 % acetonitnle, 3% DMF and 96% of the 
H3PO4/TMACI mixture (%V/V) During the following 30 mm, the mobile phase changed 
linearly until it attained a composition of 20% acetonitnle, 10% DMF and 70% of the 
H3PO4/TMACI mixture (%V/V) At 30 mm, the mobile phase was changed within 3 mm 
to the initial composition, followed by equilibration for 2 mm The flow rate was 1 2 
ml/mm The effluent was monitored at 271 nm 
Isolation of the metabolites from urine 
Column chromatography 
Two liters of urine (48 h) was brought dropwise to pH 2 5 with H3P04 (25% w/w) and allo­
wed to stand for 1 h to precipitate endogenous urates Celite 545 (40 g) was added to the 
urine, and the suspension was filtered The pH of the filtrate was adjusted to 2 5 
A preparative column (40cm χ 6cm, packed with 1 kg XAD-2) was rinsed with 2 L of 
methanol, 2 L of water and with 1 L of 0 06 M KH2PO4 buffer (pH 2 5) Thereafter, 1 L of 
urine was passed through the column, followed by 2 L of the 50-fold diluted phosphate buffer 
(pH 2 5) The column was dried by air suction for 10 mm 
Elution of the column was carried out by a mixture of methanol-1% acetic acid according to 
the following scheme First, 500 ml СНзОН-АсОН (20 80, V/V) was passed through the 
column, followed by 8 fractions of 250 ml with the methanol concentration increased by steps 
of 10% to 100%CH30H 
The effluent fractions 5 to 8 (60 40 90 10%, V/V) contained the sulphamethoxazole metabo­
lites 
This procedure was repeated with the second liter of urine on a regenerated column, and frac­
tions 5-8 from both procedures were combined Methanol was evaporated under reduced pres­
sure The combined effluent was brought onto the column, and the gradient elution was repe 
ated Most of the yellow brown urine color had now been removed, together with the parent 
compound and its N4-acetyl conjugate 
Preparative high performance liquid chromatography 
The volume of the isolated fraction from the preparative column was concentrated to 130 ml 
by evaporation under reduced pressure (Rotavapor) 
The preparative Cilson HPLC consisted of a Gilson 302 sample pump (Cilson, Meyvis, Bergen 
op Zoom, Netherlands), two 305 Cilson gradient pumps, a 811 В Dynamic mixer, a Kratos 757 
UV detector (Separations, Hendrik Ido Ambacht, Netherlands), an LKB 2211 superrac fraction 
collector (LKB, Woerden, Netherlands), and a BD7 recorder (Kipp & Zonen, Delft, Netherlands) 
The column was a C8, 8 pm particle size, 250 mm χ 10 mm ID, Ramm Dynamax 60 Ä column 
(Meyvis) 
The mobile phase consisted of 1 % acetic acid m water and acetomtnle (85 15%, V/V) for one 
mm at the start, thereafter changing linearly in 20 mm to 65 35% (V/V) The flow rate was 
4 7 ml/mm and peaks were detected at 271 nm 
Concentration of the separated metabolites was carried out on an IKA rotavapor (Janke and 
Kunkel, Staufen, Germany) equipped with a Trivac vacuum pump (Leybold-Heraeus, Woerden, 
Netherlands) Three crude samples each containing a metabolite were collected 
Final purification by preparative HPLC 
Sulphamethoxazole-N 1 -glucuronide (Sgluc) 
First isolation The mobile phase was methanol-1% AcOH (27/73%, V/V), at a flow rate 
of 4 7 ml/mm 
Second isolation The mobile phase started with a composition of acetonitnle-1% AcOH 
(5 95, V/V) and this was changed linearly in 20 mm to acetonitnle-1% AcOH (40 60 
V/V) The collected sample was concentrated to 20 ml under reduced pressure with the 
rotavapor, and thereafter reduced in volume in a smaller flask to 0 5 ml The final volume 
of О 5 ml was transferred to a small tube for freeze drying 
5-Hydroxysulphamethoxazole (SOH) 
First isolation Starting with a mobile phase of methanol-1% AcOH (20 80, V/V), the 
mobile phase changed linearly in 12 mm to methanol-1% AcOH (40 60, V/V) 
Second isolation Starting with a mobile phase of acetonitnle-water (10 90, V/V), the 
mobile phase was changed linearly in 15 mm to acetonitnle -water (35 65, V/V) 
The collected sample was concentrated to 20 ml under reduced pressure with the rotava-
por, thereafter further reduced in a smaller flask to 0 5 ml The final volume of 0 5 ml was 
transferred to a small tube for freeze drying 
N4-acetyl-5-hydroxysulphamethoxazole (N4S0H) 
First isolation Starting with a mobile phase of acetonitnle AcOH (20 80, V/V), the mobile 
phase was changed linearly in 12 mm to acetomtnle-AcOH (32 68, V/V) 
Second isolation Starting with methanol-water (40 60, V/V), the mobile phase changed 
linearly in 8 mm to methanol-water (60 40, V/V) 
The collected sample was concentrated to 20 ml under reduced pressure with the rotava-
por, thereafter reduced in volume in a smaller flask to 0 5 ml The final volume of 0 5 ml 
was transferred to a small tube for freeze drying 
Identification of the metabolites 
Mass spectrometry 
A double focussing VC 7070E mass spectrometer with direct inlet was used (Fisons 
Instruments, Weesp, Netherlands) El (70eV), positive CI methane (100 eV), and FAB 
(matrix nitrobenzylalcohol, Argon, acceleration voltage 6-7KV) were performed 
Nuclear magnetic resonance 
' H-NMR spectra were recorded on a Bruker AM 400 spectrometer (400 MHz,FT, Bruker, 
Wormer, Netherlands) on solutions in CD30D/CDCI3 (internal standard Me4Si) 13C-NMR 
spectra with ' Η-decoupling were recorded with a Bruker AM 400 spectrometer operating 
at 100 6 MHz on solutions in CD30D/CDCI3 (internal standard Me4Si) Chemical shift 
values are reported as ò-values relative to Me4Si as internal standard, 
deuteromethanol/deuterochloroform were used as solvents 
Elemental analysis 
A Carlo Erba EA 1108 element analyzer (Interscience, Breda, Netherlands) was used for 
CHNS elemental analysis 
Infrared spectrometry 
Infrared spectra in KBr were recorded on a Perkm Elmer 881 infrared spectrophotometer 
(Perkin Elmer, Couda, Netherlands) 
Deconjugation 
Deconjugation reactions with ß-glucuromdase (urine-ß glue-buffer 1 1 8, V/V/V, 9 days, 
37°C) were carried out 
Four different R-glucuronidase enzymes were tested (all from Sigma, St Louis, MO, USA) 
A 20000 U/ml ß-glucuronidase type Bl (Bovine liver, Cat No С 0251) in phosphate 
buffer at pH 5 0 
В 120600 U/ml ß-glucuronidase type H2 (Helix pomatia, Cat No C-0876) in phosphate 
buffer at pH 5 0 
С 100000 U/ml β glucuronidase type LM (lyophilized powder from limpets Patella vulga 
ta, Cat No С 8132) m phosphate buffer at pH 3 8 
D 20000 U/ml ß glucuronidase type VIIA (Escherichia coli, Cat No G 7646) in phospha 
te buffer at pH 6 8 
Deconjugation reactions with 5 M HCl (urine HCl, 1 1, V/V, 75°C 1 h) were carried out 
Limits of quantitation 
The limits of detection m water and quantitation of sulphamethoxazole and its metaboli 
tes in plasma and urine were determined at a signal to noise ratio of 3 
Standard solutions 
Standard solutions of S and the metabolites were prepared as follows 
S 9 58 mg/ml in DMF N4 9 59 mg/ml in DMF, N40H 2 62 mg/ml in methanol with 1 
mg Vitamin С, N4S0H 1 16 mg/ml in ethanol, Sgluc 3 0 mg/ml in water, SOH 0 43 
mg/ml in water 
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Recovery 
A calibration curve of 4 concentrations (0 1 60 мд/ml) of S and its metabolites m 0 9% 
NaCI solution was compared with a calibration curve of the same concentrations in plas 
ma All samples were treated with acetonitnle 1 1 (V/V) 
Pharmacokinetics 
The pharmacokinetic parameters were calculated using the MediWare" computer package 
[20] 
Results 
Identification Metabolites of S were detected in a urine sample of a volunteer after oral 
intake of 800 mg of S (Fig 2 and Table I) 
Three metabolites of S were isolated from the human urine sample SOH, N4S0H and 
Sgluc) The isolated compounds were identified as described below 
Sulfamethoxazole in urine 
149 ua/ml 
N4OH 22 9 ug/ml 
I 1 1 1 1 1 1 
0 10 20 30 mm 
Figure 2 
Chromatogram of human urine sample from a 
healthy human subject obtained 1 h after admini 
stration of a single oral dose of 800 mg S contai 
ning sulfamethoxazole (S) and the metabolites 
N4 acetylsulfamethoxazole (N4) 5 methylhydroxy 
sulfamethoxazole (SOH) N4 hydroxysulfamethoxa 
zole (N4OH) N4 acetyl 5 methylhydroxysulfamet 
hoxazole (N40H) and sulfamethoxazole N1 glucu 
ronide (Sgluc) H is hippuric acid 
5-Hydroxysulphamethoxazole (SOH) 
Figure 3 shows the El mass spectra of S and SOH. The mass spectrum of SOH 
(C10H11N304S, MW 269) reads· m/z, relative intensity; 269 [M+ ] 9.5% , 174, 30 1%, 
156, 86.3%; 108, 60%; 92, 100% 
The mass spectrum of S (Cl0HiiN303S, MW 253) reads m/z, relative intensity; 253 [M+ ] 
9 5% , 156, 70.5%; 108, 65%; 92, 100%. 
NMR spectrum of SOH in CD30D/CDCI3 (18, V/V) reads 
ò=7 61 ppm (2H,d,HA+HA\ JAB=8 8 Hz); 6.64 ppm (2H,d,HB+HB', JAB=8 8 Hz), 6 33 ppm 
(1 H,S,HD); 4.56 ppm (2H,s,Hc). 
The NMR spectrum of S in CD30D/CDCI3 (11 , V/V) reads: 
0=7 59 ppm ( 2 Н Д Н А + Н А ' , JAB = 7 0 Hz), 6 64 ppm (2НДНв+Нв\ JAB = 7 0 Hz), 6 08 ppm 
(1H,S,HD), 2.31 ppm (3H,s,Hc). 
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N4-acetyl-5-methylhydroxysulphamethoxazole (N4SOH) 
The methane chemical ionization mass spectrum of N4SOH (C12H13N3O5S, MW 311) 
showed m/z values of 296 [MH+-CH4] 4.5%, 312 [M+H+] 3.5% and 328 [MH++CH4] 
0.12%; base peak 43, 100%. 
For N4 (C12H13N3O4S, MW 295), the mass spectrum showed the m/z values of 296 
[M+H+] 100% and 311 [MH++CH4] 4 2%. 
NMR spectrum of N4SOH m CD3OD reads 
0=7.82 ppm (2H,d,HA+HA', JAB=8.8 HZ); 7.71 ppm (2H,D,HB+HB' , JAB=8.8 HZ); 6.28 ppm 
(1 H,S,HD), 4 52 ppm (2H,s,Hc), 2 14 ppm (3H,S,HJ) (fig.4.). 
The NMR spectrum of N4 in CD30D/CDÜ3 (1:1, V/V) reads. 
ò=7.80 ppm (2H,d,HA+HA', JAB = 8.8 Hz); 7 69 ppm ( 2 H , D , H B + H B \ JAB = 8.8 Hz), 6.06 
ppm (1H,S,HD), 2 29 ppm (3H,s,Hc); 2 13 ppm (3H,S,HJ). 
Hydrolysis- Acid hydrolysis of N4S0H in 5M HCl (1 h, 70°C) resulted in SOH according to 
HPLC analysis. 
Sulphamethoxazole-Nl-glucuronide (Sgluc) 
The FAB mass spectrum of Sgluc (Ci6Hi9N309S, MW 429) reads, m/z values 430 [M++H] 
5%, 308, 22%, 273, 30%; 176, 15%; 155, 100%. A mass fragment m/z 452 [M++23] 
14% shows the presence of Na 
The NMR spectrum of Sgluc in CD30D/CDCI3 (1:1, V/V) reads ò =7 52 ppm 
(2H,D,HA+HA', JAB = 8.8 Hz), 6 61 PPM (2H,D,HB+HB\ JAB = 8.8 Hz), 6 08 PPM (1 H,S,HD); 5.32 
(1 H.D.HI, JHI= 9.2 Hz); 3 91 PPM (1 H,D,HE, JEF = 9.4 Hz), 3 54 PPM (1 Η,τ,Ηο, JFC=9.0 Hz, 
JCH=9.0 Hz), 3.47 PPM (1 H,T,HF, JFG= 9.0 Hz, JEF=9.4 HZ), 3 21 PPM (1 Η,Τ,ΗΗ, JCH=9.0 HZ, 
JHI=9.2 HZ), 2.39 PPM (3H,s,Hc). 
The '^C NMR spectrum of Sgluc, shown in Table II, elucidates the presence of a ò-glucu-
ropyranoyl group and an intact sulphamethoxazole moiety. 
Elemental analysis of Sgluc: 
Proposed structure: C16H19N3SO9, MW 429 Calculated percentages: С 44 75%, Η 
4 46%, Ν 9.79%, S 7.47%. Found percentages С 42.62%, H 4 29%, Ν 8.61% and S 
6.51%. 
The IR spectrum of Sgluc shows a carbonyl moiety at 1724 nm and sulphone absorption 
at 1594 and 1620 nm 
Hydrolysis of Sgluc with ß-glucuronidase (type Lll) proceeded very slowly. After 2 weeks 
50% was hydrolyzed (fig 4) 
Table I shows the retention times, the capacity factors of parent drug and its metabolites 
and group contributions to the retention behaviour. Introduction of the hydroxyl group in 
the sulphamethoxazole isoxazoyl structure reduces the capacity factor by a factor of 0.56. 
Introduction of the acetyl group in the sulphamethoxazole structure increases the capacity 
factor by a factor of 1 27. 
Fig. 2 and fig. 5 show the chromatograms of a human plasma and urine sample respecti-
vely after oral administration of 800 mg S The chromatograms show the presence of S 
and its metabolites. Table III shows the equations of the calibration curves of sulphamet-
hoxazole and its metabolites in plasma and urine. Table IV shows the limits of detection 
in water and limits of quantitation in plasma and urine of S and its metabolites. 
Samples of pH 5 and kept in the dark were stable in the autosampler of the HLPC during 
24 h. Sgluc was stable for 9 days when kept at pH 3.8, pH 5 0 and pH 6.8. Sgluc could 
be hydrolyzed slowly by ß-glucuronidase Lll as shown in fig. 4. 
Table V and VI show respectively the intra and inter day variations of S and its metaboh 
tes in urine 
Table VII and VIM show respectively the intra and inter day variations of S and its meta 
bolites in plasma 
Fig 6 shows the plasma concentration time curves of S and the metabolites and fig 7 the 
renal excretion rate time profiles of S and its metabolites after a single oral administra 
tion of 800 mg of S in one male volunteer 
Table IX summarizes some pharmacokinetic parameters of S calculated from the plasma 
and urine concentrations of parent drug and metabolites in the pilot experiment after a 
single oral administration of 800 mg S to the human volunteer 
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Renal excretion rate-
time profiles and 
cumulative excreted 
amounts (% mol 
dose) of sulfa-
methoxazole (S), sul 
famethoxazole-Ni glu-
curonide (Sgluc), 5 
hydroxysulfa 
methoxazole (SOH), 
N4 acetylsulfame 
thoxazole (N4) 
N4 acetyl-5-methylhy-
droxysulfamethoxazo 
le (N4S0H), and N4-
hydroxylsulfamethoxa 
zole (N40H) in a 
healthy human sub 
ject after a single oral 
dose of 800 mg of 
sulfamethoxazole 
80 h 
Table I 
Retention times (tR) and capacity factors (k') of sulphamethoxazole, its metabolites and 
conjugates. 
Compound 
to 
Hippunc acid 
SOH 
S-glucuronide 
N4 SOH 
N4 OH 
S 
N4 
tR 
(mm) 
2 20 
12 29 
13 67 
18 50 
20 61 
2161 
22 60 
28 07 
4 59 
5 21 
741 
8 3 6 
8 82 
9 27 
1176 
^ Ratio 
+OH 
0 56 
0 71 
127 
•acetyl 
160 
HPLC conditions see under Gradient HPLC analysis 
Abbreviations Sulfamethoxazole (S), N4-acetylsulfamethoxazole (N4), 5 methylhydroxysulfamethoxazole (SOH), 
N4 hydroxysulfamethoxazole (N40H), N4-methylhydroxysulfamethoxazole (N4SOH), and sulfamethoxazole Nl glucu-
ronide (Sgluc) 
Table II 
Summary of the ' 3 C chemical shifts and assignments of sulphamethoxazole (S), sulphamethoxazole-Nl-glu-
curonide (Sgluc) and beta-D-glucuronopyranoic acid (24) 
С 
Aromatic ring 
Ci 
CA 
Cî+Сб 
Сз+Cs 
isoxazoyl ring 
Cr 
Ci 
C4 
Cs 
Glucuronide ring 
Cr 
C2-
Сз-
Cr­
es­
ce-
M 
s 
s 
d 
d 
s 
d 
s 
q 
d 
d 
d 
d 
d 
s 
η 
1 
1 
2 
2 
m/z (ppm) 
S 
1575 
169 8 
128 5 
1129 
124 9 
94 7 
152 2 
113 
Sgluc 
1568 
170 3 
129 9 
112 7 
123 7 
86 9 
152 6 
118 
102 3 
76 4 
76 3 
70 6 
69 4 
170 9 
QDg 
96 9 
76 3 
75 4 
74 7 
72 2 
173 8 
В  glucurono pyranoic acid 
TMS tetramethylsilane (0 ppm) 
M multiplicity in " с (s=singlet, d=doublet, q-quartet, DEPT distortionless enhanced polarization transfer) 
η number of С atoms 
Table III 
Calibration curves of sulphamethoxazole and its metabolites 
Plasma 
SOH 
Sgluc 
N4S0H 
N4ÛH 
S 
N4 
Urine 
SOH 
Sgluc 
N4S0H 
N40H 
S 
N4 
Concentration 
Mg/ml 
0 20-1 31 
0 4030 
0 20-1 16 
nd 
0 20 66 3 
0 20 15 9 
3 5 39 
4 1 75 
19 35 
14 34 
1 5 200 
1 4 476 
Curve 
y=288x 4 10 
y=151x996 
y=342x+4 71 
y=392x43 6 
y»376xl2 6 
y=87 9x19 0 
y=46 1x178 
У-86ІХ+28 8 
y-61 Ox+46 5 
У-971Х300 
y=91 2x 444 
Correlation 
(0 
0 9997 
0 9984 
0 9996 
0 9999 
0 9999 
0 9993 
0 9992 
0 9994 
0 9993 
0 9989 
0 9996 
Peak height y (integration units) and concentration χ (pg/ml) η d =not detected 
Table IV 
Recovery and limits of detection and quantitation of sulphamethoxazole and its metabolites. 
Compound 
SO H 
Sgluc 
N4SOH 
N4OH 
S 
N4 
Detection limit 
in water ^ g / m l ) 
0 064 
0 150 
0 060 
0 120 
0 035 
0 035 
Quantitation hmit (pg/ml) 
Urine Plasma 
3 5 0 20 
4 1 039 
19 0 13 
14 018 
15 010 
14 010 
Recovery of deprotemization in plasma (n=4) 
Recovery (%) CV (%) 
S 99 6 5 3 
SOH 96 4 6 6 
N4 100 6 3 9 
N4SOH 92 8 5 9 
Sgluc 100 6 5 9 
Detection limit in water, quantitation limit in the biological matrix 
Table V 
Intra-day coefficient of variation (%CV) of spiked sulphamethoxazole and its metabolites in human urine 
(n=5, in vitro). 
Compound 
SOH 
Sgluc 
N4SOH 
N4OH 
N4 
Concentration 
added 
(pgXml) 
19 58 
3915 
3738 
74 75 
1733 
34 65 
1705 
34 10 
199 
99 45 
198 9 
4 76 
2378 
475 5 
ition 
ured 
/ml) 
19 84 
40 23 
37 53 
78 39 
1704 
35 50 
16 43 
35 46 
2 06 
100 6 
200 2 
517 
244 2 
475 8 
Precision 
(%CV) 
30 
20 
51 
37 
34 
24 
23 
20 
89 
33 
32 
40 
3 1 
52 
Accuracy 
(%) 
50 
28 
04 
49 
17 
25 
36 
40 
35 
1 1 
0 66 
86 
27 
0 06 
3* 
> 
Table VI 
Inter day coefficient of variation (%CV) of spiked sulphamethoxazole and its metabolites in human urine 
(n=7, in vitro) 
Compound Concentration Concentration 
added measured 
(pg/ml) (pg/ml) 
19 58 1833 SOH 
Sgluc 
fuSOH 
N4ÛH 
N4 
39 15 
3738 
74 75 
1733 
34 65 
1705 
34 10 
1 99 
99 45 
1989 
4 76 
2378 
475 5 
38 51 
3706 
75 78 
18 54 
33 01 
1770 
35 14 
197 
100 2 
1966 
4 79 
2376 
465 3 
P'ecision 
(%CV) 
82 
3 4 
31 
3 8 
42 
34 
18 
17 
65 
35 
32 
56 
23 
28 
Accuracy 
M 
6 4 
16 
0 9 
14 
7 0 
4 7 
3 8 
3 1 
10 
0 7 
12 
0 7 
0 1 
2 2 
Table VII 
Inter-day coefficient of variation (%CV) of spiked sulphamethoxazole and its metabolites in human plasma 
(n=5, in vitro) 
Compound 
50H 
Sgluc 
N4SOH 
N4 
Concentration 
added 
fog/ml) 
0 52 
104 
120 
2 39 
0 46 
0 92 
5 30 
26 5 
53 0 
127 
6 34 
12 68 
Concentrai 
measu 
(pg/ 
:ion 
red 
ml) 
0 58 
112 
1 29 
2 67 
0 52 
0 94 
5 46 
28 0 
54 2 
131 
6 83 
134 
Precision 
(%CV) 
25 
15 
51 
20 
123 
99 
13 
1 1 
14 
20 
1 1 
13 
Accuracy 
(%) 
10 5 
77 
75 
117 
12 6 
1 7 
2 9 
5 6 
2 2 
3 3 
77 
5 7 
Table Vili 
Inter-day coefficient of variation (%CV) of spiked sulphamethoxazole and its metabolites in human plasma 
(n=7, in vitro) 
Compound Concentration Concentration 
measured 
SOH 
Sgluc 
N4SOH 
N4 
added 
(Mg/ml) 
0 52 
104 
120 
2 39 
0 46 
0 92 
5 30 
26 5 
53 0 
1 27 
6 34 
12 68 
r  
ml) 
0 56 
1 13 
128 
2 54 
0 48 
0 92 
5 42 
28 3 
54 9 
128 
6 75 
13 2 
Precision 
(%CV) 
30 
35 
44 
19 
130 
95 
25 
35 
21 
19 
29 
20 
Accuracy 
(%) 
73 
87 
67 
63 
28 
09 
22 
67 
35 
10 
65 
4 1 
Table IX 
Some pharmacokinetic parameters of sulphamethoxazole, its metabolites and conjugates from a healthy 
subject after a single oral administration of 8 0 0 mg sulphamethoxazole. 
Parameter Value 
Subject A Gender male 
Body weight (kg) 85 
Dose (mg) 800 
CMAX (pg/ml) 51 4 
tMAx(h) 0 5 
WABSORPTION (h) 0 05 
ta (h) 
5 9 6 
N4 10 6 
N4SOH 12 8 
MRT S (h) 14 0 
Total oral body clearance (L/h) О 87 
Volume of distribution (L) 12 1 
Percentage of the dose excreted (% mol) 
5 15 3 
SOH 3 4 
N4 45 5 
N4OH 0 9 
N Í S O H 5 8 
Sgluc 8 4 
Total 79 3 
Urinary pH kept acidic (between pH 5 0 and 6 0) 
Discussion 
The metabolite SOH was previously identified by Rieder [2,21], Ueda et al [6-9] and 
Woolley et al [IO ] Vree et al isolated this metabolite by preparative TLC from dog urine 
Dog's urine is relatively easy to analyse, because they are unable to acetylate sulphonami-
des [4,5,22] 
N4S0H was detected in urine by Rieder [2,11], by Woolley et al in renal calculi [10], and 
was observed in plasma of Pneumocystis carimi patients by Vree et al [23] This comp-
ound could easily be recognized because acidic hydrolysis of the isolated product resulted 
in SOH Other reported conjugates of S were the N4 glycolylsulphamethoxazole, sulpha 
methoxazole-Ni-glucuronide and the N glucuromde at the isoxazoyl ring [2,3,21] In all 
studies, the presence of an N glucuromde was reported The N-glucuronides can be hydro-
lyzed by ß-glucuronidases, as reported for the methoxysulphonamides sulphadimethoxine 
[15,16], sulpha 6-monomethoxine [17], sulphamethomidme [18] and sulphaphenazole 
[19] Of the four ß-glucuronidase systems tested, systems С and D were the most active 
ones for N-deglucuronidation of these methoxysulphonamides [15-19] 
Sgluc was only partly vulnerable to enzymatic hydrolysis by the ß glucuronidases tested 
Hydrolysis proceeded very slowly and would have been completed after approximately one 
month of reaction time, but after 2 weeks, the most active of the tested ß glucuronidases 
(Lll, system C) had lost its activity (fig 4) This enzyme was the most active in hydrolysmg 
the Ni-glucuronides of the methoxysulphonamides [15-19] Enzyme H2 (B) produced a 
similar result 
The '^C NMR spectrum showed a ring structure with 5 carbon atoms, resembling the 
spectrum of the reference compound glycuronopyranoic acid [24] The glucuromde group 
was not attached at the N4 or the N atom of the isoxazoyl group, as the two unsaturated 
bonds were still present (fig 1 ) 
In conclusion, the hydroxy metabolites of sulphamethoxazole, 5 methylhydroxysulpha-
methoxazole and N4-acetyl-5-methylhydroxysulphamethoxazole, were isolated and structu-
re analysis could be compared with those reported in the literature The N-glucuromde of 
sulphamethoxazole that was isolated was the Ni glucuromde, according to the " c NMR 
spectrum obtained 
The analysis of S and metabolites in human plasma and urine samples can be easily per-
formed with gradient HPLC with UV detection In plasma only the parent drug and N4-
acetyl metabolite were detected at higher concentrations, while the metabolites were pre 
sent as traces In urine parent drug and the metabolites were quantitated The method is 
in current use in pharmacokinetic studies in healthy subjects and HIV positive patients on 
prophylactic treatment with sulphamethoxazole/trimethoprim 
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Chapter 4 
Formation and elimination of sulphamethoxazole 
hydroxylamine after oral administration of sulpha-
methoxazole. 
AJAM van der Ven, MA Mantel, TB Vree, PP Koopmans, JWM van der Meer 
Br J Clin Pharmac 1994, 38 147-150 
Abstract 
The formation and elimation of sulphamethoxazole hydroxylamine in relation to the phar-
macokinetics of the parent compound and its N4-acetyl metabolite were investigated in 
six healthy subjects after a single oral dose of 800 mg sulphamethoxazole The apparent 
half-lives of sulphamethoxazole and its metabolites were approximately 10 h, indicative of 
formation rate-limited metabolism The mean residence time of the hydroxylamine meta-
bolite was 5 5 ± 1 5 h The renal clearance of sulphamethoxazole hydroxylamine was 4 39 
± 0 91 L/h The urinary recovery of sulphamethoxazole accounted for 16 5 ± 5 5% of the 
dose, N4-acetyl-sulphamethoxazole for 46 2 ± 6 6% and the hydroxylamine metabolite for 
2 4 ± 0 8% The remaining 35% of the dose was unaccounted for Acetylator phenotype 
was determined using sulphadimidme The renal excretion of sulphamethoxazole hydroxyl-
amine was 1 9 ± 0 9% in slow acetylators (n=3) and 2 8 ± 0 3% in fast acetylators (n=3), 
for N4-acetyl-sulphamethoxazole the values were 48 ± 6% and 44 ± 8%, respectively 
Sulphamethoxazole is metabolized, although to a limited extent, to a hydroxylamine met-
abolite This metabolite may be important for the pathogenesis of adverse reactions 
Introduction 
The high incidence of side effects to sulphamethoxazole (S) in individuals infected with 
the human immunodeficiency virus (HIV) (1) has renewed interest in the metabolism of 
this drug It is postulated that the hydroxylamine metabolite (N4OH) is critical in the 
pathogenesis of adverse reactions to sulphonamides (2 7) In HIV seropositive individuals, 
the detoxification capacity for reactive products of sulphonamide metabolism seems to be 
decreased owing to glutathione deficiency (8) Although N4OH may be an important met-
abolite, in vivo data on its formation and elimination are limited (6,9,10) 
Sulphamethoxazole hydroxylamine (N4OH) results from the hydroxylation of the para 
amino group of S, a cytochrome P450-dependent reaction (6) Besides hydroxylation, the 
para-ammo group of S can also be acetylated resulting in the parallel formation of N4-
acetyl-sulphamethoxazole (N4) (11) N-acetyl transferase exhibits a marked genetic poly­
morphism and the rate of acetylation of some sulphonamides (sulphadimidme, sulphame-
razine, sulphadiazine, and sulphapyndine) depends on the acetylator phenotype (11) A 
prominence of the slow acetylator phenotype has been reported in patients with hyper­
sensitivity reactions to sulphonamides (12) However, for some sulphonamides (like S) slow 
and fast acetylators have not been distinguished (11) 
In this study we document the formation and elimination of sulphamethoxazole hydroxy-
lamine in relation to the kinetics of the parent compound and the N4-acetyl metabolite in 
healthy subjects (3 slow, 3 fast acetylators) 
Methods 
Subjects 
Six Caucasians (4 males, 2 females) ranging in age from 23 to 50 years (mean 34 years) 
participated after approval of the study by the Ethics Committee of our university hospi­
tal Written informed consent was obtained from all participants All subjects were drug-
free and healthy by history, physical examination and routine biochemical assessment An 
800 mg dose of sulphamethoxazole was administered orally in 2 gelatine capsules on an 
empty stomach after an overnight fasting 
Sampling procedures 
Blood samples were obtained by fingertip puncture at 1, 2, 4, 6, 8, 10, 12, 24, 32, 36, 
and 48 hours after drug administration Plasma was separated immediately by centrifuga­
r o n and stored at 20°C until analysis Urine was collected over 96 hours and three 5 ml 
aliquots were stored immediately at 20°C until analysis 
Acetylator phenotype 
Volunteers were phenotyped using sulphadimidme as described previously (13) 
Chemicals 
S and N4 were obtained from Hoffmann LaRoche, Mijdrecht, the Netherlands N40H was 
obtained from Synthon BV, Nijmegen, the Netherlands All other chemicals were of analy 
tical purity and were obtained from commercial sources 
Drug analysis 
S and its metabolites were assayed by HPLC using a Spectra Physics SP8810 pump 
(Eindhoven, the Netherlands), a 757 Separations UV detector (Hendrik Ido Ambacht, the 
Netherlands) and a C8 (5μπι) column (Synthon, Nijmegen, the Netherlands) (250 mm χ 4 
mm ID) The mobile phase consisted of 45 ml of a mixture of 20 g orthophosphoric acid 
and 5 g tetramethylammoniumchloride in 1 I water, 45 ml dimethylformamide and 180 
ml acetonitnle, adjusted to 1 I with water The mobile phase was degassed with helium 
before use The flow rate was 1 5 ml/mm Detection was at 271 nm The retention times 
of N40H, S, and N4 were 8 6, 10 1, and 13 3 mm, respectively, and the chromatographic 
peaks were identified using authentic standards Intra- and mterday variation in the assay 
of both samples and standards was < 5% Quantitation limits, determined with a signal-
to-noise ratio of 3, for S, N4, and N40H were 0 0055, 0 01, and 0 01 pg/ml, respectively, 
m plasma and 0 10 pg/ml for all compounds in urine The hydroxylamme metabolite was 
stable m anaerobic plasma and urine 
Sample preparation 
After thawing, the sample (100 μΙ) was diluted with 900 μΙ 0 33 M trichloroacetic acid, 
centnfuged at 3000g, and the supernatant injected onto the column 
Data analysis 
Renal clearances were calculated from urinary recoveries of the compounds (corrected for 
molecular weight) divided by the corresponding AUC values Curve fitting to a one com­
partment model with first order drug absorbtion was carried out using the Medi-ware® 
computer program (15) AUC values were calculated using the linear trapezoidal rule with 
extrapolation to infinity using C(last)/k2 Oral clearance (CLo) of S and mean residence 
time (MRT) were calculated by standard methods (14) 
Statistics 
The Mann-Whitney test was used to compare results Pearson correlation coefficients were 
calculated Differences were considered significant when p<0 05 
Results 
Plasma concentrations and renal excretion rates of S, N40H and N4 in a representative 
subject are shown in Fig 1 Mean pharmacokinetic parameters are summarised in Table 1 
The elimination half-life of S was 9 5 h while the half-lives of N4 and N40H were 11 1 
and 11 2 h, respectively (NS) The mean residence time of S was 14 0 h and those of N4 
and N40H formed from S were 5 5 and 5 1 h, respectively 
Plasma concentrations 
and renal excretion 
rates of sulphamet 
hoxazole (S) and its 
N14 acetyl (N4) and 
hydroxylamme meta 
bol,tes (NI40H) m one 
subject after an 800 
mg oral dose of sulp 
hamethoxazole 
plasma concentration ug/jrnl 
- renal excretion rate идЛпіп 
800 mg Sulfamethoxazole p.o. 
N 4 54.4% 
S 8.2% 
The urinary recoveries of parent drug and metabolites were similar in all subjects. 
Sulphamethoxazole accounted for 16.5 ± 5.5% (percentage ± SD) of the dose, N4, for 
46.2 ± 6.6%, and N40H, for 2.4 ± 0.8%. Three subjects acetylated sulphadimidine rapidly 
and three slowly. Renal excretion of N40H accounted for 1.9 ± 0.9% of the dose of S in 
the slow acetylators and 2.8 ± 0.3% in the fast acetylators. For N4, the values were 48 ± 
6% and 44 ± 8%, respectively. 
The clearance (metabolic- and renal clearance) of S was 1.21 ± 0.21 L/h. The mean renal 
clearance of S was 0.22 ± 0.05 L/h, which differed significantly from that of N4 (2.45 ± 
0.35 L/h) and N40H (4.39 ± 0.91 L/h) (paired -t-test, p<0.05). The renal clearance of S 
but not of its metabolites correlated with the urine pH (S, r= 0.91, all samples). 
Table. 
Mean (± SD and range) of pharmacokinetic parameters describing the fate oF sulphamethoxazole in six 
healthy subjects. 
Parameter 
СмАх(мд/тІ) 
fMAX (h) 
fZ,z(h) 
MRT (h) 
MRT(m) (h) 
AUC (mg. L"1 h) 
Ciò (lyh) 
CLR(L/h) 
Ae(~)(%) 
Mean ±SD 
46.9 ± Θ.7 
0.7* 
9 5 ± 0.7 
14.0 ±0.9 
675 ±102 
1.2 ± 0.2 
0.22 ± 0.05 
16.5 ±5.5 
S 
(Range) 
(35.6-61.4) 
(0.6-1.6) 
(8.7-10.5) 
(12.B-15.4) 
(501-813) 
(1.0-1.6) 
(0.14-0.28) 
(8.3-23.4) 
r 
Mean ± SD 
8.1 ± 1.1 
5.7* 
11.1 ±1.4 
5.5 ±1.5 
189 ±29 
2.45 ±0.35 
46.2 ± 6.6 
44 
(Range) 
(6.5-9.1) 
(5.1-9.0) 
(9.3-13.4) 
(2.8-6 7) 
(161-227) 
(1.91-2.97) 
(36.9-54.4) 
N40H 
Mean ± SD 
0.3 ± 0 1 
2.9* 
11.2 ±1.2 
5.2 ±1.7 
6±1 
4.39 ± 0.91 
2.4 ± 0.8 
(Range) 
(0.2-0.4) 
(2.1-8.1) 
(9.8-12.2) 
(3.2-6.4) 
(4-7) 
(3.44-5.5!) 
(0.9-3.2) 
•Median. S* Sulphamethoxazole, N4= N4-acetyl sulphamethoxazole, N40H= sulphamethoxazole hydroxylamine, 
Cmax= Maximum plasma drug concentration, tmax= time at which Cmax occurs, B5, z= plasma half-live, MRT" 
mean residence time, MRT(m)= mean residence time of metabolite (MRT(m)= MRTm - MRT), MRTm= MRT of meta­
bolite after administration of drug, MRT= MRT parent compound, AUC« area under plasma concentration-time 
curve, CLo- oral clearance (Dose/AUC), CLR= renal clearance [Ae(<=) / AUC], Ae(°°)- amount excreted in urine 
(molar). 
Discussion 
Metabolism 
After a single 800 mg oral dose of sulphamethoxazole, the renal excretion of S, N4, and 
N40H accounted for 65% of the dose. The oral clearance of S (1.2 L/h)was much greater 
than its renal clearance (0.2 L/h). The fate of 35% of the dose is unknown. 
The hydroxylamine metabolite accounted for 2.4% of the recovered dose of S, a figure in 
agreement with those reports by others (6,9). Since N40H is unstable and can be oxidised 
to nitroso dérivâtes (15), it is possible that its urinary recovery is less than the amount for-
med in the liver. However, under physiological conditions glutathione prevents the auto-
oxidation of N40H (15). 
Mechanism of renal clearance 
After glomerular filtration, S undergoes net passive reabsorption while N4 undergoes net 
active excretion (16) Urine flow and pH govern passive reabsorption and influence the 
renal excretion of S but not that of N4 This difference in excretion is discernable from 
respective excretion rate time profiles Thus, the excretion rate time curve of N4 was 
smooth and parallel to the corresponding plasma concentration time curve, while that of 
S had an irregular profile The shape of the excretion rate-time profile of N40H was simi­
lar to that of N4 and, in a separate experiment, it was shown that the excretion of N40H 
is not dependent on urine pH (data not shown) This suggests that N40H undergoes limi­
ted passive tubular reabsorption The high renal clearance rates of N4 and N40H compa­
red to that of S are associated with similar apparent half lives 
Acetylator phenotype 
A previous study indicated that S clearance is unrelated to acetylator phenotype (16), and 
we show that the excretion of N4 is similar in both fast and slow acetylators of sulphad 
imidine Overrepresentation of the slow acetylator phenotype has been reported in 
patients with sulphonamide hypersensitivity reactions (12) Thus, it was suggested that in 
slow acetylators more of the parent drug may be available for metabolism by cytochrome 
P450 to the hydroxylamme metabolites (12) However, our data do not indicate an mere 
ased hydroxylamme formation in slow sulphadimidine acetylators, although the number of 
subjects studied was limited 
This study has documented the formation and renal excretion of the N4 acetyl and hydro 
xylamine metabolites of sulphamethoxazole in healthy subjects Sulphamethoxazole hydro 
xylamine may be critical in the pathogenesis of adverse reactions although the contribu­
tion of N hydroxylation to the metabolism of sulphamethoxazole was found to be small 
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Chapter 5 
Pharmacokinetics of sulphamethoxazole with its 
hydroxy metabolites and N4-acetyI-, Ni-glucuronide 
conjugates in healthy human Volunteers. 
TB Vree, AJAM van der Ven, PP Koopmans, EWJ van Ewijk-Beneken Kolmer, 
CPWCM Verwey van Wissen 
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S u m m a r y 
The aim of this investigation was to assess the pharmacokinetics of sulphamethoxazole (S) 
with its hydroxy metabolites (SOH, N4SOH, N4OH) and N4-acetyl (N4) and N1 glucurom-
de (Sgluc) conjugates in seven human subjects after an oral dose of 800 mg using a 
reversed phase gradient HPLC with UV detection Sulphamethoxazole was rapidly and 
completely absorbed and metabolized to 5 metabolites The plasma half life (VA) of elimi­
nation varied for parent drug and its metabolites between 9 7 and 15 hours The protein 
binding of S (67 2%) increases when the compound was acetylated (88%), and decreased 
when it is oxidized at the 5 position (40%) Clucuronidation at the N1 position reduces 
the protein binding to 20% The mam metabolite in urine was N4 (43 5±5 6%) followed 
by S (14 4±3 4%) The percentages of the Sgluc (9 8±2 6%), N4S0H (5 3±1 0%), and SOH 
(3 0±1 0%) did not differ statistically (p=NS) Only 2-3% of the N-hydroxylamme metabo­
lite (N4OH) is excreted The renal clearance values were Sgluc 176±33 ml/mm, SOH 
96 1±23 7 ml/min, N4SOH 51 2±10 4 ml/mm, N4 35 2±5 б ml/mm and S 2 7±0 9 
ml/mm The pharmacokinetic behaviour of the Nl-glucuromde was reported for the first 
time If one of the metabolites is responsible for the occurrence of side effects, then all 
metabolites must be included in this analysis 
Introduction 
The known metabolism of sulphamethoxazole (S) involves acetylation and oxidation at the 
N4 nitrogen atom leading to N4-acetylsulphamethoxazole (N4) and N4-hydroxysulphamet-
hoxazole (N40H)(1 4) The latter compound is thought to be responsible for the occurren­
ce of side effects of cotrimoxazole treatment for Pneumocystis carimi pneumonia in HIV 
positive patients (5) Hydroxylation also takes place at the C5 methyl group, leading to 5-
hydroxysulphamethoxazole (SOH) and N4 acetyl-5-hydroxysulphamethoxazole (N4SOH) 
(3,6-10) The existence of sulphamethoxazole-Ni-glucuromde in urine has been described 
(3,6-10) The molecular structure of sulphamethoxazole and its metabolites are shown in 
fig 1 
Sulphamethoxazole is predominantly eliminated by N4-acetylation, the metabolite being 
eliminated by active tubular secretion (3,11 4) The renal elimination of sulphamethoxazo­
le occurs via the passive renal processes of glomerular filtration minus passive tubular 
reabsorption, implying that the renal clearance depends primarily on the protein binding 
and urine pH, and to a minor extent on the urine flow With acidic urine pH, the renal cle­
arance of sulphamethoxazole is low (2 5 ml/mm), and with alkaline urine pH it is high 
(25 ml/mm) (11-14) 
Recently we investigated the pharmacokinetics of the N-hydroxylamine of sulphamethoxa­
zole in human volunteers by isocratic as well as gradient HPLC and observed the presence 
of the Ni-glucuronide conjugate of sulphamethoxazole (15) 
The pharmacokinetics for Ni glucuronides of sulphonamides have previously been descri­
bed for sulphadimethoxine (16, 17), sulpha-6-monomethoxine (18), sulphamethomidine 
(19), and sulphaphenazole (20), but not yet for sulphamethoxazole Ni-glucuronides of 
sulphonamides can be measured well by direct gradient HPLC analysis 
The aim of this study was to investigate the pharmacokinetics of sulphamethoxazole with 
its hydroxy metabolites, N4-acetyl- and Ni-glucuronide conjugates in human plasma and 
urine by direct gradient HPLC analysis The pharmacokinetic data obtained can thereafter 
be compared to those obtained from HIV positive patients, in order to detect discrepan­
cies in metabolism which may be related with the occurrence of side effects 
Subjects and methods 
Subjects 
Seven human subjects (4 males, 3 females, 4 fast acetylators and 3 slow acetylators of 
sulphadimidine (21), age 30±10 years and bodyweight 75±8 kg, ingested orally a single 
dose of 800 mg sulphamethoxazole in one gelatine capsule (No XX) after an overnight 
fast The study had the approval of the hospital ethics committee, and informed consent 
was obtained from the volunteers 
CDOH 
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Sampling 
Blood samples were collected in heparmized eppendorf vessels (2ml) at regular time inter­
vals during 2 days after administration by means of fingertip puncture with Monolet® lan­
cets (Monoject, St Louis, USA) After centrifuging at 3000 g, plasma samples were stored 
at -20°C pending analysis 
Urine was collected upon untimed voiding The total time of sample collection was 96 h 
Three samples (7 ml) of each void were stored at -20°C pending analysis 
Drug analysis 
Sulphamethoxazolc with all metabolites were analyzed by a direct HPLC analysis as 
described m extenso elsewhere (15) 
Sample treatment 
Plasma samples (ΙΟΟμΙ) were deproteinized with 100 μΙ acetonitnle, centrifuged at 3000 
g, and 20 μΙ of the supernatant was injected onto the column 
Urine samples 
For the measurement of N4-hydroxysulphamethoxazole urine was centrifuged at 3000 g, 
the supernatant was diluted 1 9 with 0 2 M KH2PO4 buffer pH 5 0, and 20 μΙ was injec­
ted onto the column 
For the measurement of sulphamethoxazole and the other metabolites, 50 μΙ diethylamine 
was added to the urine sample of 7 ml (pH 10) to increase the solubility of all sulpho-
namides, centrifuged at 3000 g, and thereafter the supernatant was diluted 1 9 with 0 2 
M K2P04 buffer pH 5 0 
Intraday-interday coefficient of variation 
The intraday and interday coefficients of variation of sulphamethoxazole and its metaboli­
tes were <5 per cent (15) 
Protein binding 
Protein binding (in vitro) of sulphamethoxazole and its metabolites was measured in 
blank plasma samples by means of the Amicon Micropartition system MPS 1 (Grace BV, 
Amicon Division, Capelle aan de IJssel, the Netherlands) The average protein binding was 
calculated from four spiked-plasma samples, equilibrated for 15 mm at 37°C Minimal 
drug binding to the filters was observed 
Drugs 
Sulphamethoxazole and N4-acetylsulphamethoxazole were obtained from Hoffmann-
LaRoche (Mijdrecht, Netherlands) The metabolites 5-hydroxysulphamethoxazole, N4 ace­
tyl 5-hydroxysulphamethoxazole, and sulphamethoxazole-Nl-glucuronide were isolated 
from human urine as described elsewhere (Vree et al 1994) N4-hydroxysulphamethoxazo-
le was synthesized by Synthon (Nijmegen, Netherlands) All other reagents were of pro-
analysi quality and obtained from Merck (Darmstadt, Germany) 
Pharmacokinetics 
Curve fitting was carried out, and pharmacokinetic parameters were calculated using the 
MediWare'* computer package (22) Area under the plasma concentration-time curve from 
zero to infinity (AUCO-00) values were calculated using the linear trapezoidal rule with 
extrapolation to infinity from C(last)/ lambdaz, MRT = AUMC/AUC = Vss/CL + 1/ka + 
tlag, t'/jz=ln2/lambdaz 
where MRT is the mean residence time, AUMC is the area under the moment curve, Vss is 
the apparent volume of distribution at steady state, CL is the total body clearance, ka is 
the absorption rate constant, tlag is the lag time and t'/¿z is the elimination half life 
CLo,parent= FD/AUCo-°° 
where CLo,parent is the oral clearance of the parent drug, and the bioavailability F taken 
as the total percentage of parent drug and metabolites of the molar dose (pmol) excreted 
in the urine 
CLo,metabolite = Fm D/AUCo-=° 
where CLo,metabolite is the oral clearance of the metabolite, and the bioavailability of 
the metabolite Fm is approximately equal to the percentage of the molar dose excreted in 
the urine as metabolite 
Renal clearance Clr = mg excreted/AUCo-«>, which corresponds to the average renal cle-
arance obtained from the renal excretion rate divided by the extrapolated plasma concen-
tration at the midst of the urine collection period (n=5) For the metabolites with a small 
AUCO-°°, the average renal clearance was calculated 
MRT = MRTabsorption + MRTdisposition with MRTabsorption « MRTdisposition 
MRTi= MRTmetabohte - MRTparent, where MRTi is the intrinsic mean residence time, and 
MRTll= MRTmetabohte M - MRTmetabohte l(N4SOH-N4) 
Statistics 
Regression lines, standard deviations, and analysis of variance (ANOVA) were calculated 
according to standard statistical procedures (23) Statistical difference was defined as 
p<0 05 
Results 
Figure 2 shows an example of plasma concentration-time curves and figure 3 the corre-
sponding renal excretion rate time profiles of sulphamethoxazole and its metabolites in 
one male volunteer (no 3) In this particular volunteer, the tV2 of the metabolites in plas-
ma are slightly higher than that of the parent drug Figure 4 show identical half-lives of 
parent drug and metabolites in the plasma concentration-time curves of sulphamethoxa-
zole in another volunteer (no 4) 
Table I summarizes the mean ± SD values of the measured pharmacokinetic parameters of 
sulphamethoxazole in the volunteers 
The lag time indicates the length of time elapsed before the appearance of a measurable 
plasma concentration of drug and metabolites The average sequence of appearance in 
the blood was sulphamethoxazole 0 29±0 41 h, N4 acetylsulphamethoxazole at 0 48±0 49 
h (p=NS), 5 hydroxysulphamethoxazole at 0 74±1 03 h (p=NS), N4-acetyl-5-hydroxysulpha-
methoxazole at 1 11±0 89 h (p=0 028), finally followed by sulphamethoxazole-Ni-glucu-
ronide at 1 21 - 1 00 h (p=0 049, ρ values compared to S) 
The time at which the maximum concentration (CMAX) was reached (ÍMAX) was the shortest 
for the parent drug (1 02±0 84 h), followed by that for sulphamethoxazole Ni-glucuronide 
at 5 5±3 4 h (p=0 0024), N4-acetylsulphamethoxazole at 6 9±1 7 h (pOOOOl), 5 hydro 
xysulphamethoxazole at 9 3±3 8 h (p=0 0004) and N4-acetyl-5 hydroxysulphamethoxazole 
at 10 4±1 7 h (p<0 0001, ρ values compared to S) 
The absorption half life (t'/zabsorption) of sulphamethoxazole was 0 12±0 14 h , which was 
much shorter than the calculated absorption half-lives of the metabolites The t'/iabs of 
N4 acetylsulphamethoxazole (2 3±0 9 h) was identical (p=NS) to that of sulphamethoxa­
zole Ni glucuronide (1 3±1 4 h) The same was observed for the formation of the hydroxy 
metabolites 5-hydroxysulphamethoxazole (4 7±5 0 h) and N4-acetyl-5-hydroxysulphamet-
hoxazole (4 5+2 4 h) (p=NS) 
The plasma elimination i% of elimination varied between 9 6 and 11 h (9 7±1 3 h) for 
parent drug and metabolites The Vh was slightly higher for sulphamethoxazole-Nl-glucu­
ronide (15 2±5 3 h)(p=0 0352) The VA of elimination derived from the renal excretion 
rate-time curves for all compounds was identical to that of the N4-acetyl metabolite 
The mean residence times (MRT) of the metabolites (20 25 h) were higher than that of 
the parent drug (14 4±2 2, p=0 0044) The intrinsic mean residence times (MRTi), defined 
as MRTmetabolite-MRTparent drug, for N4-acetylsulphamethoxazole was 5 7±1 9 h 
(p=0 0006), for sulphamethoxazole-Ni-glucuronide was 9 6+7 6 h (p=NS), for N4-acetyl 5 
hydroxysulphamethoxazole was 10 1+3 0 h (p=NS), and for 5-hydroxysulphamethoxazole 
was 20 6±14 2 h (p=NS, ρ values compared with MRT S) 
The intrinsic MRTM of N4SOH, when it is assumed to be formed from N4 acetylsulphamet­
hoxazole, is 3 9±1 9 h, which did not differ statistically from the MRTi of N4-acetylsulpha 
methoxazole (5 7±1 9h) 
The in-vitro protein binding of sulphamethoxazole is shown in Table 2 The protein bin­
ding of sulphamethoxazole (67 2%) increases when the compound is acetylated (88%), it 
Figure 2 
Plasma concentration 
time curves of sulpha 
methoxazole (S) sulp 
hamethoxazole N1 
glucuronide (Sgluc), 
5 methy'hydroxysulp 
hamethoxazole (SOH) 
N4 acetylsulphamet 
hoxazole (N4) and 
N4 acetyl 5 methylhy 
droxysulphamethoxa 
zole (N4S0H) in a vol 
urteer (поЗ) after a 
single oral dose of 
800 mg of sulphamet 
hoxazole For reasons 
of cleanly only the 
renal excretion rate 
time profile and 
cumulative amount 
excreted (% mol dose) 
of sulphamethoxazole 
is given 
1000-, 
S 11 5% 
decreases when it is oxidized at the 5-position (40%). Clucuromdation at the Nl-position 
reduces the protein binding to 20%. 
Renal clearance 
The main metabolite in urine was N4-acetylsulphamethoxazole (43 5±5 6%) followed by 
sulphamethoxazole (14 4±3 4%) and the Ni-glucuromde (9.8±2.6%) The percentages of 
N4S0H 5 3±1 0% and SOH 3.0±1 0% did not differ statistically (p=NS). Only 2.1 ±0 9% of 
the N-hydroxylamine metabolite (N40H) is excreted. No difference in percentage of meta-
bolites of sulphamethoxazole was found between the fast and slow acetylators of sul-
phadimidine concerning the percentages of metabolites of sulphamethoxazole. 
The highest apparent renal clearance was achieved by sulphamethoxazole-Ni-glucuronide 
with 176±33 ml/mm Corrected for the protein binding the true renal clearance was 240 
ml/mm The renal clearance value of 5-hydroxysulphamethoxazole was 96 1 ±23.7 ml/mm 
which was significantly lower than that of the Ni-glucuromde (p<0.0001) The renal clear-
ance value of N4S0H was 51.2±10 4 ml/mm and for N4-acetylsulphamethoxazole was 
35.2±5 6 ml/mm; these values were not significantly different When corrected for the 
protein binding, the true renal clearance values of 5-hydroxy-, and N4-acetyl-5-hydroxy-
sulphamethoxazole were similar (161 vs 168 ml/mm) The true renal clearance of N4-ace-
tylsulphamethoxazole is similar to that of the Ni-glucuromde (296 vs 240 ml/mm). 
Sulphamethoxazole had the lowest apparent renal clearance of 2 7±0 9 ml/mm and true 
renal clearance of 8.3 ml/mm (Table 3). 
1000 
100-
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I 
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SOH 3.4% 
Figure 3 
Renal excretion rate 
time profiles and 
cumulative amount 
excreted (% mol dose) 
of sulphamethoxazole 
N1 glucuromde 
(Sgluc), 5 methylhy 
d roxysu I pha methoxa-
zole (SOH), N4 acetyl 
sulphamethoxazole 
(N4), N4 acetyl 5 
methylhydroxysulpha 
methoxazole (N<iS0H), 
and N4-hydroxylsul-
phamethoxazole 
(N4OH) in a volunteer 
(no 3) after a single 
oral dose of 800 mg 
of sulphamethoxazole 
For reasons of cleanty. 
the renal excretion 
rate-time profile of 
sulphamethoxazole is 
omitted in this figure 
and shown in figure 2 
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Table 2. 
In vitro protein binding of sulphamethoxazole and its metabolites 
Compound 
Sulphamethoxazole 
5 Methylhydroxysulphamethoxazole 
Sulphamethoxazole N1 glucuronide 
N4 acetylsulphamethoxazole 
N4 acetyl 5 hydroxysulphamethoxazole 
N4 hydroxysulphamethoxazole 
* not stable in plasma 
Abbreviation CV = coefficient of variation 
cone mg/l 
52 0 
9 9 
10 1 
9 6 
116 
* 
Prate in bind 
67 2 
40 3 
26 7 
Θ8 1 
69 5 
* 
ing% CV% 
4 3 
5 4 
1 1 
4 7 
15 
• 
Table 3. 
Apparent and true renal clearance values of sulphamethoxazole and its metabolites 
Compound 
Sulphamethoxazole 
5 Methylhydroxysulphamethoxazole 
Sutphamethoxazole N1 glucuronide 
N4 acetylsulphamethoxazole 
N4 acetyl 5 hydroxysulphamethoxazole 
N4 hydroxysulphamethoxazole 
* Not stable in plasma 
Abbreviation CLr=renal clearance 
C L R APPARENT 
ml/mm 
2 7 ± 0 9 
96 1 ± 2 3 7 
176 ± 3 3 
3 5 2 ± 5 6 
5 1 2 ± 104 
Protein binding 
% 
67 2 
40 3 
26 7 
88 1 
69 5 
CIR TRUE 
ml/mm 
8 3 
161 
240 
296 
168 
Discussion 
Sulphamethoxazole is relatively well absorbed after oral administration The percentage of 
the dose excreted in the urine as parent drug and metabolites varied between 7 0 and 
9 0 % (11-14) The lag time (tLAc) gives the sequence of appearance in plasma and an indi­
cation regarding the dissolution rate and the absorption rate of the parent drug and the 
apparent rate of formation of the metabolites (ZIAG METABOLITE - ÍLAC PARENT) 
The ÍMAX is also a hybrid parameter, determined by the processes of absorption or forma-
tion and the intrinsic rate of elimination Absorption of sulphamethoxazole is readily com-
pleted as the ÍMAX occurs at 1 h, those of the primary conjugates (N4 acetyl-, and Nl-glu-
curomde) occur at 5 to 7 h The oxidation to 5-hydroxysulphamethoxazole and N4-acetyl-
5 hydroxysulphamethoxazole proceeded slower but for a longer period, ÍMAX IS achieved at 
l O h 
The absorption half-life of the metabolites is a hybrid of the rates of formation and elimi-
nation Like the ГМАХ, this variable demonstrates that the rates of formation of N4 acetyla 
tion and N1 glucuronidation were similar (P=0 3 6 ) , and as fast as the oxidation at the 5 
position (P=0 0 8 ) The CMAX and AUCo ~ values of N4-acetylsulphamethoxazole were 10 
times higher than that of sulphamethoxazole-Ni-glucuromde With equal absorption/for 
mation rates and equal rates of elimination by renal clearance, it may suggest that the 
maximun velocity of the capacity-limited process (VMAX) or the enzyme concentration of 
the N-acetylase(s) is 10 times higher than that of the Ni-glucuronyltransferase(s) 
The apparent elimination half-life of all metabolites is similar, as has been demonstrated 
many times previously for sulphamethoxazole and its acyl metabolite (11 14) A slight 
variation in tV2 is observed between S and N4, the tV2 of S is 9 h and the f'/2 of the N4 is 
10 h This occurred when the urine pH of the subject vanes between pH 6-8 and renal cle 
arance of sulphamethoxazole contributes noticeably to the overall oral clearance When 
the tV7 of S was 10 h, it was identical to that of the N4-acetyl metabolite In the latter 
case the rate of acetylation of sulphamethoxazole governs the t'/? of both sulphamethoxa-
zole and of N4-acetylsulphamethoxazole (fig 4) These differences were observed within 
one subject, but do not reach statistical difference in the whole group of volunteers The 
metabolites SOH and Sgluc showed very small AUC values, the plasma concentrations 
were 5-10 times the quantitation limit In these cases, the parallellism of the renal excre-
tion rate-time profiles demonstrated the similarity of the half lives 
When the apparent plasma elimination half lives of the metabolites are identical to that 
of the parent drug, the total body clearances of the metabolites are higher and the intrin 
sic MRT values must be smaller than that of the parent drug, which indeed is the case 
(fable 1) Sulphamethoxazole is eliminated predominantly by metabolic conversion into 
the metabolites, which in turn are eliminated predominantly by renal excretion The acety-
lator phenotype for sulphadimidine did not result in measurable differences in the percen-
tage of the metabolite, nor in differences in the half-lives (13, 14, 21 ) Thus, in the in vivo 
situation an acetylator phenotype for sulphamethoxazole can not be distinguished (24) 
Sulphamethoxazole-Nl-glucuronide and N4-acetylsulphamethoxazole showed the highest 
true renal clearance values as the result of glomerular filtration and active tubular secre 
Hon All metabolites are excreted by active tubular secretion, as their renal clearance valu 
es exceed the glomerular filtration rate Furthermore, urine pH and urine flow have little 
Figure 4 
Plasma concentration 
time curves of sulpha 
methoxazole (S) sul 
phamethoxazole Nl 
glucuromde (Sgluc) 
5 methylhydroxysul 
phamethoxazole 
(SOH) N4 acetylsul 
phamethoxazole (N4) 
and N4 acetyl 5 
methylhydroxysulpha 
methoxazole (N4S0H) 
in a volunteer (no 4) 
after a single oral 
dose of 800 mg of 
sulphamethoxazole 
For reasons of cleanty 
only the renal excre 
Hon rate time profile 
of sulphamethoxazole 
is given 
1000 
S 8 1 % 
effect on the renal clearance, and the renal clearance of N4-acetylsulphamethoxazole can 
be reduced by probenecid co-medication (12,13) The renal clearance of the metabolites 
equalled their total body clearance, indicating that they were not further metabolized 
The renal clearance of sulphamethoxazole-Nl glucuronide is twice that of the calculated 
total body clearance, which may indicate that this glucuronide is synthesized in part by 
the human kidney, as previously reported for the methoxysulphonamides (16-18) 
The electrophilic metabolite N4-hydroxysulphamethoxazole (N4OH), which may be held 
responsible for the occurrence of side effects (5,25) is excreted for 2 1 % of the dose in 
the urine This means that only the free or unreacted N40H was excreted and that the 
part causing side effects is not measured When comparing the pharmacokinetics of sul-
phamethoxazole between healthy volunteers and HIV positive patients, discrepancies m 
metabolism may reveal a relationship with the occurrence of side effects in HIV positive 
patients If the percentage of N4OH excreted in the urine of HIV patients were less than 
in healthy volunteers, it must be guaranteed that this is not the result of alterations m 
the C-oxidation, N4-acetylation and Nl-glucuromdation (26 28) 
In conclusion sulphamethoxazole is well absorbed from the gastrointestinal tract and bio-
transformed to 5 metabolites It is oxidized and conjugated by acetylation and glucuroni-
dation The pharmacokinetics of the Nl glucuronide is for the first time reported The 
parent drug is eliminated by mainly metabolism, while the metabolites are eliminated by 
mainly renal excretion, resulting in similar apparent half lives 
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Chapter 6 
Urinary recovery and kinetics of sulphamethoxazole 
and its metabolites in HIV seropositive patients and 
healthy volunteers after a single oral dose of sulpha-
methoxazole. 
AJAM van der Ven, TB Vree, EWJ van Ewijk- Beneken Kolmer, PP Koopmans, 
JWM van der Meer 
Br J Clin Pharmacol 1995, 39 621-625 
Abstract 
The urinary excretion of sulphamethoxazole and its metabolites was compared between 
healthy volunteers and HIV-seropositives in order to get a better understanding of why 
HIV-seropositives are more predisposed to idiosyncratic toxicity of sulphonamides A single 
800 mg oral dose sulphamethoxazole was administered to 7 healthy volunteers and 7 
asymptomatic HIV seropositives without previous use of sulphonamides Urine was collec-
ted for 4 days and drug analysis was performed by HPLC No difference was observed 
between seropositive and seronegative individuals in the urinary recovery of sulphamet-
hoxazole, N4 acetyl-, 5-methylhydroxy-, N4-acetyl-5-methylhydroxy-sulphamethoxazole and 
the N1 glucuronide conjugate Only the recovery of the hydroxylamine metabolite of sulp-
hamethoxazole was significantly lower in the HIV-seropositives (0 50 ± 0 51 vs 2 23 ± 
0 85%, 95% CI on the difference, -0 90 to -2 25, p=0 0006) 
Introduction 
The frequency of adverse reactions to sulphonamides is much higher in HIV-seropositive 
individuals (6-80%) as compared to seronegative individuals (<5%) (1-10) It has been 
postulated that the reactive hydroxylamine metabolites of sulphonamides mediate these 
adverse reactions (11-13) Toxicity is more likely to occur when the scavenging system for 
such reactive intermediates is deficient, like glutathione deficiency in HIV infection 
(14,15) ln-vitro studies confirmed the relation between an increased toxicity of hydroxyl-
amines towards lymphocytes of HIV-infected individuals and decreased glutathione con-
centrations in these cells (16) 
The known metabolism (figure 1) of sulphamethoxazole (S) involves acetylation leading to 
N4 acetylsulphamethoxazole (N4), glucuronidation leading to Ni glucuronide conjugate 
(Sgluc) and oxidation (17,18) The latter reactions are cytochrome P450 mediated (19,20) 
and take place at the C5 carbon atom, leading to 5-methylhydroxysulphamethoxazole 
(SOH) and N4-acetyl-5-methylhydroxy sulphamethoxazole (N4SOH), as well as at the N4 
nitrogen atom leading to the hydroxylamme metabolite (N40H) This last compound is an 
unstable and toxic metabolite (21) Hydroxylamines can underqo auto-oxidation to nitroso 
dérivâtes, a process prevented by glutathione 
We have previously reported the formation and elimination of S and all its known meta-
bolites in healthy volunteers after administration of a single oral dose (22,23) In the pre-
sent study we performed similar experiments in HIV- seropositive individuals in order to 
obtain more insight in the reasons why HIV seropositives are more predisposed to sulpho-
namide toxicity 
Methods 
Subjects 
Seven healthy volunteers (4 males, three females) ranging in age from 23 to 50 years 
(mean 34 years) and seven HIV- seropositive volunteers participated m the study after 
approval of the Ethics Committee of University Hospital Nijmegen A routine biochemical 
assessment (including liver function) were all within normal limits in all participants The 
HIV-seropositive individuals (1 woman, 6 men, age ranging from 31 to 53 (mean 39 
years) were all asymptomatic, CDC class II, a mean CD 4 count 294 ±111 /mm3 (range 
140-480 /mm3) and without previous sulphonamide treatment after seroconversion 
A written informed consent was obtained from all participants A 800 mg dose of sulpha-
methoxazole was administered orally in 2 gelatine capsules after overnight fasting Two 
volunteers participated twice in the study in order to determine the reproducibility 
Sampling procedures 
Blood samples were only taken from the healthy volunteers while urine samples were col 
lected from both healthy volunteers and seropositives Blood samples were obtained by 
fingertip puncture at 1, 2, 4, 6, 8, 10, 12, 24, 32, 36, and 48 hours after drug administra-
tion Plasma was separated immediately by centrifugaron and stored at -20°C until ana-
ism of sulpha 
methoxazole 
COOH 
SultBfneVKixa2ote-N1-glucufOnide 
О 
N4-hydrojtysuttamettKn*2ûte Sulfamethoxazole 
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S ^ t h y t t y d r o i y s u l t a m e t t a n z Q l » N4-acetyW5-nwtriy№ydnHtytuffem»№OM^ 
lysis Urine was collected over 96 hours and three 5 ml aliquots were stored immediately 
at -20°C until analysis 
Sampling treatment, chemicals and drug analysis were done as described in extensively 
elsewhere (18,21) 
Data analysis 
Curve Fitting of the plasma concentration- and renal excretion rate-time curves was carried 
out using a one compartment model with first order drug absorption (r2 < 0 98) and 
pharmacokinetic parameters calculated using the Medi-ware® computer program (24) 
The following parameters for N4 were calculated from the renal excretion rate-time profi-
les elimination half-life (t'¿,z), lag time (tlag), time at which maximum concentration 
occurs (tmax), mean residence time (MRT=Vss/CL + 1/ka + tlag), maximal renal excretion 
rate (Umax) and area under renal excretion rate time curve (AUCu), AUC values were cal-
culated using thelmear trapezoidal tule with extrapolation to infinity 
In addition, t'/5,z, tmax, tlag, and MRT were calculated for N4 in plasma of healthy volun-
teers t'/$,z was also estimated for NOH-SMX in plasma of healthy volunteers 
Statistics 
95% confidence intervals on the differences of the differences of the means for unpaired 
(or paired when appropriate) observations were determined 
Results 
The urinary recoveries of parent drug and metabolites were similar in both HIV-negative 
and HIV-positive subjects with the exception of the urinary excretion of N40H (see table 
1) The recovery of the hydroxylamine metabolite of sulphamethoxazole was lower in HIV 
seropositives compared to healthy volunteers The results of the 2 volunteers that partici-
pated in the study twice were similar 
For healthy volunteers the value (mean ± 1 s d or median) of t'A, ÍMAX, ÍLAC and MRT of N4 
calculated from renal excretion rate-time profiles was 10 34 ± 1 42 h, 7 48h, 0 34 ± 0 24 
h and 19 40 ± 2 85 h respectively The 95% confidence interval on the differences 
between the mean t'¿, ÍMAX, ÍLAG AND MRT FOR N4 calculated from the plasma metabolite con-
centration-time curves (22) and the renal excretion rate-time profiles were -0 51 to 2 87, -
1 93 to 0 28, -0 44 to 0 76 and -0 89 to 2 44 respectively Also the half-lives of N4 and 
N40H in urine of healthy volunteers did not differ statistically (p>0 8) 
The pharmacokinetic parameters of N4 in urine of healthy volunteers and HIV seropositi-
ves are listed in Table 2 Only the maximum excretion rate (UMAX) of N4 was significantly 
different in the two groups 
Table 1 
Urinary recovery of sulfamethoxazole and its metabolites in 7 healthy volunteers and 7 HIV seropositives 
(expressed as percentage of the dose of sulfamethoxazole) after an oral dose of 8 0 0 mg SMX Mean values 
± SD, and 9 5 % confidence intervals on differences between the mean values are given 
N4 
5 
Sgluc 
IM4S0H 
SOH 
^40H 
Total 
HIV seropositives 
(n-7) 
50 27 ± 8 63 
12 66 ± 5 02 
12 68 ± 2 68 
5 50 ± 1 59 
3 64 ± 1 94 
0 50 ± 0 51 
83 9 + 6 2 3 
Healthy volunteers 
(n-7) 
43 21 ± 6 25 
14 64 ± 3 80 
9 66 ± 3 00 
5 20 ± 107 
2 70 ± 1 19 
7 23 ± 0 85 
7 8 2 5 ± 5 2 3 
95% С 1 
172 to 15 84 
7 18 to 3 20 
0 29 to 6 33 
1 28 to 1 88 
2 82 to 0 94 
0 90 to 2 55 
104 to 12 35 
Ρ 
011 
0 42 
0 07 
0 68 
0 29 
0 001 
0 09 
N4 acetylsulphamethoxazole (N4) sulphamethoxazole (S) Ni glucuronide conjugate (Sgluc) N4 acetyl 5 methylhy 
droxy sulphamethoxazole (N4S0H) 5 methylhydroxy sulphamethoxazole (SOH) and suiphamethoxazole hydroxylami 
ne(MOH) 
Table 2 
Pharmacokinetic parameters of N4 acetylsulphamethoxazole in urine of HIV seropositives and healthy 
volunteers after an oral dose of 8 0 0 mg sulphamethoxazole Mean values ± SD (range) are given as well as 
9 5 % confidence intervals (C I ) on the differences between the mean values 
t'A ζ (h) 
tmax (h) 
tlag (h) 
MRl (h) 
Umax (m 
AUCu (m 
g/h) 
g) 
HIV seropositives 
(n=7) 
8 69 ± 2 12 
7 4 8 * (5 60 8 57) 
0 57 ± 0 48 
1743 ± 2 11 
23 28 ± 6 16 
478 ± 90 
Healthy volunteers 
(n-7) 
10 34 ± 142 
6 56* (5 96 1106) 
0 34 ± 0 24 
19 40 ± 2 85 
17 16 ± 3 27 
405 ± 53 
95% CI 
3 74 to 0 46 
2 05 to 1 41 
0 22 to 0 67 
4 89 to 0 96 
0 37 to 1187 
12 55 to 15883 
Ρ 
011 
0 69 
0 29 
0 17 
0 04 
0 09 
t'/г z = half life 'MAX= time at which maximum excretion occurs 'expressed as median (range) 'LAC= lag time 
MRT= mean residence time UMAX= Maximum renal excretion rate AUCu- area under renal excretion rate time 
curve 
Discussion 
The formation and elimination of sulphamethoxazole and all its known metabolites in 
healthy volunteers and HIV- seropositive individuals were compared to better understand 
the predisposition of HIV seropositives to sulphonamide toxicity Only the urinary recovery 
of sulphamethoxazole hydroxylamine differed between healthy volunteers and HIV seropo­
sitive individuals No difference was observed m urinary recovery of S, N4, Sgluc, N4S0H 
and SOH The formation of the latter metabolite is, like N 4 0 H and probably N4S0H, cata­
lyzed by cytochrome P450 ( 2 0 ) These findings suggest that there is no difference in oxi­
dation, acetylation and glucuronidation of S in healthy volunteers and HIV seropositive 
individuals The reduced urinary recovery of the hydroxylamine metabolite may be explai­
ned by secondary metabolism of an unstable compound that can be further oxidized to 
reactive metabolites ( 2 0 ) This process is prevented e g by glutathione Glutathione pro-
tects cells from the toxicity of N40H largely by preventing its further oxidation to reactive 
metabolites (20). These results suggest that the formation of the hydroxylamine metaboli-
te is similar in both groups but that only HIV-seropositives further metabolise N40H. This 
could explain the increased frequency of adverse reactions and the diminished recovery of 
N4OH in this group of individuals. 
The renal excretion rate-time profile of the main metabolite N4 was taken as the main 
parameter for comparison of the metabolic and kinetic behaviour of S in healthy volun-
teers and HIV-seropositives. Although the maximum renal excretion rate (Umax) was diffe-
rent, other parameters like ÍMAX, UAG, MRT and AUCu were not. It may therefore be conclu-
ded that the renal excretion of N4 does not differ between seropositives and healthy vol-
unteers 
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Chapter 7 
Oxidation of sulphamethoxazole by human liver 
microsomes. 
AJAM van der Ven, WHM Peters, TB Vree, PP Koopmans, JWM van der Meer 
Abstract 
Sulphamethoxazole (S) was oxidized in vitro in a cytochrome P-450 dependent reaction by 
human liver microsomes Microsomes were isolated from 17 different human liver speci-
mens S (2mM) was incubated with 0 5 mg protein of each microsomal preparation in pre-
sence of a NADPH generating system Both the hydroxylamine metabolite (N40H) as well 
as 5-methylhydroxy sulphamethoxazole (SOH) were formed Formation rates of N40H and 
SOH were 108 ± 55 pmol/mm mg protein (range 22-297 pmol/min mg protein) and 74 
± 38 pmol/mm mg protein (range 14-168 pmol/min mg protein), respectively 
Significantly more S was N-hydroxylated than 5-methylhydroxylated (p=0 01) in-vitro 
Immunostaming of cytochrome P-450 3A4 on Western blot correlated with the formation 
rates of SOH (r=0 63, p<0 01 ) but not with that of N4OH (r=0 35, p=0 19) which suggests 
that formation of SOH was catalyzed by cytochrome P-450 3A4 No correlation was found 
between immunostaming of cytochrome P-450 1A2 and the formation of N40H or SOH 
Introduction 
The hydroxylamine metabolite of sulphamethoxazole (N4OH) has been postulated to play 
a role in the development of adverse reactions to this drug In vitro studies have shown 
that hydroxylamine metabolites of sulphonamides are more cytotoxic towards lymphocytes 
of patients with a clinical history of sulphonamide hypersensitivity, as compared with 
lymphocytes from non-allergic individuals (1,2,3) The cytotoxicity of the hydroxylamine 
dérivâtes towards those lymphocytes diminished when comcubated with glutathione 
Therefore it was hypothesized that glutathione protects cells from the toxicity of N4OH 
largely by preventing its further oxidation to reactive metabolites (4) In patients infected 
with the human immunodeficiency virus (HIV), the deficiency of this glutathione detoxi-
fying system (5) could lead to the high incidence (40-80%) of adverse reactions to sulp-
hamethoxazole (6) The problematic application of S in these patients resulted in a rene-
wed interest in the metabolism of this drug 
Sulphamethoxazole is conjugated by N-acetyltransferase to N4-acetyl-sulphamethoxazole 
(7), by UDP-glucuronyl transferase to Ni-glucuronide sulphamethoxazole (8), and by cyto 
chrome P-450 dependent reactions to 5-methylhydroxy sulphamethoxazole (SOH) (7) and 
sulphamethoxazole N hydroxylamine (N40H) (9,10) The in vitro oxidation of S to the 
hydroxylamine metabolite by human liver microsomes was reported before (11), however a 
limited number of liver samples was used (n=2) whereas the formation and relative impor­
tance of SOH was not reported 
No information on the cytochrome P-450 isoenzyme involved in the oxidation reactions of 
sulphamethoxazole is available until now It was suggested that cytochrome P-450 1A2 
was a likely candidate (11) The contribution of cytochrome P-450 3A4 was also studied 
because the N-oxidation of dapsone is predominantly mediated by this isoenzyme (12) 
The chemical structures of dapsone and sulphonamides are similar, both metabolized to 
hydroxylamines and cause similar hypersensitivity reactions (13) 
The objective of the present study was to investigate the intermdividual variation in the 
oxidation of sulphamethoxazole to N40H and SOH in microsomal preparations isolated 
from 17 different human liver specimens and to elucidate whether cytochrome Ρ 450 1A2 
or P-450 3A4 were involved in the oxidation of sulphamethoxazole 
Methods 
Chemicals. 
S and NA acetylsulphamethoxazole were obtained from Hoffmann LaRoche, (Mijdrecht, 
the Netherlands) SOH was isolated as described previously (14) Ν Ί Ο Η was obtained from 
Synthon BV, (Nijmegen, the Netherlands) All other chemicals were of analytical purity 
and obtained from commercial sources 
Preparation of microsomes. 
Human liver specimens were homogenized in 5 volumes of Tris/sucrose buffer (0 25M 
sucrose, 20 mM Tns/HCI pH=7 4 and 1 5 mM dithiothreitol) in a motordnven 
glass/Teflon potter (5 strokes at 1OO0 rpm) The homogenate was centrifuged at 10,000 
g for 20 mm, and subsequently the supernatant was centrifuged at 150,000 g for 50 mm 
The microsomal pellet was resuspended in the above mentioned Tris/sucrose buffer, fro­
zen in small aliquots in liquid nitrogen and stored at -80°C until use Liver samples were 
obtained at surgery when the organs were removed for transplantation Demographic 
characteristics of the donors were not available Total cytochrome P-450 content of the 
microsomal samples was determined using the method of Omura and Sato (15) 
Microsomal assay. 
Incubations were performed as described by Cribb and Spielberg (16) with minor modifi­
cations In brief , 0 5 mg microsomal protein was incubated in a 15 mM HFPES buffer, 
pH=74 in presence of a NADPH generating system (lOmM glucose, 2 units glucose 6 
phosphate dehydrogenase, 2 4 mM glucose 6-phosphate, 0 6 mM NADP) in a total volu­
me of 1 ml in a shaking water bath at 37°C up to 120 mm Control incubations were also 
performed without adding the NADPH generating system Sulphamethoxazole dissolved in 
dimethylsulphoxide was added (maximal dimethylsulphoxide cone 0 1 % v/v, S concentra 
tion during incubation 2 mM) to start the reaction The kinetics of the reaction were stu­
died by incubating S in preliminary experiments for 0, 10, 20, 30, 60, 90 and 120 mm, 
incubations were performed with and without the addition of 1 mM ascorbic acid in order 
to study the stability of N40H under these experimental conditions (n=4) Thereafter incu­
bations were performed for 0 and 60 mm (n=17) Reactions were stopped by adding 1 ml 
of ice-cold methanol and placing the samples on ice Samples were stored at 80°C until 
analysis After thawing, the samples were diluted 1 1 with 0 33 M trichloroacetic acid and 
centnfuged at 3000g for 5 mm The supernatant was injected onto the HPLC column (see 
below) 
Four of the microsomal preparations were repeatedly incubated (n=4) to determine the 
interday variation 
Analytical Procedures. 
S and its metabolites were analysed by HPLC using a Spectra Physics SP8810 pump 
(Eindhoven, the Netherlands) and a 757 Separations UV detector (Hendrik Ido Ambacht, 
the Netherlands) Detection was achieved at 271 nm A C8, 5μιτι 250 mm χ 4 mm ID 
column (Synthon, Nijmegen, the Netherlands) was used The mobile phase consisted of 
0 9 g/l orthophosphoric acid, 0 225 g/l tetramethylammoniumchloride, 4 5% (v/v) dim-
ethylformamide and 18% (v/v) acetomtnl, adjusted to 1 I with water The flow rate was 
1 5 ml/mm Under these conditions the retention times for SOH, N40H and S were 4 0, 
8 6 and 10 1 mm, respectively The identity of SOH, N40H and S was confirmed by using 
authentic standards Calibration curves of peak heights versus known concentrations of 
each component were constructed (r>0 99) Intraday variation of both samples and stan­
dards was < 5%, interday variation < 10% The limit of quantitation (signal/noise ratio of 
3) of N40H and SOH was 0 01 pg/ml 
Immunoquantification of cytochromes P-450 1A2 and P-450 3A4 
Microsomes were subjected to SDS Polyacrylamide gel electrophoresis (7% acrylamide, 
v/v) and Western blots of these gels were incubated with a mouse monoclonal antibody 
against cytochrome P-450 3A4 (Ko3 13 7-10, ref 17) and a rabbit antibody against cyto 
chrome P-450 1A1.2 (Human Biologies Ine, Phoenix Arizona, USA) As second antibodies, 
peroxidase conjugated rabbit anti mouse and swine anti-rabbit (Dakopatts, Clostrup, 
Denmark) were used, respectively Peroxidase staining was performed with 4-chloro-l-
naphthol and H2O2, as described before (18) Staining on immunoblots was quantified by 
densitometry analysis (Ultrascan XL, LKB, Bromma, Sweden) 
Statistics 
t test for paired differences was applied to judge the differences between the paired 
N4OH and SOH formation rates Pearson correlation coefficients were calculated 
Differences are considered statistically significant when P<0 05 
Results and discussion 
Total cytochrome Ρ 450 content was determined in five microsomal preparations (0 22 ± 
0 07 nmol/mg protein, range 0 07-0 50) and was similar to values published by other 
investigators (0 11-0 87 nmol/mg protein, ref 19) This indicates that our human liver 
microsomes are comparable to those used in other laboratories 
Sulphamethoxazole was metabolized to N4OH and SOH by human liver microsomes The 
yield of SOH formed by 4 different microsomal isolates was not different in presence or 
absence of 1 mM ascorbic acid, a reducing agent which is potentially able to decrease the 
spontaneous oxidation of hydroxylamines The time dependence of the oxidation reactions 
was studied in preliminary experiments by incubating S with 4 different batches of micro­
somes Concentrations of both metabolites increased in time and plateau values were 
reached after 120 mm Similar data were reported for murine hepatic microsomes by 
Cnbb and Spielberg (16) Further experiments were performed incubating S for 0 and 60 
mm using 17 different liver specimens as the source for microsomes (Table 1) 
Formation rates of N40H and SOH are 108 ± 55 pmol/mm mg protein (range 22 297 
pmol/min mg protein) and 74 ± 38 pmol/min mg protein (range 14-168 pmol/min mg 
protein), respectively Earlier reported hydroxylamine concentrations (10) were in the 
range of our present data More S is N hydroxylated than 5-methylhydroxylated (p=0 01 ) 
m vitro There is a large variation m formation rates of both N40H and SOH m vitro (14 
and 12 fold, respectively) The percentages of a dose S that are renally excreted as N40H 
(11) and SOH (7) are similar (2 3%), suggesting a similar formation rate in vivo Possibly 
the formation of SOH is differentially impaired in-vitro or as was suggested before N40H 
is further metabolized or covalently bound ιπ-νινο (9) 
The formation of N40H and SOH in the absence of a NADPH generating system was 
below the limit of quantitation of the HPLC assay, indicating that both oxidation reac­
tions are cytochrome P-450 dependent The possible involvement of cytochromes P-450 
1A2 and Ρ 450 3A4 m the oxidation of sulphamethoxazole was also investigated The 
immunostaimng of cytochrome Ρ 450 1A2 (Figure 1) did not correlate with the formation 
rates of either SOH (r=0 32, p=0 21 ) or N40H (r=0 14, p=0 59) whereas staining of cyto­
chrome P-450 3A4 correlated with the formation rates of SOH (R=0 63, p<0 01 ) but not 
with that of N40H (r=0 35, p=0 19) This indicates that formation of SOH but not N40H 
is apparently mediated by cytochrome Ρ 450 3A4 
Because of the large number of different microsomal preparations tested we could also 
address the question of the intenndividual variation in the oxidation of sulphamethoxazo­
le (Table 1 ) Fourfold incubation of S with samples of the same microsomal preparation 
yielded similar results (coefficient of variation <10%) and therefore it can be concluded 
that the difference between the measured formation rates using different microsomal pre 
parafions is largely due to intenndividual variation Therefore it can be concluded that the 
extent to which S is N-hydroxylated m vitro differs markedly between various microsomal 
preparations Possibly this difference contributes to the intenndividual variation in suscep 
tibility to sulphonamide hypersensitivity 
Figure 1 
Immunoquantification of specific " 
cytochrome Ρ 450 isoforms in 
human liver microsomes 
Human liver microsomes (100 pg ^ ^ 
protein in panel A 10 pg protein in >«-
panel B) were analysed by immuno 
blotting as described under 
Methods Cytochrome Ρ 450 1A2 
was detected in panel A and cytoch 
rome Ρ 450 3A4 was detected in В 
panel В Numbers indicate the diffe 
rent samples of human liver micro ^ ^ 
somes 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Table 1 
Oxidation of sulfamethoxazole to its hydroxylamine- (N4OH) and 5-hydroxymetabolite (SOH) by human liver microsomes 
(n=17). _ 
60 mm incubation 
Sample 1 2 3 4 5 6 7 θ 9 10 11 12 13 14 15 16 17 Mean ±SD 
N4OH 63 85 22 71 85 94 128 110 110 126 117 93 116 136 297 70 112 108 ± 55 
SOH 95 25 93 36 72 35 109 US 88 90 69 38 51 67 168 69 14 74 ±38 
Values are given in pmol/min. mg protein. 
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Chapter 8 
Monochlorobimane does not selectively label glutat­
hione in peripheral blood mononuclear cells. 
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Abstract 
Monochlorobimane (MCB) has been used by several investigators as a fluorescent label to 
quantify glutathione (GSH) levels in human peripheral blood mononuclear cells (PBMC) 
This paper describes a biochemical evaluation of this approach 
PBMC were incubated with MCB (1O-100 μΜ) and the fluorescence in extracellular medi­
um and cell lysates was measured Non-linear curves were obtained m both cases and no 
'plateau' was reached The majority of the fluorescence was in the medium Gel perme 
ation (Sephadex C-25) of the lysate indicated a linear increase in protein-bimane adduct 
formation, reaching about 50% of the intracellular fluorescence after 1 h Fractionation 
of the de-protemized samples with Sephadex С 10 showed that only about one-third of 
the "low-MW" fluorescence could be ascribed to GSH bimane, either in the lysate or the 
medium Furthermore about 40% of the free GSH in lysates appeared unbound even after 
1 h of incubation These data are in line with our observation of an extremely low activity 
in PBMCs of glutathione-S-transferase under the conditions employed Our findings indica 
te that many variables influence the cellular fluorescence, including the presence of alter­
native metabolic pathways for MCB and the rapid excretion of GSH-bimane out of the 
cell This lack of specificity limits the value of MCB as a GSH probe for PBMC, and con­
firms earlier suggestions that a careful biochemical evaluation is a pre-requisite for its 
application to any particular cell type 
Introduction 
Glutathione (glutamylcysteinylglycine, GSH) is a major cellular anti oxidant and, because 
it plays a central role in the maintenance of thiol redox status, is essential for the optimal 
functioning of numerous enzymes In addition it is conjugated to many xenobiotics, cata­
lysed by the enzyme glutathione-S-transferase (GST) GSH is therefore critical for cellular 
viability and is generally found in high concentrations (1 -10 mM) in animal cells Various 
pathological states have been associated with low normal CSH levels including malignan­
cies (1,2), idiopathic pulmonary fibrosis (3) and the acquired immunodeficiency syndrome 
(4-8) CSH metabolism has been extensively reviewed (9,10) 
Lymphocyte function is particularly dependent on CSH levels CSH is known to influence 
lymphocyte growth and activation as well as their responsiveness to cytokines (11-13) A 
number of workers (7,8,14,15,16) have therefore attempted to measure CSH concentrations 
in subsets of peripheral blood mononuclear cells (PBMC) by flowcytometry Obviously mul­
tiparameter flowcytometry is an attractive approach for this purpose, since the cell type 
can simultaneously be defined using a monoclonal antibody directed against the approp­
riate cell surface antigens Several fluorescent probes have been used for flowcytometric 
CSH measurement, but in recent years monochlorobimane (MCB) has become the reagent 
of choice MCB, itself non-fluorescent, is conjugated to CSH by glutathione S transferase 
to yield a fluorescent adduct, comprehensively reviewed in (17) 
It is clear that there are certain pre requisites for such a probe First, the reagent itself 
must be freely permeable through the cell membrane, secondly it must be specific for 
CSH, and finally the adduct must be retained within the cell Although these conditions 
have, to some extent, been verified in certain cell types (for example hepatocytes [18], 
fibroblasts [19] and Chinese hamster ovary cells [20]), it remains uncertain in how far 
they hold true for PBMC Here we report an investigation using biochemical fractionation 
procedures to evaluate the validity of MCB as a fluorogemc reagent for quantification of 
CSH in this cell type 
Materials and methods 
Subjects and cell isolation 
Subjects were healthy volunteers (n=4), age 30-60, who had used no medication in the 
previous 24 hours Blood (20ml) was taken by venepuncture, and PBMCs were isolated 
immediately by density gradient centrifugaron using standard techniques (21) After was 
hing, the cells were resuspended in 2 ml phosphate buffered saline (PBS) containing 
0 5% bovine serum albumin Analysis was initiated within 15 mm, meanwhile the cells 
were kept on ice 
The total yield of PBMCs in the suspension ranged between 2 3 x l 0 7 cells/ml, and diffe­
rential counts indicated an average of about 80% lymphocytes and 20% monocytes 
Contamination with polymorphonuclear leucocytes was less than 2%, and no significant 
contamination with erythrocytes was seen 
Fluorimetry and general techniques 
A 10 mM stock solution of monochlorobimane (Molecular Probes Ine, Eugene, USA) was 
prepared in ethanol, and aliquots were stored at -80°C in the dark 
In preliminary experiments, 0 5x106 PBMCs, suspended m PBS (pH=7 4, Na+=163 9 mM, 
Cl"=140 3 mM, HP042 + =10 9 mM, H2P04+-1 8 mm), were brought to final concentra­
tions in the range 10-ΙΟΟμΜ MCB (total volume 1 ml) Tubes were incubated at 37°C, 
and the fluorescence was measured at intervals up to 60 mm using a Perkin-Elmer LS-5 
fluonmeter (excitation 392 nm, emission 480 nm, excitation slit 5, emission slit 20) 
Both controls without MCB and without cells were included Exposure to light was avoi­
ded as far as possible throughout this work, the use of a small excitation slit contributes 
to minimizing photodecomposition 
In order to distinguish between fluorescent material released into the medium and that 
retained within the cells, tubes were centrifuged (400g, 5 mm) immediately after incuba­
tion and the fluorescence of the supernatant was measured The pellet was washed once 
with PBS and the cells resupended m 1 ml PBS Cells were disrupted by sonication at 0°C 
(3x10 sec, ΙΟμιτι peak probe amplitude) and the lysate was centrifuged (10,000g, 2 mm) 
Fluorescence of the supernatant was measured as before 
The effect of the experimental manipulations on cell membrane integrity was checked 
with propidium iodide inclusion Propidium iodide (Sigma, St Louis MO, USA) was added 
after isolation of the cells, after washing the cells twice in PBS (400g, 5 mm) and after 
incubation of the PBMC for 10, 30 or 60 mm with 100 μΜ MCB (with or without washing 
the cells in PBS) Resuspended cells in 0 1 % Noninet P40 (BDH Chemicals LTD, Poole, UK) 
in PBS were used as a positive control Propidium iodide inclusion measurements were car­
ried out on a Coulter Elite Flow Cytometer 
The presence of an ATP dependent CSH-bimane efflux pump was studied by pre-incuba-
ting samples for 15 mm with 1 mM probenicid (Sigma, St Louis MO, USA) before the cells 
were incubated with MCB 
Gel permeation chromatography 
Sephadex C-25 (fine grade, Pharmacia, Uppsala, Sweden) was employed to separate rela­
tively low-molecular weight (MW) MCB derivatives (ι e CSH bimane adduct and other 
fluorescent MCB metabolites) from protein-bimane adducts Sephadex G-10 was used to 
distinguish the CSH bimane adduct (MW=498) from possible hydrolytic- or oxidation-pro­
ducts of MCB (MW<250) in de-protemized samples 
Columns (1x28 cm) were prepared and washed with PBS until fluorescence of the eluate 
was negligible (approximately 3 bed volumes) The sample (200 500μΙ) was brought onto 
the column and eluted with PBS at a flow rate of 1 ml per mm Fractions of 1 ml were 
collected and the fluorescence measured as before 
Free ('unbound') glutathione measurement 
In order to quantify free GSH in the presence of pre-formed GSH bimane adduct an enzy 
matic technique was used PBMC (5x106 cells/ml) were incubated with 50μΜ MCB for 
appropriate times (0 60 mm) After pelleting, the cells were washed and lysed as before 
An aliquot of the lysate (containing 0 1 1 0 nmol free GSH) was diluted to 970 μΙ in PBS, 
20 μΙ 1 mM MCB added, and the fluorescence recorded until a stable signal was obtai­
ned Α ΙΟμΙ aliquot of a crude GST preparation was added (a mouse liver homogenate 
200 mg/ml, centrifuged at 30,000g for 30 mm and dialysed against several changes of 
PBS), and the recording continued An abrupt increase in fluorescence (<1 mm) was folio 
wed by a plateau which remained stable for several minutes Blanks (minus GST, minus 
PBMC, minus bimane) and appropriate GSH standards were included with each batch of 
assays 
Glutathione concentration in the cytosolic fraction was also quantified on Η PLC using the 
method of Fahey and Newton (22) A 200x3 mm Chromsep HPLC column with a 
Chromspher 5C18 cartridge (Chrompack, the Netherlands) was employed 
Measurement of glutathione-S-transferase activity 
The reaction tube contained 860μΙ PBS, 20μΙ 1 mM glutathione and 20 μΙ 1 mM MCB ( 
prepared as a 1 10 dilution of ethanolic stock in PBS ) Fluorescence was recorded until a 
linear plot was obtained, the slight increase of fluorescence with time ("blank") presuma-
Ыу resulted from chemical reaction and/or photodecomposition of MCB by the exciting 
light 
The enzymatic reaction was initiated by the addition of ΙΟΟμΙ centrifugated PBMC lysate 
(equivalent to 2-3x106 cells), bringing the total volume to 1 ml The recording was conti­
nued until a linear plot was again established After correction for the non-enzymatic 
blank, GST activity was calculated from the slope by reference to a CSH standard (see 
below) For compantive purposes, GST activity was also determined using 100 μΙ aliquots 
of a dilute mouse liver homogenate in place of the PBMC lysate 
The protein concentrations of lysates were measured by direct fluorescence (excitation 
280 nm, emission 340 nm) of appropriate dilutions, using bovine serum albumin as stan­
dard GST activities of all samples were expressed as nmol MCB adduct formed per mm 
per mg protein 
Results 
Reaction of intact cells with MCB 
The fluorescence of a suspension of PBMCs incubated with MCB increased rapidly with 
time The curves were non linear (Fig 1), and the fluorescence was still rising even after 1 
h at 37°C Experiments using different PBMCs concentrations showed that the fluorescen­
ce at any time-point was proportional to cell number As shown in Figure 1, the rate of 
increase of the fluorescence was greater at higher MCB concentrations, although again 
the relationship was clearly non linear The initial fluorescence of the cell-free controls 
was dependent on the MCB concentration but little increment was observed with time 
(Fig 1) Minimal autofluorescence of the PBMC was noticed 
Centrifugation of the intact cells following incubation showed surprizmgly- that at all 
time-points the majority of the fluorescent material was in the extracellular medium rat 
her than in the cells After 5 mm at 37°C only 3 1 % was found in the cells, after 60 mm 
this value had fallen to 17% 
Experimental manipulations did not influence membrane integrity, propidium iodide inclu­
sion did not exceed 3%, even after incubation with MCB for 60 mm and washing the cells 
in PBS More than 95% propidium iodide positive cells resulted from resuspending the 
cells in Nonidet in PBS 
Pre-mcubatmg cells with probenicid decreased fluorescence in the extracellular medium 
up to 30% 
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Figure 1 
Effect of incubation time on flúores 
cence at two different MCB concen 
trations PBMCs (0 5x106) were 
incubated with 10μΜ (open sym 
bols) or ΙΟΟμΜ (closed symbols) 
MCB up to 60 mm Broken lines 
indicate the corresponding blanks 
(without cells) Fluorescence expres 
sed in arbitary units "Zero time" 
blanks have been subtracted ( 
Samples containing 10 μΜ MCB 11 
units 100 μΜ MCB 98 units) 
Results were corrected for quen 
ching Values represent the mean of 
at least 4 independent experiments 
Protein-bimane adduct formation 
Since it is well established that a non-enzymatic reaction may occur between cytosolic proteins and 
bimanes (23), we fractionated PBMC lysates using gel permeation on Sephadex G-25 following incu­
bation of the intact cells with the reagent Typical results are shown in Figure 2 and Table 1 It appe­
ars that there is a linear increase in the absolute concentration of the protein-bimane adduct with 
time, after 1 h this material is responsible for about 50% of the total intracellular fluorescence 
Samples of the incubation medium showed, as expected, very little protein-bimane adduct This was 
less than 5% even after 1 h incubation This small quantity is presumably the result of chemical 
reaction with extracellular protein and was not investigated further The contribution of the blanks 
(cell-free control) to the fluorescence was 25% and 8% after incubation of 5x106 PBMCs with 
50μΜ MCB for 5 or 30 mm respectively 
Sephadex G-10 chromatography 
The low MW fluorescent material was further fractionated using Sephadex G-10 Samples of either 
lysate or extracellular medium were de proteimzed with trichloroacetic acid (TCA), and the superna-
tes were subjected to gel permeation as before At all time-points two distinct fluorescence peaks 
were present for both the medium and the lysate (Fig 3) the earlier peak co-ran with the reaction 
product of GSH and MCB obtained using mouse liver GST Less than half of the fluorescent material 
eluted at a volume compatible with a MW of 498 (GSH-bimane adduct) The majority of the fluores­
cence appeared appreciably later as a distinct peak 
Free ('unbound') glutathione levels of PBMC 
The enzymatic GSH assay described here proved to be exceedingly sensitive (detection limit about 
50 pmol) and reproducible (average differences for duplicates < 5%). It is unaffected by the presen­
ce of preformed bimane adducts, and the use of liver GST presumably confers a high degree of spe­
cificity Typical recordings are seen in Figure 4 
Using this technique, free GSH levels following freshly-isolated PBMC were found to be 1 7 ± SD 0 3 
nmol/106 cells (equivalent to 28 3 ± SD 5 nmol/mg protein), and is similar to GSH levels found by 
others (24,25) Since experiments were in general complete within 2-3 h of cell isolation, we also 
measured GSH levels after maintaining the PBMC for 3 h on ice in order to examine possible spon­
taneous depletion It appeared that the loss of GSH did not exceed 15% during this time The accur­
acy of the enzymatic GSH assay was checked by an independent HPLC analysis Both methods 
agreed to within 10% in the analyis of several lysates of fresh PBMC. 
Figure 2 
Typical elution profile of PBMCs 
lysates on Sephadex С 25 PBMC 
(5x106) were incubated with 50μΜ 
MCB for 5 mm (open symbols) or 
30 mm (closed symbols) and lysed 
as described in the text 
Fluorescence was measured in the 
different fractions 
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Figure 3 
Typical elution profile of PBMCs 
lysates (closed symbols) or medium 
(open symbols) on Sephadex С 10 
PBMCs (5x106) were <ncubated with 
50μΜ MCB for 5 mm Samples were 
de proteinized with TCA prior to gel 
permeation 
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Table 1 
Distribution of fluorescence 
Time (mm) 5 
Low MW 79% 
Protein bimane 2 1 % 
15 
76% 
74% 
30 
62% 
38% 
60 
50% 
50% 
Note PBMCs lysates were fractionated using gel permeation on Sephadex С 25 following incubation of the intact 
cells (5x106) with 50μΜ MCB up to 60 mm Values represent the distribution of fluorescence between protein 
bimane adduct and low MW material at various times 
Table 2 
Distribution of total CSH (free, intracellular bimane adduct and extracellular bimane adduct) at various 
times before and after incubation of 5x106 PBMCs with 50 μΜ MCB 
Time (mm) 0 5 60 
Intracellular free ('unbound') CSH 7 5 5 2 3 1 
Intracellular CSH bimane adduct - 0 4 0 5 
Extracellular CSH bimane adduct - 0 7 3 3 
Total CSH 7 5 6 3 6 9 
Note Values are nmol, note that 1 nmol is equivalent to 70 fluorescence units 
Figure 4 
Typical recordings of the enzymatic 
CSH assay Arrow indicates the 
addition of 10 μΙ mouse liver CST 
A= Inmol CSH standard. B= 
0 5x106 PBMC lysate Recording 
time was about 3 mm per sample, 
measured increaments up to 70 
fluorescent units, expenmerts were 
carried out in duplicate 
-π η ~i —\ 
To determine the residual intracellular levels of free GSH (ι e excluding pre-formed CSH-
bimane adduct) we incubated intact PBMC with MCB for various times. A gradual deple­
tion was seen, intracellular CSH levels reaching about 4 0 % of their initial value after 1 h 
incubation Complete 'balance-sheets' are now possible, these are illustrated in figure 5A 
(intracellular) and 5B (medium) and are summarized in Table 2 It is clear that the total 
CSH (intracellular free, intracellular adduct and extracellular adduct) remains rather con­
stant after 1 h incubation, confirming the validity of the fractionation procedures, and 
excluding the possibility of ongoing CSH synthesis 
Glutathione-S-transferase activity 
The GST activity of PBMC was extremely low, even when using concentrated lysates (up to 
3x107 cells/ml) and despite the very sensitive fluorimetrie assay, the slope barely excee­
ded that of the blank In absolute terms, the activity of PBMC lysate was 0 08 ± SD 0 01 
nmol adduct formed/mm mg protein (n=3) By contrast, mouse liver yielded a value of 94 
nmol adduct formed/mm mg protein, about a thousand-fold higher 
Figure 5 (A and B) 
Distribution of total fluorescence in 
the cytosol (Fig A) and in the ex 
tracellular medium (fig B) at diffe 
rent times after incubation of PBMC 
(5x106) with 50μΜ MCB Total fluo 
rescence closed square, protein 
bimane adduct open square CSH 
bimane adduct open circle, other 
low MW MCB metabolite(s) closed 
circle The broken line represents 
equivalent fluorescence of residual 
unbound CSH (1 nmol CSH - 70 
fluorescence units) Fluorescence 
expressed m arbitary units "Zero 
time" blanks have been subtracted 
Values represent the mean of at 
least 3 measurements 15 30 45 
Time (min) 
60 
Time (min) 
Discussion 
The answer to our original question regarding the validity of flowcytometric data using 
MCB is clear, at least two of the three pre-requisites do not hold for human PBMC First 
the specificy of MCB is poor A flowcytometer registers the total fluorescence in the cell, 
and as shown in Figure 5A, the CSH bimane adduct contributes only a small part of this 
fluorescence, regardless of the incubation time Secondly, it is apparent that the great 
majority of the CSH-bimane adduct is released from the cell and accumulates in the medi-
um (Table 2) 
The low MW peak shown by gel permeation on Sephadex G-10 was only detectable in the 
presence of PBMCs, and clearly is a major metabolic product of MCB Indeed, the appe-
arence of hydrolysed fluorescent dérivâtes has been reported following the incubation of 
monobromobimane with various biological materials (26) The observation that most of 
the CSH-bimane product leaves the cell is in accord with the presence of an ATP-depen-
dent CSH S-conjugate export pump (27,28) ATP-dependent secretion of MCB CSH adducts 
by rat fibroblasts was reported before and this efflux pump was inhibited by exposing the 
cells to probenicid (29) The present data demonstrate similar results, the accumulation of 
fluorescence in the extracellular medium was inhibited in the presence of probenicid 
Our present data seem to be in contrast with results obtained with studies of other cell 
types For example, in the original study of MCB as a flowcytometric reagent, Rice et al 
(20), using Chinese hamster ovary cells, stated that very little reaction with protein sul 
phydryls was observed and that the only low MW fluorescent derivative was the GSH bima 
ne adduct The apparent discrepancy between these and our findings may be the extremely 
low GST activity of human PBMC Clearly if the conjugation rate of MCB with CSH is sever-
al orders of magnitude lower then in other cells, than the relative contribution of flúores 
cence due to decomposition or coupling of MCB to protein will be magnified accordingly 
It should be noted that our values for GST activity are probably well below VWx, since the 
KM for MCB of the human isoenzymes is in excess of 200μΜ (15) However, our purpose in 
this study was simply to establish in pragmatic terms the rate at which GSH can be den 
vatized under conditions generally employed It is possible, although unlikely in our view, 
that higher MCB concentrations might yield a somewhat greater proportion of GSH-bimane 
adduct 
Previous work with lymphocytes (14) was done at comparable MCB concentrations, howe­
ver the labeling time was brief (10 mm at 37°C plus an unspecified time on ice), the cells 
were pelleted (which will remove extracellular fluorescence) and proteins were removed by 
acid precipitation before analysis by reversed-phase HPLC Thus in this earlier report only 
acid soluble, intracellular fluorescent adducts were detected The authors conclude that 
more than 99% of the MCB fluorescence is associated with the GSH peak (14) thereby 
validating MCB as a fluorescent reagent to measure GSH levels in these cells However the 
other contributions to the fluorescence as reported in the present study were missed and 
the interpretation of data by application of MCB is therefore much more complex The 
same considerations apply to a report (17) in which lymphocytes were GSH-depleted by 
pre-treatment with dmitrochlorobenzene It is indeed probable that GSH depletion reduces 
the formation of the acid soluble adduct, but it does not validate the application of the 
flowcytometric GSH assay to PBMC 
Despite certain limitations which have already been pointed out by others (15,30,31) (in 
particular the incompleteness of GSH denvatization resulting from low GST activity), cer 
tain authors suggest that the use of MCB as a fluorescent probe may be of value for the 
measurement of "relative differences" in CSH levels of human PBMC (17). Our findings 
indicate that in addition to the CSH level many other variables influence the total cellular 
fluorescence obtained with monochlorobimane in human PBMC. These include CST activi-
ty, the decomposition rate of MCB to other fluorescent products, and the transport rate of 
the CSH-bimane adduct out of the cell All these variables may differ between cell subsets 
or may altered by disease or drugs and will further complicate the interpretation of data 
obtained when using MCB as a fluorescent label The MCB CSH assay should be validated 
for each particular cell type and experimental condition. 
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Chapter 9 
Protein-bound glutathione is increased in CD4 positi­
ve Τ cells and reduced in plasma in HIV seropositive 
individuals. 
AJAM van der Ven, HJ Blom, WHM Peters, LEH Jacobs, TJG Verver, PP Koopmans, 
Ρ Demacker, JWM van der Meer 
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Abstract 
Glutathione concentrations were determined in plasma, whole blood and in cytosol of 
CD4+ T-cells and CD14+ cells of HIV-seropositive individuals and healthy controls Total 
and free non-protein bound glutathione levels were measured Total glutathione concen­
trations in CD4+ T-cells from HIV-seropositive individuals were significantly higher (0 48 ± 
0 17 nmol/10 6 CD4+ T-cells, p=0 02) compared to healthy controls levels (0 36 ± 0 15 
nmol/10" CD4+ T-cells) while free glutathione concentrations were not different (0 36 ± 
0 19 and 0 43 ± 0 22 nmol/10^ CD4+ T-cells) Total and free glutathione concentrations 
of CD14+ cells were not significantly different in HIV-seropositive patients and healthy 
controls In plasma, total glutathione concentrations were reduced in HIV-infected indivi­
duals (4 0 ± 1 1 μΜ versus 5 0 ± 1 3 μΜ in controls, p=0 003) while free concentrations 
were not different Whole blood levels of free glutathione were identical in seropositives 
and controls Measurement of glutathione precursors in plasma did not reveal any diffe­
rence, cysteine levels in CD14+ cells were, if anything, marginally higher (p=0 05) In con­
trast to previous reports by others, above findings do not produce evidence in support of 
a systemic glutathione deficiency in HIV-seropositive individuals, but document that in 
these patients total glutathione is increased in CD4+ Τ cells and lowered in plasma 
Possibly, increased oxidative stress could play a role in the redistribution of glutathione 
Oxidizing processes are known to augment plasma glutathione turnover, and may cause a 
paradoxal increase of cellular glutathione 
Introduction 
Reduced glutathione is important in the defense against oxidative stress and plays a key 
role in the maintenance of cellular thiol redox status In addition, it is conjugated to 
many xenobiotics and essential for the optimal functioning of numerous enzymes and 
thus critical for cellular viability Glutathione enhances immune functions and in particu 
lar lymphocyte function is dependent on glutathione concentrations (1,2) Several groups 
have reported decreased glutathione levels in plasma, bronchoalveolar lavage fluid, perip­
heral blood mononuclear cells (PBMC) as well as in the immunocompetent CD4+ and 
CD8+ T-cells of HIV infected individuals (3-7) Also reduced plasma cysteine levels were 
reported (3), and it was postulated that cysteine deficiency plays a role in the progressive 
destruction of the immune system in HIV-infected patients (8) It has been suggested that 
cellular glutathione content of lymphocytes are regulated by macrophages via the supply 
of cysteine (9) 
In the above mentioned studies , different analytical techniques were used to determine 
glutathione levels Measurements in CD4+ and CD8+ T-cells were performed using 
monochlorobimane as a fluorescent label (5,6) After evaluation of this approach, we 
reported that monochlorobimane does not selectively label glutathione in these cells and 
most of the cellular fluorescence could be attributed to поп-glutathione compounds (10) 
Interpretation of data on glutathione levels in CD4+ and CD8+ Τ cells measured with 
monochlorobimane as described by Staal et al (5,6) seems therefore disputable Validated 
methods for measuring glutathione and other thiols are based on high performance liquid 
chromatography (11-14) or enzymatic techniques (10,15) Handling and storage of the 
samples may also largely influence results In plasma, a rapid redistribution of thiols 
occurs whereas under influence of air the protein bound glutathione fraction increases at 
the expense of the free acid soluble (13, 16) and total glutathione concentration (16) 
Blood samples should be collected in evacuated tubes containing EDTA preferably without 
using a tourniquet, and processed immediately (17) Fasting also affects leucocyte and 
plasma glutathione concentrations (18) 
In the present study the concentrations of glutathione and other thiols were determined 
in plasma, whole blood, CD4+ Τ and CD14+ cells in time matched samples of HIV seropo 
sitive individuals and healthy controls 
Subjects and methods. 
Subjects 
Thirtyfive healthy controls and 35 HIV-seropositive individuals participated in this study 
The presence of HIV infection was confirmed by enzyme-linked-immunosorbent assay 
(ELISA) and western blot tests The healthy controls (12 females, 23 males) did not have 
risk factors for HIV infection, and had a mean age of 33 ± 7 years (range 22-53) The 
HIV-seropositive group included 26 homosexual males, 4 bisexual males, 3 heterosexual 
females and 2 female intraveneous drug users Mean age was 39 ± 7 years (24-54) and 
according to CDC classification, 11 (31%) had AIDS, 7 (20%) were diagnosed as ARC and 
17 (49%) subjects were asymptomatic Mean CD4+ T-cell counts of all HIV seropositives 
were 232 ± 2 2 4 / m m 3 (20-1000), and 83 ± 5 5 / m m 3 (20-200) for the patients with 
CD4+ T-cell counts below 2 0 0 / m m 3 
From all participants, 30 50 ml blood was taken without the use of a tourniquet and col­
lected into Vacutamer tubes containing EDTA (Sherwood Medical, N Ireland) After fas­
ting overnight, blood sampling was performed in the morning in the laboratory in order to 
accelerate sample processing Only two individuals participated a time and notice was 
taken that all samples were identically processed 
Analytical methods , 
Definitions Total glutathione (thiols) covers all forms of glutathione, the sum of non pro­
tein-bound and protein-bound glutathione (thiols) Free glutathione is the fraction of non 
protein-bound glutathione In some experiments we also measured reduced glutathione, 
the tripeptide with a free sulphydryl moiety 
Free glutathione in whole blood: 1 ml EDTA blood was added to a conical tube contai­
ning 200μΙ 6% (v/v) acetic acid and then mixed with 800μΙ 10% sulfosalicylic acid After 
centrifugaron (4°C, 5 mm, 2000 g), total glutathione was measured in the supernatant 
by an enzymatic method (15) Some samples were kept on liquid nitrogen and analyzed 
within hours in order to measure reduced glutathione Haemoglobin was measured by 
spectophotometry (Sysmex NE-8000, USA) 
Free glutathione in plasma: After centrifugaron of the EDTA blood, 400μΙ plasma was 
immediately deproteinized by mixing with 200 μΙ 10% trichloroacetic acid, centrifuged 
(4°C, 10 mm, 2000 g), and stored at -80°C until analysis Glutathione concentrations 
were quantified by high performance liquid chromatography (11, 12) 
Total thiols in plasma: After centrifugaron of EDTA blood, plasma was stored at -80°C 
until analysis Total glutathione, cysteine, cystemylglycme, glutamylcysteine and homocys 
teme concentrations were quantified by high-performance liquid chromatography (13,14) 
Total thiols and free glutathione in CD14+ and CD4+ T-cells: CD14+ and CD4+ T-
cells were sequentially isolated using anti-CD14 or anti-CD4 coated immunomagnetic (IM) 
beads (Dynabeads M-450, Dynal, Oslo, Norway) CD14+ cells were isolated first since 
these cells may contain a CD4 receptors Peripheral blood mononuclear cells (PBMC) were 
obtained from 20-40 ml EDTA blood by Isopaque-Ficoll gradient centrifugaron, according 
to the instructions of the manufacturer (Lymphoprep, Nycomed AS, Oslo, Norway) PBMC 
were washed and resuspended in phosphate-buffered saline (PBS) containing 1 % human 
serum albumin PBMC were subsequently mixed on an apparatus that provides gentle til­
ting and rotation with 20-40 χ 10° anti-CD14 coated Dynabeads for 15 mm at 4-6°C 
Rosetted cells were isolated by application of a magnet to the side of the test tube and 
the remaining cell suspension (including CD4+T-cells) was transferred The isolated 
CD14+ cells were washed three times by magnetic separation in cold PBS, resuspended in 
300 μΙ PBS, lysed by freeze thawing twice and beads were separated from the cytosol by 
application of the magnet Part of the cytosol was kept at -80°C, part was deproteinized 
by adding 1 volume of 10% trichloroacetic acid and after centrifugaron (4°C, 5 mm, 
4000 g) the supernatant was stored at 80°C 
CD4+ T-cells were isolated from the remaining cell suspension by incubating and mixing 
with anti-CD4 coated Dynabeads for 45 mm at 4-6°C A roughly constant Dynabeads to 
CD4+ T-cell ratio (about 3 1) was obtained by either using double amounts of EDTA blood 
of seropositives with low CD4+ T-cell counts or dilution of blood of healthy volunteers 
Rosetted cells were isolated by application of a magnet to the side of the test tube and 
resuspended and mixed in PBS, albumin and 20μΙ DetachaBead (Dynal, Oslo, Norway) for 
45 mm at ambient temperature Beads were removed by application of a magnet to the 
side of the test tube Suspended cells were washed twice m cold PBS and albumin by cen­
trifugaron (600 χ g, 10 mm) and resuspended in 300 μΙ PBS Cells were counted (hemo-
cytometer) and viability determined by tryphan blue exclusion Cells were lysed by freeze 
thawing twice After centrifugaron (4°C, 5 mm, 4000 g) part of the cytosol was stored at 
-80°C until analysis and another part was deproteinized by adding 1 volume of 10% 
trichloroacetic acid After recentrifugation (4°C, 5 mm, 4000 g) the supernatant was sto-
red at -80°C Similar to the results of Brmchman et al (19), the isolated CD4+ T-cells 
were >95% pure with high viability (>95%) 
Free glutathione and total thiol concentrations were quantified in the cytosol of the CD14+ 
and CD4+T-cells by high performance liquid chromatography Protein content of CD 14+ 
cytosol was determined by fluorometry (ext 280nm/em340nm) using human serum albu­
min as standard (20) Linearity was confirmed in the range 1-200 pg/ml protein 
Analysis of glutathione (thiols) by high performance liquid chromatography. Free 
glutathione was quantified by high performance liquid chromatography after reaction 
with monobromobimane using the method of Fahey and Newton (11) with minor modifi­
cations (12) In short, separations were carried out with a high Precision Pump model 480 
equipped with an autosampler model Marathon, a spectrophotometric detector model 
Jasco 821-FP (all from Separations, the Netherlands), a 200x3 mm Chromsep HPLC 
column with a chromspher 5C18 cartridge (Chrompack, the Netherlands) A glutathione 
stock solution with high concentration (50μΜ) and low pH ( 1 % v/v acetic acid) was pre­
pared to minimize loss due to oxidation The experimental samples were diluted with 10% 
trichloroacetic acid, centnfuged for 2 mm in an Eppendorf microfuge, and the clear super 
natant was used in the assay Assay, 33 μΙ sample, 167 μΙ sodium borohydnde solution 
(2 5 mg/ml in 100 mM 4-ethyl-morpholine, pH=8), 100 μΙ monobromobimane solution 
(2mM in acetonitnle) After 30 mm the reaction was stopped with 20 μΙ 10% v/v trichlo­
roacetic acid The elution protocol (flow rate 0 35 ml/mm) with linear gradient was as 
follows 0 mm, 100% solvent A (10% v/v methanol, 0 25% v/v acetic acid, 10 mM tetra-
butylammoniumhydrogensulfate, adjusted to pH 3 5 with sodium hydroxide), 0% solvent 
В (0 25% v/v acetic acid in methanol), 20 mm, 100% solvent B, 22 mm, 100% solvent 
A, 36 min reinjection 
Total glutathione and other thiols were quantified by high performance liquid chromato­
graphy after reaction with monobromobimane using the method of Fiskerstrand (13) with 
minor modifications (14) In short a programmable sample processor (Cilson model 232 
BIO, Dilutor 401) was used for automated thiol reduction, denvatization and sample injec­
tion After equilibration with 30 mM ammonium nitrate, 40 mM ammonium formate and 
4 mM tetra-n butylammonium hydrogen sulfate (pH 3 22), the thiol derivatives were elu-
ted from the column (Supelcosil LC-18 15 cm, 4 6 mm, 3 μπι) with a 0 to 10 5% acetoni-
tril gradient in 11 mm with a flow rate of 1 ml/mm The retention times of cysteine, cys-
teinylglycine, glutamylcysteme, homocysteine and glutathione were 9 6, 10 7, 11 2, 11 6 
and 11 9 mm respectively 
Results 
Total plasma glutathione levels were lower m HIV seropositives compared to healthy con­
trols and a more significant difference was noticed in patients with CD4+ T-cell counts 
below 200/mm^ Free glutathione concentrations in plasma and whole blood, including 
the samples of HIV infected patients with low CD4+ T-cell counts, were not different 
(Table 1) In whole blood, oxidized glutathione accounted for less than 5% of the glutat­
hione concentrations in 8 healthy volunteers and 8 HIV-seropositives 
Analysis of cytosol of CD4+ T-cells also revealed a discrepancy between total and free glu­
tathione concentrations, however, total glutathione concentrations in cytosol of CD4+ T-
cells were higher in HIV seropositives compared to healthy controls Again a more signifi­
cant difference was noticed in patients with low CD4+ T-cell counts, while free glutathio 
Table 1 
Total and free glutathione concentrations in plasma and whole blood of healthy controls and HIV seroposi-
tiveindividuals. The values of HIV seropositives with CD4 Τ cell counts above and below 200/mm3 are also 
given. 
Plasma (μΜ) 
A) Healthy controls 
B) HIV seropositives 
C) CD4 > 200 
D) CD4 < 200 
A) different B) 
A) different D) 
η 
25 
25 
10 
15 
Total glutat 
Mean ± SD 
5.0 ± 1.3 
4.0 ± 1 1 
4.5 ± 0 9 
3.8 ± 1.2 
p-0.003 
p-0.001 
hione 
(range) 
(2.7-8.2) 
(1.8-5.8) 
(2.9-5.7) 
(18-5.8) 
Free glutathi 
Mean ±SD ( 
1.7 ±0.8 
1.7 ±0.7 
1.8 + 0.9 
1.6 ± 0 6 
n.s. 
n.s. 
ione 
range) 
(0.9-3.7) 
(0.9-3.7) 
(1.0-3.7) 
(0.9-3.5) 
Whole blood (nmol/gr haemoglobin) 
A) Healthy controls 25 72 ±1.9 (5-13.1) 
B) HIV seropositives 25 6.9 ± 1 8 (3.1-11.2) 
C) CD4S200 10 6 4 ±1.1 (4-7.8) 
D) C D 4 < 2 0 0 15 7.1 ± 1.9 (3.1 11.2) 
A) different B) or D) n.s. 
Ρ values were calculated using a two tailed Student's-t-test for unpaired samples 
Table 2 
Total and free glutathione concentrations in cytosol of CD14+ and CD4+ Τ cells of healthy controls and HIV 
seropositive individuals. The values of HIV seropositives with CD4 Τ cell counts above and below 200/mm3 
are also given. 
CD 14+ 
A) 
B) 
C) 
D) 
cells (nmol/mg protein) 
Healthy controls 
HIV seropositives 
CD4 > 200 
CD4 < 200 
A) different B) or D) 
π 
22 
22 
9 
13 
Total glutathi one 
Mean ± SD (range) 
34.8 ± 10.2 
39.3 ±9.6 
38.2 ±9.6 
39.9 ±9.9 
n.s. 
(21.8-54.7) 
(22.2-60.5) 
(22.2-50) 
(27.4-60 5) 
Free glutathi 
Mean ± SD ( 
31.5 ±5.3 
31 8 ±4.8 
30.3 ± 5.9 
32.9 ±3.6 
n.s. 
one 
range) 
(16.8-41.4) 
(22.4-41.1) 
(22.4-38.6) 
(28-41.1) 
CD4+ Τ cells (nmol/million cells) 
A) 
B) 
C) 
D) 
Healthy controls 
HIV seropositives 
CD4 > 200 
CD4 < 200 
A) different B) 
A) different D) 
17 
17 
10 
7 
0.36 ±0.15 
0.48 ±0.17 
0.44 ±0.14 
0.56±0.19 
0.02 
0.01 
(0.17-0.64) 
(0.28-0.82) 
(0.28-0.75) 
(0.28± 0.82) 
0.36 ±0.19 
0.43 ± 0.22 
0.43 ± 0.22 
0 44 ±0.24 
n.s. 
n.s. 
(0.16-0.75) 
(0.2-0.79) 
(0.2-0.79) 
(0.2-0.75) 
Ρ values were calculated using a two tailed Student's-t-test for unpaired samples. 
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ne concentrations of CD4+ T-cell cytosol were not different (Table 2) The differences in 
free and total glutathione concentrations in CD14+ cell cytosol were not significant 
between the studied groups CD14+ and CD4+ T-cell glutathione levels are expressed in 
different units due to a difference in isolation procedure Anti CD4-coated beads could be 
detached from the target cells while anti CD14-coated beads could not Therefore cytosol 
of CD14 coated cells could be obtained only by lysmg the cells For the isolation of the 
CD4+ Τ cells, the beads to cell ratio was kept constant and anti CD4 coated beads were 
detached before lysmg the cells Mean numbers of CD4+ Τ cells isolated from HIV seropo­
sitives and healthy controls were 15 χ 10" and 12 χ 10" respectively No correlation was 
found between glutathione levels and CD4+T-cell yield (R=0 02) 
Apart from glutathione, other thiols involved in synthesis and degradation of glutathione 
were quantified as well In plasma total cysteine, cystemylglycine, glutamylcysteine and 
homocysteine concentrations were not different (Table 3) In cytosol, most concentrations 
were measured just around detection limits and no reliable data can be given Cysteine 
and cystemylglycine concentrations could be determined m CD14+ cell cytosol and only 
the difference in cysteine concentrations between seropositives and controls just reached 
significance 
Discussion 
This study demonstrates that a systemic glutathione deficiency in HIV infected individuals 
is not present but shows that glutathione is redistributed in these patients Glutathione is 
located predominantly intracellular^ and intracellular concentrations were either normal 
or increased in CD14+ and CD4+ Τ cells of HIV infected patients respectively Total gluta 
thione concentrations were significantly raised in CD4+ Τ cells of HIV infected patients 
and the difference becomes more significant in patients with a CD4+ T-cell count of less 
than 200/mm^ Free glutathione concentrations in these cells were not different between 
patients and controls Also no difference was noticed in total and free glutathione con­
centration in CD14+ cells between HIV-seropositives and healthy controls An increase in 
intracellular glutathione concentration may be explained as a reaction to increased oxida­
tive stress or conjugation of toxic compounds with glutathione These processes can lead 
to a paradoxal increase m cellular total glutathione levels (21,22) Thiol reactive com 
pounds or oxidizing agents cause an increase in glutathione synthesis since the rate-limi-
tmg step of glutathione synthesis is feedback inhibited by glutathione (23) In case of oxi­
dation, the protein-bound fraction increases at the expense of free glutathione 
Two reports on HIV infected individuals have been published where intracellular free glu 
tathione concentrations within PBMC were measured with high performance liquid chro­
matography or enzymatic recycling (3,7) In one report the concentration of glutathione in 
PBMC of HIV infected patients (n=9) was similar to controls (n=6), but was significantly 
lower in patients (n=4) with more advanced disease or low CD4+ T-cell counts (7) A limi­
tation of this study was the small number of subjects studied The other study (3) repor­
ted significant differences in glutathione concentrations between controls (n=29) and un­
treated HIV patients with lymphadenopathy syndrome (n=18) and AIDS patients (n=4), 
however the difference reduced substantially in AIDS patients treated with zidovudine 
(n=17) It was not indicated whether the difference remained significant in these patients 
and it is unclear whether the results were influenced by zidovudine or the selection of the 
patients Also the storage of the heparmized blood samples at room temperature for 90-
120 mm may have an effect on the results In the present report all AIDS patients were 
treated with antiretroviral therapy, mostly zidovudine In the above cited studies, only free 
glutathione was measured and the paradoxal increase of total glutathione in CD4+ T-
cells, as shown here, was therefore not noticed. 
This is the first study whereby free and total glutathione concentrations were compared in 
plasma of the healthy controls and HIV seropositives The values of the healthy controls 
agreed well with values of publications addressing some pitfalls of these measurements 
(16,17) It was found that total glutathione concentrations in plasma of HIV seropositive 
individuals were at most 76% of those of healthy controls, while no difference in free glu­
tathione levels of HIV seropositives and healthy controls could be observed Thus, the 
plasma protein-bound form of glutathione is reduced in HIV infection and since free plas­
ma glutathione and intracellular glutathione levels are not compromised, our study does 
not warrant the conclusion made by several other investigators (3-7) of a systemic gluta­
thione deficiency in HIV infection Our observations that glutathione is redistributed in 
these patients could be reflection of increased oxidative stress. Conditions creating a pro-
oxidant enviroment may influence thiol-disulphide redox cycling by favoring disulfide for­
mation (24) Our findings of higher protein-bound glutathione levels m CD4+ T-cells of 
HIV seropositives may indicate increased oxidative stress in these cells which may be 
important for the pathogenesis of a HIV infection 
Thiols involved in glutathione homeostasis were also quantified Cysteine, glutamylcystei-
ne and homocysteine are precursors of glutathione, whereas cysteinylglycine is a degrada­
tion product. No differences between healthy controls and HIV seropositives were obser­
ved in the plasma concentrations of these thiols, which indicates that the availability of 
precursors of glutathione is not decreased The marginally increased concentrations in 
CD14+ cells indicate also that the cysteine supply of lymphocytes via macrophages is not 
compromised in HIV infection, as was suggested before (9). 
N-acetyl cysteine (NAC) has been suggested as treatment for HIV. Numerous in-vitro tests 
have demonstrated a protective role for NAC in HIV infection by inhibition of HIV replica­
tion (25-29), protection against tumor necrosis factor induced cytotoxicity (30) and 
enhancement of function and growth of Τ cells (31 ) Considering the findings of the pre­
sent m-vivo study, there is no basis for NAC administration in order to replenish cysteine 
and glutathione in HIV-induced deficiency, as was suggested before (8, 32-35) Possibly 
the favorable effect of NAC in these studies is caused by its anti-oxidant properties. 
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Cutaneous reactions to trimethoprim-sulphametrole 
in AIDS patients treated for Pneumocystis carinii 
pneumonia. 
AJAM van der Ven, An Rieger, A Branten, R Reimann, TB Vree, PP Koopmans, 
JWM van der Meer 
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Abstract 
Objective Evaluation of all HIV-positive patients (n=58) treated for Pneumocystis carinii 
pneumonia with trimethoprim-sulphametrole (=co-soltnm) from 1985 till 1994 Design 
Sulphametrole and sulphamethoxazole have similar half lives but are differently metaboli-
zed It was postulated that an oxidation product of sulphonamides (=hydroxylamine meta-
bolite) cause adverse reactions Unlike sulphamethoxazole, no metabolites of the oxidation 
pathway of sulphametrole can be detected in vivo Methods Retrospective study in two 
university hospitals Results Rash or fever developed in 18 patients after 10 (7-14) days 
(duration similar to cotrimoxazole) For toxicity evaluation treatment duration was too 
short in 6 patients In 2 patients the rash might have been caused by concomittant medi-
cation Hypersensitivity was therefore definitely attributed to co-soltrim m 30% of the 
patients (16 out of 52 patients) and possibly or probably in 35% No differences were 
recorded between hypersensitive and non hypersensitive patients in demographic data, HIV 
related diseases, drug history and laboratory values at start of PCP treatment In 8 hyper-
sensitive patients treatment was changed to a regimen also containing trimethoprim and 
no rashes were noticed Conclusions was that skin rash during co soltrim is at the lower 
range of what is reported before for cotrimoxazole 
Introduction 
Dihydropteroate synthetase (DHPS) and dihydrofolate reductase (DHPR) are enzymes 
responsible for the 'de novo' synthesis of the Folate molecule in the microbial cell 
Sulphonamides function as anti-metabolites for DHPS while trimethoprim is an inhibitor of 
DHPR The combination of these two compounds has a synergistic antimicrobial effect 
Trimethoprim and sulphamethoxazole have a similar plasma elimination half-life (tV4=10h) 
and the combination is well known as cotrimoxazole cotrimoxazole is effective against a 
broad spectrum of micro-organisms (bacteria, protozoa) and is an important medication for 
treatment (1) and prevention (2) of Pneumocystis carinii pneumonia (PCP) In HIV-infected 
individuals, the use of cotrimoxazole is hampered by the frequent occurrence of adverse 
reactions (3) Rash and fever mostly occur but hepatotoxicity, renal failure, hemolytic ane-
mia, thrombocytopenia and leukopenia are also reported It has been postulated that an 
oxidized metabolite of sulphamethoxazole, that is sulphamethoxazole hydroxylamine, plays 
a key role in the pathogenesis of the adverse reactions (3-6) 
Metabolic pathways of sulphamethoxazole are complex and involve oxidation, N4-acetyla 
tion and N1 glucuromdation (7,8) Oxidation of sulphamethoxazole leads to the toxic and 
unstable sulphamethoxazole hydroxylamine as well as to 5-hydroxy sulphamethoxazole and 
N4-acetyl-5-hydroxy sulphamethoxazole (7,8) Sulphametrole is another sulphonamide clas-
sified as medium long acting (7) Like sulphamethoxazole it has the same half-life as tri-
methoprim (10h) Sulphametrole is combined with trimethoprim in a fixed ratio 5 1, and 
named co-soltrim (Lidaprim®) Co soltrim and cotrimoxazole have a similar spectrum of 
antimicrobial activity (9) Also the pharmacokinetics of both combinations is similar (10) 
In mice the efficacy of co-soltrim and cotrimoxazole for Pneumocystis carinii was similar 
(11) The metabolism of sulphametrole is less complex compared to sulphamethoxazole 
and the mam metabolite is N4 acetylsulphametrole (10,12) In our experience no metaboli-
tes of the oxidation pathway of sulphametrole can be detected in vivo As a consequence 
of this finding, the question was raised whether the difference in metabolism of sulpha-
methoxazole and sulphametrole results in different tolerability of cotrimoxazole and co-sol-
trim in HIV-infected individuals treated for PCP The aim of this retrospective study was to 
gain information about tolerability of co-soltrim in HIV infected patients 
Methods 
Study population 
Co soltrim has been used for the treatment of PCP in the Department of Dermatology of 
the University of Vienna Medical School and in the University Hospital Nijmegen In 
Nijmegen co soltrim is only administered intravenously, when a patient can take oral 
medication the treatment is switched to cotrimoxazole In Vienna co soltrim is given both 
parenterally and orally All HIV-positive patients treated with co soltrim for PCP at both 
institutions were included in the study Excluded were the patients simultaneously treated 
with sulphadiazine for cerebral toxoplasmosis In Vienna a fixed daily dose of 5760 mg is 
given while in Nijmegen the daily dose varied from 3840 to 9600 mg No data were aval 
lable for mechanically ventilated patients in Vienna 
Data collection 
The patient files were reviewed retrospectively, and the following clinical data were recor-
ded for each PCP treatment episode origin of the patient, history of prior drug hypersensi-
tivity, the use of primary prophylaxis with a sulphonamide containing medication, major 
AIDS defining illness(es), type(s) and dates of commencement and cessation of therapy, 
use of corticoids as therapy, the concomittant use of other sulphonamides, need for assis-
ted ventilation, clinical outcome, type and date of onset of drug hypersensitivity as well as 
concomittant medication in case of adverse events The following parameters were recor-
ded at start of therapy concentration of arterial O2, hemoglobin, creatinine, lactate dehy-
drogenase and alanine aminotransferase, counts of neutrophils, platelets and CD4+ cells 
Hypersensitivity was defined by the development of fever (temperature > 38 5°C) or a 
cutaneous morbilliform eruption after institution of co-soltnm that resolved after its dis­
continuation Hypersensitivity was attributed to co-soltnm even when other drugs common­
ly associated with hypersensitivity, had been commenced concurrently Severity of the cuta 
neous eruption could not be defined retrospectively but treatment was always discontinued 
when a rash was noticed 
Statistical analysis 
To identify factors that could predict whether patients might develop a hypersensitivity 
reaction logistic regression was used Some variables had missing values and were omit­
ted Differences in these variables between the groups with and without hypersensitivity 
were tested using the Mann-Whitney U test All ρ values are two sided 
Results 
From 1985 till October 1994, 58 HIV positive patients were treated for PCP with trimet-
hoprim/sulphametrole Fifty one patients were treated in Vienna and 7 in Nijmegen 
Pneumocystis carinii was present in broncho alveolar lavage fluid or induced sputum in 52 
patients (85%), in 9 patients the diagnosis PCP was not confirmed but suspected on the 
base of clinical- and radiographic findings only 
Typically, adverse reactions developed after 8 to 12 days and all the patients treated for a 
shorter period did indeed not develop hypersensitivity The following patients were there­
fore excluded 5 patients died within 7 days after start of treatment and in 1 patient 
medication was switched when changing the route of administration after 3 days 
Eighteen out of the remaining 52 patients developed a hypersensitivity reaction and cau­
sing a change in treatment (see table 1) Rash developed in 17 patients and one patient 
reacted exclusively with fever In 7 hypersensitive patients treatment was changed to tri-
methoprim/dapsone and in 1 patient to trimethoprim/sulphamethizole and no hypersen­
sitivity was noticed anymore in any of these patients The treatment of the remaining 9 
patients was altered to intravenous pentamidine A switch to alternative treatment regi­
mens was always caused by the occurrence of a rash but not a consequence of treatment 
failure Other toxicities were also noticed but never resulted in a change of medication 
serum alanine aminotransferase increased in three patients between two and four times 
base line levels, serum creatinine increased in one patient to 180 pmol/L and thrombocy­
topenia developed between 40 and 100 χ million/L in one patient These adverse reac­
tions are generally accepted as not severe Two patients developed psychosis, but the rela­
tion with co-soltnm was uncertain All these adverse events were temporary and resolved 
spontaneously Three patients received blood transfusions but all had severe anemia at 
start of the PCP treatment 
Fifty eight patients started treatment with high dose trimethopnm/sulphametrole and 12 
patients died The cause of death in 4 cases was treatment failure, in 6 cases either cere­
bral cryptococcus neoformans, lymphoma or Pseudomonas sepsis and in two cases no 
direct cause of death could be determined Other HIV-related diseases were also noticed 
5 patients with cytomegalovirus disease, 3 patients with Kaposi sarcoma, 1 patient with 
HIV encephalopathy, 1 patient with Mycobacterium avium intracellulare bacteremia None 
of these patients was mechanically ventilated All patients (n=3) that were intubated and 
mechanically ventilated recovered 
Not all PCP diagnosis were parasitologically confirmed and the presence of Pneumocystis 
carinii was demonstrated in 7 out of 12 ( 5 8 % ) of the deceased and in 9 1 % of the survi­
vors. Treatment failure and a confirmed PCP was reported in 4 ( 7 % ) of the patients. 
Logistic regression analysis was tried to find variables predicting drug intolerance and no 
such variables were found (see table). There was a tendency of younger patients to deve­
lop adverse reactions otherwise no differences were noticed in the variables between the 
group with and without hypersensitivity to co-soltrim. 
Table. 
Comparison of baseline data, clinical- and laboratory variables in patients with and without hypersensitivi­
ty reactions to treatment with trimethoprim-sulfametrole for Pneumocystis carinii pneumonia. Analysis with 
Mann-Whitney U test and logistic regression analysis (*). 
Hypersensitives Non-hypersensitives ρ value 
0.4' 
0.50* 
0 16* 
0.07 
1* 
1* 
0.7* 
0.4* 
Number (%) 
Origin Ni|megen/Vienna 
Homosexual (%) 
IV drug abuse (%) 
Mean age, years (range) 
HIV related diseases (%) 
Kaposi sarcoma 
Mycobacterial infection 
Cytomegalovirus disease 
Lymphoma 
Drug history (%) 
Prophylaxis with sulfonamide 
Prior sulfonamide allergy 
Prior other drug allergy 
Mean lab. values at start treatment (range) 
CD4 (x 106/ml) 
p02 (kPa) 
Hb (g°/o) 
Neutrophils (xl06/ml) 
Platelets (xl06/ml) 
AL AT (U/L) 
LDH (U/l) 
Mean treatment characteristics (range) 
Duration (days) 
Cumulative dose (gram) 
Corticosteroids added 
Co-medication with known allergy 
Outcome (%) 
Died 
-Due to treatment failure 
Cured/improved 
Secondary prophylaxis 
cotrim/co-soltrim/penta 
18 
1/17 
11 
5 
36 
5 
2 
3 
1 
1 
0 
2 
B9 
9.9 
11.0 
3.8 
197 
21 
401 
9.9 
57 
4 
2 
0 
18 
18 
1/1/14 
(35%) 
(61%) 
(27%) 
(24-53) 
(27%) 
(11%) 
(16%) 
(5%) 
(5%) 
(11%) 
(5-320) 
(5.3-13.8) 
(8-14) 
(1.1-10.9) 
(30-363) 
(6-79) 
(1651140) 
(7-14) 
(40-80) 
(22%) 
(11%) 
(0%) 
(100%) 
34 
5/29 
26 
5 
41 
β 
5 
8 
5 
6 
0 
3 
63 
9.3 
11.0 
3.9 
232 
19 
390 
18.5 
106 
β 
(65%) 
(79%) 
(15%) 
(28-58) 
(25%) 
(15%) 
(25%) 
(15%) 
(18%) 
(9%) 
(10-320) 
(5 614) 
(6.9-14.5) 
(0.6-10.4) 
(22-649) 
(2-66) 
(129-1549) 
(8-29) 
(39167) 
(25%) 
unknown 
7 
4 
27 
26 
(21%) 
(12%) 
(82%) 
11/12/3 
0.4* 
0.5 
0.6 
0.9 
0.8 
0.5 
0.9 
0.9 
Discussion 
In this retrospective study in 58 HIV-seropositive patients rash and fever were documen-
ted in 18 patients (31%) treated for PCP with high dose tnmethoprim-sulphametrole Like 
cotrimoxazole, these adverse reactions occurred after about 10 days of treatment In 6 
patients, the duration of the treatment was too short to evaluate the occurrence of a rash 
and therefore it can be concluded that actually 18 (35%) out of 52 patients developed 
fever or rash In 2 patients comedication could have been responsible for the adverse 
events as well, therefore 30% of the toxicity was definitively due to co-soltrim and 5% 
possibly or probably In all cases the drug was discontinued when a cutaneous eruption 
was noticed, even if the rash was only mild The other known toxicities of sulphonamides 
were not a reason to discontinue medication In two patients hypersensitivity was attribu-
ted to co soltrim although other drugs commonly associated with hypersensitivity, had 
been commenced concurrently 
The reported incidences of adverse reactions to cotrimoxazole vary from 0% to 100% (13-
21) and the range of incidences is wide due to differences in criteria for drug reactions 
and differences in dosage regimens In their recent review, Jung and Paauw reported an 
overall incidence of cutaneous reactions to cotrimoxazole of 37-50% (1 ) Although the 
percentage found in the present study is at the lower extreme, it does not clarify whether 
the incidence of adverse reactions differs between cotrimoxazole and co-soltrim However 
it shows that somewhat contrary to our expectations, cutaneous eruptions also occur with 
co-soltrim In addition, the data are compatible with a major role for the sulphonamide 
compound in the development of toxicity in all cases the rash disappeared when tnme-
thoprim-sulphametrole was changed to trimethoprim-dapsone 
It has been postulated that sulphamethoxazole hydroxylamine plays a pivotal role in the 
pathogenesis of adverse reactions to cotrimoxazole (3) More in detail the hydroxylamine 
metabolite of sulphamethoxazole undergoes auto-oxidation to the toxic nitroso derivative, 
a process that is prevented by reduced glutathione (22) In vivo sulphamethoxazole is oxi 
dized to the unstable hydroxylamine metabolite as well as to the stable 5 hydroxy deriva 
tive both metabolites can be detected by high pressure liquid chromatography (HPLC) in 
urine and plasma (lower concentrations) after an oral dose of sulphamethoxazole We 
have recently reported their pharmacokinetics (7,8) For HPLC analysis reference comp-
ounds are needed sulphamethoxazole hydroxylamine was therefore synthesized by the 
method as described by Rieder (4), and 5 hydroxy-sulphamethoxazole was isolated from 
urine (23) 
The pharmacokinetics of sulphametrole were studied by Hekster and Vree (12) in 1981 
and at that time only the acetylated metabolite of sulphametrole was detected and repor-
ted The metabolism of sulphametrole was studied again with special attention to hydro-
xylamine formation Sulphametrole hydroxylamine could not be synthesized by the method 
of Rieder (4), therefore HPLC could not be used to detect the presence of this metabolite 
Mass spectrometry was used instead but no indication for the presence of any oxidated 
metabolite of sulphametrole could be detected in urine samples of HIV-seropositive and 
seronegative patients (n=3) treated with high dose co-soltrim for PCP (W Welz, Linz, 
Austria personal communication) 
An additional argument to investigate sulphametrole was provided by the following expe-
rience A known side-effect of sulphamethoxazole is hemolysis in individuals deficient in 
glucose-6-phosphate dehydrogenase These patients lack the capacity to keep glutathione 
in its reduced form especially in red blood cells and sulphamethoxazole, like dapsone is 
known to cause hemolysis in these patients (24) The role of the hydroxyl.imme mctaboli 
te in this drug induced hemolytic anemia has been documented for dapsone (25,26) In 
contrast to sulphamethoxazole, sulphametrole appeared not to be associated with hemoly­
sis in persons deficient in glucose-6 phosphate dehydrogenase (27), a finding supporting 
the role of the hydroxylammes m this hemolysis Traditionally, hepatic metabolism has 
been considered the major source of reactive intermediates responsible for xenobiotic toxi­
city (28) However hepatic cytochrome P450 mediated oxidation products may not be 
involved in the pathogenesis of skin rashes of sulphametrole since these oxidation pro­
ducts were not detected and their hemolytic effect was not observed If there is a role for 
sulphametrole hydroxylamme in the pathogenesis of rash, it is more likely that this meta­
bolite is skin formed 
Because the percentage of skin rash that occurs during co soltrim treatment is at the 
lower range of what is reported before for cotrimoxazole, a prospective study comparing 
co-soltrim and co-trimoxazole is needed to elucidate whether the difference in pharmaceu­
tical formulation, chemical properties and metabolism results in a different incidence of 
adverse reactions 
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Abstract 
The aim of the present study was to determine the sensitivity of Toxoplasma gon 
du in vitro for dihydrofolate reductase inhibitors and sulphonamides alone, and in 
combination It was found that pyrimethamine had the most potent anti-
Toxoplasma activity while sulphadiazme, sulphamethoxazole and sulphametrole 
were about equally effective but only at a high concentration The 5 0 % inhibitory 
concentration of sulphamethoxazole was determined m-vitro using different fixed 
concentrations pyrimethamine or trimethoprim It was found that a 10-fold incre-
ment of the concentration of pyrimethamine, reduces the ICso of sulphamethoxa-
zole 1000 times The influence of trimethoprim on the IC50 of sulphamethoxazole 
is less dose-related Addit ion of dihydrofolate or tetrahydrofolate did not influence 
the IC50 of pyrimethamine in vitro Conclusion the present dose recommendations 
for sulphonamides, when combined with pyrimethamine, are unnecessary high 
There may be a rationale for dose reduction of sulphonamides in order to prevent 
side effects 
Introduction 
Cerebral toxoplasmosis is a common opportunistic infection in patients infected with 
human immunodeficiency virus (HIV) [21 ] The combination of pyrimethamine and sulpha 
diazine is the standard treatment, with documented efficacy for Toxoplasma encephalitis 
However, the use of this combination is hampered by the frequent occurrence of adverse 
reactions in HIV-seropositive individuals [5,11,15,23] Side-effects, especially rash and 
fever, occur in up to 60% of the AIDS patients treated with a sulphonamide 
Pyrimethamine is mostly associated with bone marrow depression [13,14], but this toxicity 
may be prevented or reversed by the concomitant use of folimc acid (6,8) The incidence 
of these adverse reactions is dose dependent, both for sulphonamides and pyrimethamine 
[15,22] It is therefore important to select the lowest possible dose for treatment in HIV 
infected patients 
Sulphadiazme and pyrimethamine both exert their effect on two different steps in folic 
acid metabolism Sulphonamides function as anti-metabolites for dihydropteroate synthe­
tase (DHPS), while pyrimethamine is an inhibitor of dihydrofolate reductase (DHFR)[1,12] 
Trimethoprim is another DHFR inhibitor and the combination with sulphamethoxazole is 
used in HIV-seropositive patients for the treatment and prophylaxis of Pneumocystis can-
mi pneumonia This combination also has an anti Toxoplasma effect [3,9] Trimethoprim is 
also available in combination with sulphametrole but less is known about this combina­
tion Sulphametrole has been associated with less toxicity, especially m patients deficient 
for glucose 6 phosphate dehydrogenase [18] Unlike DHPS, DHFR is present both in Τ 
gondii and mammalian cells but the affinity of pyrimethamine for Toxoplasma DHFR is 
much higher compared to mammalian DHFR Mammalian cells possess a carrier-mediated 
active transport system responsible for the uptake of preformed folates while Τ gondii 
lacks this system [2] 
The aim of the present study was to determine the sensitivity of Τ gondii for DHFR inhibi­
tors and sulphonamides alone and in combination We also addressed the question to 
what extent a dose increase of pyrimethamine could lead to a reduction of the sulpho-
namide dose with similar ant\-Toxoplasma effect Since higher dosages of DHFR inhibitor 
could possibly require the use of folimc acid, the influence of folimc acid was studied as 
well 
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Materials and methods 
The in-vitro tests were performed as described before [17,20] In brief HEp-2 cells were 
prepared in 96-well tissue culture plates (Costar, Cambridge, Mass ) and grown to conflu­
ence At the start of the assay, Τ gondii parasites of the RH strain were transferred to fresh 
culture medium at a concentration of 10^ parasites per ml The drugs to be studied were 
supplemented to the culture medium m the concentrations to be tested The HEp 2 cells 
were overlaid with 150 μΙ of the parasite suspension (parasite-to-cell ratio, 0 7), and incu­
bated at 5% C02, 90% humidity and 36°C for 90 h Each test included eight wells wit­
hout parasites and eight wells with parasites but no drugs Each drug concentration was 
tested eightfold, and each test was performed three times After 90 h incubation, parasite 
growth was quantified using an enzyme-linked immunosorbent assay, which was performed 
directly on Τ gondi i-\nfected HEp-2 cells, as described before [20] After incubation with 
human antiserum against Τ gondii, horseradish peroxidase labeled rabbit anti human 
immunoglobulin (Dakopatts, Kopenhagen, Denmark) was supplemented and the color reac­
tion with o-phenylenediamine (Sigma, St Louis, MO) with perhydrol 30% H2O2 (Merck, 
Darmstadt, Germany) was quantified in a spectophotometer 
Pyrimethamine and trimethoprim were obtained from Wellcome (Kent, England), sulphadia­
zine was obtained from OPC (Utrecht, the Netherlands), sulphamethoxazole was obtained 
from Hoffman laRoche (Basel, Switserland), sulphametrole from Nycomed (Vienna, Austria) 
The 50% inhibitory concentrations (ICso) were determined by testing the drugs at the fol­
lowing concentrations pyrimethamine 5, 1, О 5, 0 4, 0 3, 0 2, 0 1, 0 075, 0 05 and 
0 01mg/L, trimethoprim 100, 50, 20, 15, 10, 5, 2, 1, 0 5 and 0 lmg/L, sulphadiazine, 
sulphamethoxazole, sulphametrole 1000, 900, 800, 700, 600, 500, 400, 300, 200 and 
100mg/L The ICso of sulphamethoxazole was also studied in combination with a fixed 
dose of pyrimethamine and trimethoprim In these experiments, the concentrations pyri­
methamine were 0 0001, 0 0005, 0 001, 0 005, 0 01, 0 025, 0 05, 0 1, 0 15, 0 2, 0 4 
mg/L, and trimethoprim concentrations were 0 5, 1, 2, 3, 4, 5, 6, 7, 8, 9 10 mg/L The cor­
responding IC50 of sulphamethoxazole was quantified by testing sulphamethoxazole at the 
following concentrations 200, 100, 50, 20, 10, 5, 1, 0 5, 0 5, 0 1, 0 05, 0 01, 0 005, 0 001, 
0 0005, 0 0001, 0 00005 mg/L 
The addition of 0 3 mg/L, 1 mg/L tetrahydrofolate or 1 mg/L dihydrofolate to the culture 
medium was also studied for the effects on the ICso of pyrimethamine 
Statistical analysis The ICso were calculated as has been described before [20] 
Table 
In vitro effect (50% inhibitory concentrations) of different drugs on Τ gondii 
ICso (mg/L) 
Trimethoprim 510 
Pyrimethamine 0 2 
Sulphadiazine 600 700 
Sulphamethoxazole 400 500 
Sulphametrole 600 700 
Results 
The ICso for pyrimethamine, trimethoprim and the three sulphonamides is given in the 
table It was found that pyrimethamine has the most potent anti Toxoplasma activity and 
trimethoprim is some 25 50 times less active in vitro The tested sulphonamides were 
about equally active but on a weight basis are 40 3500 times less active compared to the 
tested DHFR inhibitors Sulphamethoxazole was used to test the combination with a 
DHFR inhibitor Figure l a presents the IC50 for sulphamethoxazole at various concentra­
tions of pyrimethamine and trimethoprim and shows that a 10-fold increment of the con­
centration of pyrimethamine reduces the IC50 of sulphamethoxazole 1000 times Figure 
1 b demonstrates that the апЬ-Toxoplasma effect of the combination trimethoprim sulpha 
methoxazole is not as dose related The addition of tetrahydrofolate or dihydrofolate to 
the culture medium did not change the IC50 for pyrimethamine (results not shown) 
Discussion 
All the tested compounds possessed antimicrobial activity against Τ gondii but the hig 
hest in vitro activity was observed using DHFR inhibitors and in particular pyrimethamine 
ICso and attainable plasma concentrations may, however, only be compared cautiously 
The ICso of pyrimethamine (0 2mg/L) in this in-vitro system is in the range of plasma 
concentrations obtained after a once weekly dose of 75 mg pyrimethamine [17] 
Trimethoprim has a higher ICso (5 10 mg/L) and concentrations in this range are only 
reached when patients are treated with the relatively high dose of trimethoprim of 20 
mg/kg body weight daily [10] The ICso's of the three sulphonamides are all within the 
same range and are well above the concentrations found in patients treated with a high 
dose of sulphonamides of 100 mg/kg body weight daily [10] 
The ICso of sulphamethoxazole of 500 mg/L is reduced considerably when a DHFR inhibí 
tor was added to the incubation medium The addition of 0 005 mg/L pyrimethamine to 
the incubation medium reduced the ICso of sulphamethoxazole to 50 mg/L and even to 
0 05 mg/L when 0 05 mg/L pyrimethamine was used, pointing to a strong potentiation 
Because of the strongly potentiating effect of pyrimethamine, sulphonamides will remian 
effective at much lower doses than presently recommended It is likely that dose reduction 
of sulphonamides will not reduce efficacy but will only reduce toxic side effects 
Trimethoprim combined with a sulphonamide is not as potent as a combination with pyri-
methamine This is a reason to be cautious to reduce cotrimoxazole dosages in HIV 
patients on PCP prophylaxis The protective effect of 960 mg cotrimoxazole daily is alre-
ady questionable [16] and further dose reduction may hamper concomittant Toxoplasma 
protection 
Pyrimethamine serves to trap cellular folates in the nonfunctional dihydro state The accu-
mulation of dihydrofolate reduces the effectiveness of the pyrimethamine The effect of 
newly formed dihydrofolate is eliminated by the simultaneous application of a sulpho-
namide and by feedback inhibition of accumulated dihydrofolate on its synthesis [12] 
This may explain why an increment of the concentration pyrimethamine dramatically redu-
ces the need for a sulphonamide with similar effect on Γ gondii The affinity of 
Toxoplasma DHFR for trimethoprim is less compared to pyrimethamine [4] This may 
explain that the anti Toxoplasma effect of the combination trimethoprim sulphamethoxa 
zole is not as dose related 
These findings suggest that the dose of pyrimethamine should be high for the treatment 
of Τ gondii infection When haematologic toxicity occurs during pyrimethamine treatment, 
concomitant use of folmic acid will not reduce the effectiveness of the anti-Toxoplasma 
therapy This is in contrast with a report on the treatment of Pneumocystis carimi pneu­
monia in AIDS patients with trimethoprim sulphamethoxazole where adjunctive folmic 
acid was associated with increased therapeutic failure [19] 
In conclusion the present dose recommendations for sulphonamides, when combined with 
pyrimethamine or trimethoprim, do not account for the potentiating effect of the combi­
nation and may therefore be too high This can lead to unnecessary toxicity m HIV infec­
ted patients and further investigations are needed to determine the optimum dose ratio 
of such combination in these patients 
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Chapter 12 
Adverse reactions to cotrimoxazole 
in HIV infection: a reappraisal of the glutathione 
hydroxylamine hypothesis. 
AJAM van der Ven, TB Vree, PP Koopmans, JWM van der Meer 
J Antimicrob Chemother, In press 
Summary 
It was postulated that the unstable hydroxylamine metabolite of sulphamethoxazole is 
causing the adverse reactions to cotrimoxazole and that in HIV infection a systemic glu­
tathione deficiency leads to a reduced capacity to counteract the toxicity of the hydroxyla-
mmes, thereby increasing the intolerance to this drug This hypothesis was investigated by 
the study of the metabolism of sulphamethoxazole, assessment of glutathione status in 
HIV infection and the exploration of treatment modification It was concluded that the 
toxicity of sulphamethoxazole hydroxylamine in plasma is counteracted by normal glutat­
hione concentrations, also in HIV seropositive patients, but the presence of increased oxi­
dation within certain cells in HIV infected individuals may possibly lead to increased con­
centrations of reactive intermediates of sul phamethoxazole Sulphametrole and sulpha­
methoxazole have a similar half life but are differently metabolized in vivo no oxidated 
metabolites of sulphphametrole could be detected In a retrospective study the rate of 
adverse reactions to trimethoprim-sulphametrole seemed in the lower range of what is 
reported before for trimethoprim-sulphamethoxazole, also an indication that this combina­
tion may be more favorable The ratio of the dose trimethoprim sulphonamide is 1 5 but 
m-vitro studies with Toxoplasma gondii indicate that, because of the synergistic effect of 
both compounds, the dose sulphonamide is possibly unneccessary high 
Introduction 
The combination of trimethoprim and sulphamethoxazole (cotrimoxazole) is an important 
drug for the treatment and primary and secondary prophylaxis of Pneumocystis carinii 
pneumonia (PCP) in patients with infection caused by the human immunodeficiency virus 
(HIV) However, the administration of cotrimoxazole in these patients is often hampered, 
because the frequency of adverse reactions to cotrimoxazole in HIV infected patients is 
much higher compared to seronegative individuals (Kovacs et о/,1984) These side effects, 
which are often labeled as "allergic", consist of rash, fever and damage of liver parenchy-
mal cells Although HIV seropositive individuals are more susceptible to similar side 
effects to a number of other, unrelated drugs [reviewed by Coopman et al, et al 1993, 
Koopmans et a/,1995], this review focuses on the side effects of cotnmoxazole Some 
years ago, we have hypothesized that this increased frequency of toxicity to cotnmoxazole 
is caused by a combination of two factors (van der Ven et al, 1991, 1994b) First of all, 
the hydroxylamme derivative of sulphamethoxazole is an unstable metabolite that can 
undergo auto-oxidation to become a protein-reactive nitroso derivative, and this substan­
ce could be responsible for the adverse reactions to cotnmoxazole (Rieder et al, 1988, 
1989, Shear et al, 1986) This means that the sulphonamide component of cotnmoxazole 
is expected responsible for the side-effects, although the oxidation of trimethoprim could 
possibly also lead to hydroxylamme formation Secondly, HIV infected individuals have a 
systemic glutathione deficiency according to the literature (Buhl et al, 1989, Eck et al, 
1989) This deficiency implies that there is a reduced capacity to prevent auto oxidation 
of the unstable sulphonamide intermediates and a reduced capacity to scavenge reactive 
compounds As a consequence, there is an increased exposure of the cells of the patient 
to toxic intermediates and this could lead to the adverse reactions 
The hypothesis was the subject of a series of investigations carried out by our group 
The investigations comprised of studies of the metabolism of sulphamethoxazole and 
other sulphonamides, of the assessment of the glutathione status in HIV-infected patients 
and the exploration of treatment modifications 
Sulphamethoxazole metabolism 
Sulphamethoxazole is extensively metabolized in vivo, its metabolic pathways involve ace-
tylation, oxidation and glucuronidation (Vree et al, 1987, 1994) Oxidation takes place at 
different positions of the molecule the unstable, reactive hydroxylamme metabolite is for­
med by oxidation of the N4 nitrogen atom while oxidation of the C5 methyl group leads 
to the stable 5-methylhydroxy metabolite Formation of both metabolites by cytochrome 
P450 mediated reaction was demonstrated in-vitro using human liver microsomes In-vitro 
more sulphamethoxazole was N-hydroxylated than 5-methylhydroxylated (van der Ven et 
al, 1995a) 
The pharmacokinetics of sulphamethoxazole and its metabolic products was reported in 
healthy volunteers after a single oral dose (Vree et α/,1994, 1995) The pattern of the for­
mation and elimination of sulphamethoxazole hydroxylamme was similar to the other 
metabolic products, and the renal excretion of sulphamethoxazole hydroxylamme accoun­
ted for 2 4 % of the dose (van der Ven et al, 1994c) The mean residence time of the 
hydroxylamme metabolite was 5 5 hours, the renal clearance amounted 4 39 l/hr Thus, 
under physiological conditions most sulphamethoxazole hydroxylamme seems to be sta­
ble, escapes the liver and is excreted by the kidney 
Next, the pharmacokinetics of sulphamethoxazole and its metabolites was also investiga­
ted in HIV-seropositive individuals after a single oral dose (van der Ven étal, 1995b) 
Sulphamethoxazole hydroxylamme is the only compound for which the urinary recovery 
was found to be different from healthy volunteers The impaired recovery of sulphamet-
hoxazole hydroxylamme in HIV seropositive patients (50% reduction) may be explained by 
secondary metabolism to the protein reactive nitroso derivatives At the time of the inves-
tigations, it was not clear whether this auto-oxidation occurred in the urine ex vivo or in 
vivo because of glutathione deficiency Because the urinary excretion of all other metabo-
lites of sulphamethoxazole, including 5-methylhydroxy sulphamethoxazole and N4-acetyl-
5-methylhydroxy-sulphamethoxazole, was similar between HIV-seropositive individuals and 
healthy controls, we concluded that there was no difference in oxidation, acetylation and 
glucuronidation 
Taken together, we can conclude that the sulphamethoxazole hydroxylamme indeed is 
being formed during treatment with sulphamethoxazole by normals and by HlV-seropositi-
ve patients 
Although the cytotoxic potential of hydroxylamines of sulphonamides can be demonstra­
ted in vitro (Rieder et al, 1988, 1989), the relative toxicity of these compounds, as com­
pared to the parent compounds (which also exert cytotoxicity, van der Ven, unpublished), 
has not been worked out in terms of the relative concentrations in vivo 
Glutathione status 
Glutathione is the mam intracellular defense against oxidative stress and is of major 
importance for xenobiotic metabolism Intracellular concentrations of glutathione are 
high, while plasma concentrations are low 
Several groups have reported decreased glutathione concentrations in HIV infection, in 
particular in plasma, bronchoalveolar lavage, peripheral blood mononuclear cells (Buhl et 
al, 1989, Eck et al, 1989) and also in CD4+ and CD8+ Τ lymphocytes (Roederer et al, 
1991) Based on these investigations, it was concluded that HIV infection is associated 
with a systemic glutathione deficiency 
Glutathione concentrations in CD4+ and CD8+ Τ lymphocytes were determined using 
monochlorobimane as a fluorescent label However, when we evaluated this method, we 
found that many variables influenced the cellular fluorescence, including the presence of 
alternative metabolic pathways for monochlorobimane and the rapid excretion of gluta-
thione-bimane conjugate out of the cell We had to conclude that this label cannot be 
used to assess glutathione levels m these cells (van der Ven et al, 1994a) High perfor 
mance liquid chromatography is a validated method to measure glutathione concentra­
tions and this method was employed to measure free and protein-bound glutathione con­
centrations in HIV seropositive individuals and healthy controls Both forms of glutathione 
were determined because free glutathione is important for the maintenance of thiol redox 
status, while increased concentrations of protein-bound glutathione indicate oxidative 
stress We found that free intracellular glutathione concentrations of erythocytes, CD14+ 
cells and CD4+ cells were not different between HIV seropositive individuals and healthy 
controls (van der Ven et al, manuscript in preparation) In addition, we found that plasma 
concentrations of free glutathione were not different either Based on these findings, we 
concluded that HIV infection is not associated with a systemic glutathione deficiency It 
was found, however, that the protein bound form of glutathione was increased in particu­
lar m CD4+ cells of HIV seropositives which strongly suggests the presence of increased 
oxidative stress 
So far, we tend to conclude that the toxicity of sulphamethoxazole hydroxylamme in plas­
ma is counteracted by normal glutathione concentrations, also in HIV-seropositive 
patients It could be speculated that in these patients, the presence of increased oxidation 
within certain cells may lead to increased concentrations of reactive intermediates of sul­
phamethoxazole It is clear that further research is needed in this area 
Treatment modification 
Treatment modification with regard to the choice of the sulphonamides was also investi­
gated We explored the metabolism of a number oF different sulphonamides to try and 
select a sulphonamide that would generate less hydroxylamine Ten different sulphonami­
des were incubated in-vitro with human liver microsomes and these experiments indicated 
that all tested sulphonamides generated stable as well as unstable oxidated metabolites, 
but not all to the same extent The generation of oxidated products was least for sulpha-
metrole In vivo the rate of oxidation between the various sulphonamides also differs, and 
the same holds for the rate of acetylation and glucuronidation (Vree et al, 1987) It is 
generally accepted that the acetylated compound is поп toxic (Rieder et α/,1991 ), thus, a 
sulphonamide that is accessible for acetylation but not for oxidation may be more favora­
ble than an extensively metabolized compound like sulphamethoxazole The acetylation of 
sulphametrole in vivo has been reported before (Hekster et al, 1981 ), and is till today the 
only metabolic reaction Restudy of sulphametrole metabolism using mass spectrometry 
did not indicate the presence of any oxidated metabolite in urine of healthy controls and 
HIV seropositives (W Welz, Linz, Austria, personal communication) Since a stable hydroxy 
metabolite could not be detected, it is well possible that sulphametrole is not accessible 
for cytochrome P450 mediated reactions in vivo Like sulphamethoxazole, sulphametrole is 
commercially available in a 5 1 dose ratio with trimethoprim (Co soltrim) 
Sulphamethoxazole and sulphametrole have similar half-lifes (lOh) 
From the inability to detect hydoxylamine metabolites of sulphametrole, we were eager to 
know whether administration of sulphametrole would meet with fewer adverse effects, 
especially in HIV-seropositive patients This was supported by a report in the literature, in 
which sulphametrole did not appear to be associated with hemolysis administered m a 
population with a high prevalence of glucose 6-phosphate dehydrogenase (Plummer et ai, 
1983) These patients lack the capacity to keep glutathione in its reduced form, especially 
in the red blood cells, and sulphamethoxazole is known to cause hemolysis in these 
patients (Beutler, 1991) Recently we could perform a retrospective analysis of 58 HIV 
patients treated for PCP with Co-soltrim in two centers The analysis showed that only skin 
reaction or fever was an indication to change the medication and that adverse reactions 
occur at a lower rate of what has been reported before for cotrimoxazole (van der Ven et 
al, manuscript in preparation) These results would justify a prospective controlled study 
comparing the frequency of side effects of sulphamethoxazole with that of sulphametrole 
in HIV positive patients 
Since our hypothesis points to a concentration-dependent mechanism rather than to a 
allergic (ι e , concentration independent) mechanism, dose reduction would be an option 
Such a strategy finds some support in the study of Schneider et al (1992), which demon­
strated that a relatively low dose (480 mg daily) of cotrimoxazole for PCP prophylaxis in 
HIV-positive patients was associated with a delayed occurrence of side effects than a high 
dose (960 mg daily) 
In view of the dose dependency, we investigated the optimal dosage ratio of sulphonami­
de and dihydrofolate reductase (DHFR) inhibitors (trimethoprim, pyrimethamine) At pre­
sent the aimed plasma concentration of the sulphamethoxazole (100-200 pg/ml) is much 
higher than that of the DHFR inhibitor (for trimethoprim 5-10мд/тІ) The dose recom 
mendations are based on inhibitory concentrations of each compound separately without 
taking into account the synergistic effect of the combination This synergistic effect was 
demonstrated in an in vitro study using Toxoplasma gondii We found that the 50% inhi-
bitory concentration of sulphamethoxazole reduced from 500 to 0 05pg/ml when 
0 05pg/ml pyrimethamine was added to the medium, considering that plasma concentra­
tions pyrimethamine obtained with once weekly a dose of 75 mg are around 0 2 м д / т і 
(van der Ven et al, manuscript in preparation) These findings could imply that the pre­
sent dose recommendations for sulphonamides, when combined with trimethoprim or pyri­
methamine, are too high, and thereby result in unnecessary high toxicity It should be 
investigated whether the toxicity of the current first line treatment for Pneumocystis can-
nil and Toxoplasma gondii may be reduced by selection of a less toxic sulphonamide used 
with an DHFR inhibitor at an adjusted dosage ratio 
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Samenvatting 
Pneumocystis carimi pneumonie (PCP) is een belangrijk opportunistische infectie bij patiën-
ten die geïnfecteerd zijn met het humane immunodeficientievirus (HIV) Behandeling vindt 
plaats door middel van hoge dosis Cotrimoxazol Dit is een combinatie van twee genees 
middelen, namelijk trimethoprim en sulfamethoxazole Cotrimoxazol geeft bij AIDS patiën-
ten vaker (40 80%) aanleiding tot het ontstaan van bijwerkingen in vergelijking met niet 
HIV geïnfecteerden (ï>%), ook indien die patiënten om een andere reden een gestoorde 
immuniteit hebben De oorzaak van de hoge frequentie van bijwerkingen bij HIV- geïnfec-
teerden is onbekend Dit proefschrift is een studie naar de factoren die hiervoor verant 
woordelijk zouden kunnen zijn 
In hoofdstuk 1 wordt een hypothese geformuleerd over een mogelijk ontstaansme-
chamsme Er wordt gesteld dat de bijwerkingen van Cotrimoxazol worden veroorzaakt door 
een instabiel stofwisselmgsprodukt (hydroxylamme metaboliet) van Sulfamethoxazol HIV-
patienten hebben een gebrek aan glutathione waardoor het vermogen om hydroxylamme 
metabolieten te neutraliseren is verminderd Glutathione is een belangrijke stof in het 
lichaam, onder andere voor het metabolisme van lichaamsvreemde stoffen en het "wegvan-
gen" van reactieve verbindingen HlV-seropositieve patiënten kunnen dus in een hogere 
mate blootgesteld worden aan reactieve stofwisselingsprodukten Dit zou de verhoogde fre-
quentie van bijwerkingen van cotrimoxazole kunnen verklaren 
In hoofdstuk 2 wordt beschreven dat niet alleen de behandeling van een PCP met 
Cotrimoxazol vaak leidt tot huidreacties en koorts bij HlV-geinfecteerde patiënten maar dat 
dit probleem ook bij andere geneesmiddelen vaker voorkomt 
In een reeks onderzoeken werd deze hypothese verder uitgewerkt Met name werd aan-
dacht besteed aan de stofwisseling van Sulfonamiden (hoofdstuk 3-7), de glutathione sta-
tus van HIV patiënten (hoofdstuk 8,9) en mogelijkheden om de kans op bijwerkingen te 
verminderen (hoofdstuk 10,11) 
In hoofdstuk 3 wordt de isolatie, identificatie en analyse van Sulfamethoxazol en 
diens metaboheten in menselijke plasma en urine door middel van High Performance 
Liquid Chromatography (HPLC) beschreven Sulfamethoxazole wordt uitgebreid gemetaboli-
seerd de stofwisselingsreacties omvatten hoofdzakelijk acetylering (leidend tot N4 acetyl-
sulfamethoxazol), glucuronidering (leidend tot sulfamethoxazol-Nl-glucuronide) en oxida-
tie Oxidatie van de C5 methyl groep leidt tot de stabiele 5-methylhydroxysulfamethoxazol 
en de stabiele N4-acetyl-5-methyl hydroxysulfamethoxazol Oxidatie van het N4 stikstof 
atoom leidt tot het onstabiele hydroxylamme metaboliet De moeder verbinding en de 
geacetyleerde metaboliet zijn commercieel verkrijgbaar en Sulfamethoxazol hydroxylamine 
werd synthetisch vervaardigd De andere metabolieten werden uit de urine geïsoleerd Het 
is van belang om ook de stofwisselingsprodukten van Sulfamethoxazol in zuivere vorm in 
handen te hebben wanneer men de volledige pharmacokinetiek wil bestuderen Talloze in 
vitro studies hadden in het verleden de schadelijkheid van Sulfamethoxazol hydroxylamine 
aangetoond maar in vivo gegevens ontbraken op dat moment 
In hoofdstuk 4 wordt de pharmacokinetiek van Sulfamethoxazol hydroxylamine bij 
gezonde vrijwilligers beschreven na een eenmalige gift Het bleek dat het patroon van de 
vorming en de uitscheiding van deze metaboliet hetzelfde was als de andere (stabiele) 
metabole Produkten Men kan hieruit afleiden dat onder physiologische omstandigheden 
Sulfamethoxazol hydroxylamine (grotendeels) stabiel is, in staat is de lever te verlaten en 
in de urine wordt uitgescheiden De uitscheidmg van de hydroxylamine metaboliet via de 
nier bedroeg 2 4% van de toegediende dosis Sulfamethoxazol 
In hoofdstuk 5 wordt de pharmacokinetiek van Sulfamethoxazol en alle andere meta-
bolieten beschreven bij gezonde vrijwilligers na een eenmalige gift Sulfamethoxazol werd 
snel en vrijwel volledig door het lichaam opgenomen De geacetyleerde metaboliet was in 
grootste hoeveelheid in de urine aanwezig (43 5%), gevolgd door de moeder verbinding 
(14 4%) en het glucuromde (9 8%) De renale uitschelding van de som van alle geoxideer-
de verbindingen samen bedroeg ongeveer 10% van de ingenomen dosis 
In hoofdstuk 6 wordt de kinetiek van Sulfamethoxazol bij HIV- geinfecteerden en 
gezonde vrijwilligers vergeleken na een eenmalige gift BIJ de HIV geinfecteerden werd 
alleen de urine geanalyseerd Het bleek dat alleen de uitscheiding van Sulfamethoxazol 
hydroxylamine in de urine verschilde (50% reductie), terwijl alle andere metabolieten geen 
verschil vertoonden tussen HlV-gemfecteerden en vrijwilligers Er werd geconcludeerd dat 
de mate van acetylering, glucuronidering niet verschillend was tussen de twee onderzochte 
groepen, alsmede oxidatie omdat de opbrengst van de stabiele 5 methyl hydroxy- en de sta-
biele N4-acetyl-5-methylhydroxy Sulfamethoxazol niet verschilde De vermindering in 
opbrengst van Sulfamethoxazol hydroxylamine kan verklaard worden doordat deze verbin-
ding door auto-oxidatie aanleiding kan geven tot eiwit-reaktieve nitroso derivaten die niet 
verder te meten zijn Het is onduidelijk of dit proces plaatsvond in- of ex vivo 
In hoofdstuk 7 wordt de in-vitro oxidatie van Sulfamethoxazol beschreven door micro-
somen die geïsoleerd waren uit 17 verschillende humane levers De mate van N-hydroxyla-
tie door de diverse microsomale preparaten in vitro verschilde aanzienlijk en mogelijk 
draagt deze variatie bij aan de mtenndividuele variatie in de gevoeligheid voor sulfonami 
den De synthesesnelheid van 5-methylhydroxy Sulfamethoxazol was 68% van die van Sul-
famethoxazol hydroxylamine Pharmacokinetische experimenten met de gezonde vrijwil h 
gers lieten echter zien dat er meer 5 methylhydroxy Sulfamethoxazol werd uitgescheiden in 
de urine Mogelijk dat de vorming van 5 methylhydroxy Sulfamethoxazol in vitro differen-
tieel verminderd is of dat een deel van de Sulfamethoxazol hydroxylamine in vivo verder 
wordt gemetaboliseerd 
In hoofdstuk 8 wordt het gebruik van monochlorobimane geëvalueerd om glutathio-
ne te meten m mononucléaire cellen uit perifeer bloed Onderzoekers hadden deze stof 
gebruikt om glutathione te meten in CD4- en CD8 positieve T-cellen ZIJ maakten daarbij 
gebruik van het gegeven dat monochlorobimane gebonden aan glutathione een fluoresce-
rend produkt geeft De evaluatie wees uit dat de fluorescentie niet alleen onder invloed 
van binding aan glutathione ontstond maar dat vele factoren het ontstaan ervan bepalen 
Ook bleek dat het gevormde glutathione bimane produkt aktief de cel werd uitgepompt 
zodat de meeste fluorescentie zich buiten de cel bevond, terwijl de meting door de flowcy-
tometer in de cel werd verricht Het gebrek aan specificiteit maakt monochlorobimane 
ongeschikt om glutathione te meten in mononucléaire cellen De waarde van eerdere glu-
tathione metingen in CD4- en CD8 positieve Τ cellen van HlV-geinfecteerden en gezonde 
vrijwilligers door middel van monochlorobimane wordt hierdoor twijfelachtig 
In hoofdstuk 9 worden glutathione concentraties vergeleken in plasma, vol bloed en 
in cytosol van CD4 en CD14 positieve cellen van HlV-geinfecteerden en gezonde vrijwilli­
gers Met gevalideerde methoden (HPLC) werden het totale en het vrije (dat wil zeggen 
niet eiwit gebonden) glutathione gemeten Het vrije glutathione is de biologisch belang­
rijke vorm, terwijl de hoeveelheid eiwit gebonden fraktie een maat is voor oxidatieve 
stress Het bleek dat de hoeveelheid vrij glutathione niet verschillend was in plasma, vol 
bloed en in de cytosolen van CD4- en CD14 positive cellen van HlV-gemfecteerden en 
gezonde vrijwilligers Alleen de concentraties totaal glutathione verschilden in CD4 posi­
ti eve-T-ce II en was het verhoogd en in plasma verlaagd in HlV-gemfecteerden Ook sommi­
ge bouwstoffen en afbraakprodukten van de glutathione synthese (totaal cysteine, cystei-
nylglycine, glutamylcysteine, homocysteine) werden gemeten in plasma zonder dat een 
verschil werd gevonden tussen de twee groepen Al deze gegevens ondersteunen dus met 
de gedachte, zoals die werd geopperd door andere onderzoekers, dat HIV- infectie samen­
hangt met een gebrek aan glutathione Wel is er mogelijk een toename van oxidatieve 
stress in bepaalde cellen 
In de twee volgende hoofdstukken worden mogelijkheden om de behandeling gunstig 
te beïnvloeden besproken 
In hoofdstuk 10 wordt een retrospectieve studie beschreven waarin AIDS patiënten 
werden behandeld voor een PCP met trimethoprim-sulfametrol (co-soltrim) Sulfametrol en 
sulfamethoxazole hebben een zelfde half waarde tijd maar worden verschillend gemetabo-
liseerd Van sulfametrol werd tot nu toe slechts één metabool produkt aangetoond, name-
lijk N4-acetyl sulfametrol De urines van zowel HIV positieve als HlV-negatieve patiënten, 
behandeld met een hoge dosis co-soltrim, werden geanalyseerd met HPLC en massaspec-
tometrie en hierin konden geen geoxideerde metabolieten van sufametrole worden aange-
toond Alle HIV- positieve patiënten (n=58) die werden behandeld met trimethoprim-sulfa-
metrol voor PCP van 1985 tot en met 1994 in de universiteitsziekenhuizen van Wenen en 
Nijmegen werden bestudeerd Huidreacties of koorts traden op bij 18 patiënten na gemid 
deld 10 dagen (7 14), de tijdsperiode is gelijk aan die van Cotrimoxazol gebruik Zes 
patiënten werden te kort behandeld om de toxiciteit te kunnen evalueren, daarom traden 
koorts of huidreacties bij 18 van de 52 patiënten (35%) op Echter twee patiënten 
gebruikten gelijktijdig andere medicijnen die ook vaak geassocieerd zijn met bijwerkingen 
Co-soltrim veroorzaakte dus zeker bijwerkingen in 30% van de gevallen en mogelijk of 
waarschijnlijk in 35% BIJ 8 patiënten met overgevoeligheidsreacties werd de behandeling 
voortgezet met de combinatie trimethoprim-dapson en in alle gevallen verdwenen de 
huidreacties Dit laatste suggereert dat sulfametrole een cruciale rol speelde bij het ont-
staan van de huidreacties op co-soltrim Verder vermeldt de literatuur in het algemeen 
een hoger percentage bijwerkingen bij gebruik van Cotrimoxazol Sulfonamiden worden 
meestal gebruikt in combinatie met een dihydrofolaat reductase (DHFR) remmer, zoals tri-
methoprim en pyrimethamine De dosis en gewenste plasma concentratie van de sulfo-
namide is veel hoger dan die van de DHFR remmer 
In hoofdstuk 11 wordt een in vitro onderzoek beschreven waarin wordt onderzocht 
bij welke verhoudingen van concentraties van sulfonamide en DHI-R remmer een antimi-
crobieel effect optreedt De in-vitro anti Toxoplasma gondii aktiviteit van trimethoprim, 
pyrimethamine en drie verschillende Sulfonamiden werd getest Het bleek dat pyrimetha-
mine het sterkste anti-Toxoplasma effect had, en de sulfonamides de laagste aktiviteit De 
combinatie van DHFR remmer en sulfonamide had een synergistisch effect en er werd 
aangetoond dat een 10-voudige verhoging van de pyrimethamine concentratie de concen-
tratie van sulfonamide waarbij groeiremming optreedt een factor 1000 doet verlagen De 
huidige dosis aanbevelingen houden geen rekening met dit synergistisch effect en het is 
dus mogelijk dat sulfonamides te hoog worden gedoseerd wanneer deze samen met een 
DHFR remmer worden gebruikt Dosis reductie zou in minder bijwerkingen kunnen resulte-
ren zonder een verandering van de effectiviteit van de behandeling 
Abbreviations 
AIDS Acquired Immunodeficiency Syndrome 
CSH Glutathione 
GST Clutathione-S-Transferase 
HIV Human Immunodeficiency Virus 
HPLC High Performance Liquid Chromatography 
MCB Monochlorobimane 
PBMC Peripheral Blood Mononuclear Cells 
PCP Pneumocystis Carimi Pneumonia 
S Sulphamethoxazole 
N40H Sulphamethoxazole hydroxylamine 
Sgluc Sulphamethoxazole-Nl-glucuronide 
N4 N4 Acetyl-Sulphamethoxazole 
N4SOH N4-Acetyl-5-(Methyl)Hydroxy-Sulphamethoxazole 
SOH 5-(Methyl)Hydroxy-Sulphamethoxazole 
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Antwerpen behaald. Na een assistentschap Chirurgie/Gynaecology in het St. 
Laurensziekenhuis te Breda, werkte hij vijf en een halfjaar als tropenarts in Botswana, 
In 1988 begonnen met de opleiding tot internist; twee jaar Canisius Wilhelmina zie-
kenhuis (opleider Dr IH Go), drie jaar Academisch Ziekenhuis Nijmegen (opleider prof 
Van 't Laar, later prof Van der Meer), voltooiing opleiding april 1993. Vanaf september 
1993 werkte hij op de afdeling Algemeen Interne Geneeskunde van het Academisch 
Ziekenhuis Nijmegen aan de tot standkoning van dit proefschrift en volgde er de 
opleiding tot internist-infectioloog. 
Hij is getrouwd met Marjolein Roeland en heeft drie zonen, Menno, Viktor en Oscar. 
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Dankwoord 
Dit proefschrift kon alleen maar tot stand komen dankzij de interesse en energie van veel 
mensen In de eerste plaats zijn er de patiënten die herhaalde malen extra voor bloedaf-
name naar het ziekenhuis zijn gekomen Ook zijn er (mede)-auteurs die ik apart vermeld 
al deze mensen hebben een wezenlijke bijdrage geleverd aan de verschillende hoofdstuk-
ken 
Het meeste laboratoriumwerk is verricht op het Radboudziekenhuis en in het bijzonder 
wil ik vermelden Noor van Ewijck, Michelle Broekman, (sulfonamide bepalingen), Addi de 
Craaf-Hess, Henk Blom, (thiol bepalingen), Wilbert Peters, (microsoom onderzoek en glu-
tathione bepalingen), Wil Camps, Willem Melchers, (toxoplasma onderzoek), Harry 
Dolstra, Frank Preyers, (gebruik flowcytometer), Piet van Erp, Joost Schalkwijk, 
(gebruik fluorometer en flowcytometer) en Pierre Demacker, (laboratorium faciliteiten) 
Liesbeth Jacobs en Trees Verver hebben met grote inzet veel van het laboratoriumwerk 
gedaan Ook hebben zij mij vaak psychisch ondersteund 
Verder wil ik Peter Koopmans en Jos van der Meer danken voor het vertrouwen en de 
ruimte die ZIJ mij gaven, zodat ik zelfstandig aan dit onderzoek gestalte kon geven en 
toch altijd binnen kon lopen voor overleg 
Paul Mier wil ik bedanken voor zijn bijzonder stimulerende manier van samenwerking 
Door het 'bench work' dat we samen deden, leerde ik ook veel over de basis principes van 
goed (biochemisch) onderzoek 
Tom Vree zijn uitgebreide kennis loopt als een rode draad door dit proefschrift Ik bewon-
der zijn gedrevenheid voor onderzoek, loyale houding en boven alles eerlijkheid 
Martijn Luns heeft als typograaf geprobeerd dit proefschrift, ondanks de tekst, toch lees-
baar te krijgen 
Marjolein, this is the end. 

Stellingen 
Behorend bij het proefschrift 
Adverse reactions to cotrimoxazole in HIV infection 
studies to explore the mechanism 
André van der Ven 
27 november 1995 
BIJ gezonde vrijwilligers loopt het patroon van de vorming en uitscheidmg van 
sulfamethoxazole hydroxylamine paralel met die van de andere metabole Produkten 
van sulfamethoxazole Dit wijst erop dat onder fysiologische omstandigheden 
sulfamethoxazole hydroxylamine stabiel is 
HIV infectie leidt niet tot een systemische glutathione deficiëntie 
Bepaalde cellen van HIV geïnfecteerde patiënten vertonen tekenen van oxidatieve 
stress en onder die omstandigheden kan de toxiciteit van sulfamethoxazole toe 
nemen 
Er is een rationale om te onderzoeken of het profiel van bijwerkingen van sulfa 
metrole gunstiger is dan dat van sulfamethoxazole, vooral bij patiënten met een 
glucose 6 fosfaat dehydrogenase deficiëntie en bij HIV gemfecteerden 
De aanbeveling voor de dosis sulfonamide, wanneer gecombineerd met pyrime tha-
mine voor de behandeling van Toxoplasmosis, houdt geen rekening met het synergis-
tisch effect van de combinatie en is daarom onnodig hoog 
De internist in Nederland die gespeciahceerd is in tropische ziekten, hoeft geen 
verstand te hebben van gezondheidszorg van ontwikkelingslanden 
Wat de patient met weet, wat de dokter niet deert 
In Holland is men vooral gedienstig aan de principes van de groep, 
in Vlaanderen eerder aan die van zichzelf 
Bepaalde omgangsvormen worden belast doordat men spreekt van ongewenste 
intimiteit terwijl men sexuele intimidatie bedoelt 



